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Abstract 
Acute myeloid leukaemia refers to cancer of the blood and bone marrow 
characterised by the rapid expansion of immature blasts of the myeloid lineage. The 
aberrant proliferation of these blasts interferes with normal haematopoiesis, resulting 
in symptoms such as anaemia, poor coagulation and infections. The molecular 
mechanisms underpinning acute myeloid leukaemia are multi-faceted and complex, 
with a range of diverse genetic and cytogenetic abnormalities giving rise to the acute 
myeloid leukaemia phenotype. Amongst the most common causative factors are 
mutations of the FLT3 gene, which codes for a growth factor receptor tyrosine kinase 
required by developing haematopoietic cells. Disruptions to this gene can result in 
constitutively active FLT3, driving the de-regulated proliferation of undifferentiated 
precursor blasts. FLT3-targeted drugs provide the opportunity to inhibit this 
oncogenic receptor, but over time can give rise to resistance within the blast 
population. The identification of targetable components of the FLT3 signalling 
pathway may allow for combination therapies to be used to impede the emergence of 
resistance. However, the intracellular signal transduction pathway of FLT3 is 
relatively obscure. The objective of this study is to further elucidate this pathway, 
with particular focus on the redox signalling element which is thought to be 
involved. Signalling via reactive oxygen species is becoming increasingly recognised 
as a crucial aspect of physiological and pathological processes within the cell.  The 
first part of this study examined the effects of NADPH oxidase-derived reactive 
oxygen species on the tyrosine phosphorylation levels of acute myeloid leukaemia 
cell lines. Using two-dimensional phosphotyrosine immunoblotting, a range of 
proteins were identified as undergoing tyrosine phosphorylation in response to 
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NADPH oxidase activity. Ezrin, a cytoskeletal regulatory protein and substrate of 
Src kinase, was selected for further study.  
The next part of this study established that NADPH oxidase is subject to regulation 
by FLT3. Both wild type and oncogenic FLT3 signalling were shown to affect the 
expression of a key NADPH oxidase subunit, p22phox, and FLT3 was also 
demonstrated to drive intracellular reactive oxygen species production. The NADPH 
oxidase target protein, Ezrin, undergoes phosphorylation on two tyrosine residues 
downstream of FLT3 signalling, an effect which was shown to be p22phox-
dependent and which was attributed to the redox regulation of Src. The cytoskeletal 
associations of Ezrin and its established role in metastasis prompted the investigation 
of the effects of FLT3 and NADPH oxidase activity on the migration of acute 
myeloid leukaemia cell lines. It was found that inhibition of either FLT3 or NADPH 
oxidase negatively impacted on the motility of acute myeloid leukaemia cells. The 
final part of this study focused on the relationship between FLT3 signalling and 
phosphatase activity. It was determined, using phosphatase expression profiling and 
real-time PCR, that several phosphatases are subject to regulation at the levels of 
transcription and post-translational modification downstream of oncogenic FLT3 
activity.  
In summary, this study demonstrates that FLT3 signal transduction utilises a 
NADPH oxidase-dependent redox element, which affects Src kinase, and modulates 
leukaemic cell migration through Ezrin. Furthermore, the expression and activity of 
several phosphatases is tightly linked to FLT3 signalling. This work reveals novel 
components of the FLT3 signalling cascade and indicates a range of potential 
therapeutic targets.  
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1. Leukaemia 
1.1       Classification of Leukaemia 
The term leukaemia is derived from the Greek leukos (white) and aima 
(blood), and refers to a spectrum of haematological neoplasms of the blood and bone 
marrow characterised by the de-regulated expansion of white blood cells. With an 
incidence rate of 12.3 per 100,000 in adults, leukaemia accounts for approximately 
3% of cancers diagnosed each year and accounts for a third of all cancer-deaths in 
children under 15 years (LLS, 2011a).  Leukaemia is classified according to the 
lineage of white blood cells affected, myeloid or lymphoid, as well as whether the 
rate of progression is chronic or acute. Acute leukaemia, which is the most common 
form in children, refers to the rapid accumulation of immature blasts, while chronic 
leukaemia describes the excessive build up of more mature abnormal cells over a 
period of months or years (LLS, 2011b).   
1.2 Acute Myeloid Leukaemia 
Acute Myeloid Leukaemia (AML) accounts for about 25% of all leukaemias 
and is the second most frequent form after Chronic Lymphocytic Leukaemia (CLL) 
(Jemal et al., 2002). AML is characterised by the rapid expansion of immature 
precursor myeloid blasts, which do not differentiate into mature and functional 
monocytes or granulocytes, but accumulate in the bone marrow and interfere with 
normal haematopoiesis (Bonnet and Dick, 1997).  It is thought that a small sub-
population of leukaemic stem cells are responsible for the generation and 
maintenance of leukaemia as the leukaemic blasts themselves are limited in their 
proliferative capacity (Bonnet and Dick, 1997). The leukaemic stem cells originate 
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from haematopoietic stem cells of the myeloid lineage which have undergone a 
disruption in their development due to transforming mutations. This disruption leads 
to a block in the differentiation of the progenitor cell which then gives rise to the 
pool of leukaemic blasts which are similarly halted at that level of differentiation. 
The transformation event can occur at various stages of stem cell development, 
which is why there is an extensive degree of heterogeneity amongst patients with 
AML at the genetic, phenotypic and clinical levels (Fialkow et al., 1981; Griffin and 
Lowenberg, 1986). There are two classification systems for AML; the French-
American-British (FAB) classification system which divides AML into 8 subtypes, 
M0-M7, according the type of cell affected and the stage of differentiation using 
light microscopy and cytogenetics (Bennett et al., 1976), and the World Health 
Organisation (WHO) classification which uses morphology, immunophenotype, 
genetics, and clinical features to describe the sub-types (Vardiman et al., 2002).  
Phases of the disease 
AML can arise very rapidly and if untreated can prove fatal in a matter of 
months. Some AML sub-types are preceded by a pre-leukaemic blood disorder such 
as myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS), 
periods of anaemia and poor blood cell production which can then develop into 
leukaemia. These disorders are more common in the elderly and are viewed as a 
phase in a multi-step pathogenesis with approximately 30% of patients with MDS 
going on to develop AML (Nolte and Hofmann, 2011). It is thought that the 
accumulation of genetic and molecular abnormalities in the early stages of MDS 
trigger the progression from dysplasia to neoplasia (Nolte and Hofmann, 2011). The 
progression to AML is diagnosed by the percentage of defective bone marrow blasts 
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with cut-off points of 30% for FAB classification and 20% in the WHO system 
(Vardiman et al., 2002). AML can also occur in patients who have undergone 
chemotherapy for another malignancy (Thirman et al., 1993), been exposed to 
benzene or other carcinogenic aromatic compounds (Austin et al., 1988) or high 
doses of ionising radiation (Bizzozero et al., 1966). In these cases the exposure to the 
mutagen causes genetic mutations or chromosomal abnormalities which lead to 
AML. Familial AML, caused by the transmission of inherited mutations accounts for 
the increased likelihood of members of the same family developing the disease 
(Gunz and Veale, 1969). AML can also arise as the result of other genetic disorders 
such as Down‟s syndrome (Evans and Steward, 1972), Li-Fraumeni (Anensen et al., 
2006), Fanconi‟s anaemia (Butturini et al., 1994), neurofibromatosis type 1 
(Balgobind et al., 2008), or Noonan syndrome (Chantrain et al., 2007).  
Molecular mechanisms of disease 
AML refers a heterogeneous group of diseases, the molecular basis of which 
can be complex and multi-factorial. A range of genetic as well as cytogenetic 
abnormalities have been identified which lead to the molecular alterations giving rise 
to the AML phenotype. Chromosomal aberrations including balanced translocations, 
inversions, deletions, monosomies
 
and trisomies are detected in 51% of AML cases 
(Dohner and Dohner, 2008),  and were widely used in the past as both diagnostic and 
prognostic factors in AML. The advancement of molecular genetics techniques in 
recent years, such as microarray technology, has allowed high density genomic-wide 
analysis and has resulted in the identification of specific gene mutations and de-
regulations which contribute to the initiation and progression of AML.  
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Chromosomal abnormalities 
The most common chromosomal aberrations which occur in AML are; 1% 
inversion(3)/translocation(3;3), 1% translocation(6;9), 2% translocation(11q23), 2% 
translocation (9;11), 6% inversion(16)/translocation(16;16), 5% translocation(8;21), 
23% are defined as having a various karyotypes including trisomy 8, 11, 13, 21 and 
22, loss of 5q, chX , Y or 7, and 11% as being a complex karyotype of multiple 
losses, gains and rearrangements (Dohner and Dohner, 2008; Nolte and Hofmann, 
2011).  
Gene mutations 
The cytogenetic abnormalities mentioned above can give rise to gene 
mutations, but in the 49% of AML cases which are defined as karyotypically normal 
(CN-AML), these mutations can occur independently of any chromosomal changes. 
The most common gene mutations associated with AML fall into two classes, signal 
transduction genes which do confer a proliferative or survival advantage but do not 
affect differentiation (Class I), and transcription factor genes which affect 
differentiation and apoptosis (Class II). The Class I genes are nucleophosmin 1 
(NPM1), Fms-related tyrosine kinase II (FLT3), NRAS, and KIT whereas Class II 
genes include  CBFB/SMMHC, AML1/ETO, RUNX, PML/RARα, EVI1 and WT1 
(Nolte and Hofmann, 2011; Gilliland and Griffin, 2002). It is proposed in the „two-
hit‟ hypothesis of leukaemic progression, that expression of both classes of genes 
together contributes to the AML phenotype of impaired differentiation and enhanced 
survival (Gilliland and Griffin, 2002).  
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Additionally, in AML sub-types classified as being of a complex aberrant 
karyotype, mutations in the TP53 gene are more common than in CN-AML 
(Haferlach et al., 2008). As a tumour suppressor which triggers apoptosis in DNA-
damaged and potentially tumourigenic cells, disruption or loss of one or both alleles 
of TP53 is common  in a wide range of tumour types and  is associated with genomic 
instability and aneuploidy (Schmitt et al., 2002).  
Mutations in the cytosolic isocitrate dehydrogenase I (IDH1) gene and its 
mitochondrial homolog IDH2 have been linked to the activation of HIF-1α, which 
promotes tumour growth in low oxygen conditions (Ward et al., 2010; Zhao et al., 
2009), as well as disruptions of the epigenetic regulation (Prensner and Chinnaiyan, 
2011). IDH mutations have been identified in breast, colon cancers (Yen et al., 2010) 
and glioblastomas (Dang et al., 2010; Prensner and Chinnaiyan, 2011), and when 
IDH mutations occur in AML they are viewed as poor prognostic indicators and are 
thought to drive disease progression (Prensner and Chinnaiyan, 2011).   
Epigenetic modifications 
While not strictly a gene mutation, epigenetic alterations can prove as 
disruptive to gene expression and function as conventional sequence mutations. 
Hypermethylation of DNA and acetylation of histones are the mechanisms by which 
genes are rendered silent while the gene sequence itself remains unchanged.  The 
addition of methyl groups to CpG islands in gene promoters prevents the binding of 
transcription factors and other proteins that affect transcription (Watt and Molloy, 
1988). Hypermethylation is detected in the promoter region of  P15
INK4B
, an inhibitor 
of the complex cyclin D/cyclin dependent kinase 4, in gliomas, acute lymphoblastic 
leukaemia (ALL) and AML (Herman et al., 1997; Jaenisch and Bird, 2003). Other 
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targets for hypermethylation in AML are the oestrogen receptor gene (Issa et al., 
1996), E-Cadherin gene (CDH1)(Corn et al., 2000) and the zinc finger transcription 
factor gene HIC-1 (Aggerholm et al., 1999; Issa et al., 1997).   
Histone acetylation is the process whereby acetyl groups are added to lysines 
in the N-terminal tail of histone proteins, resulting in a neutralisation of the overall 
positive charge on the histones leading to a looser association between the histone 
proteins and the negatively charged DNA (Clayton et al., 2006). This process is 
carried out by histone acetylases and facilitates increased access to the DNA by 
transcription factors and RNA polymerases, allowing increased transcription. 
Acetylation is a reversible process and the acetyl groups can be removed by histone 
de-acetylases (HDAC), the recruitment of which is altered in a range of tumour types 
including AML, leading to repression of genes. Crucially in AML this results in the 
silencing of transcription factor determinant C/EBPα which regulates granulocytic 
maturation (Pabst et al., 2001).  
Single nucleotide polymorphisms 
 In addition to these mutations and modifications, in which the genes affected 
can be functionally linked to AML progression, single nucleotide polymorphisms 
(SNPs) in the TET2 oncogene have been detected in ~15% of MDS and AML 
(Kosmider et al., 2009).While the function of this gene in leukemogenesis and 
normal haematopoiesis is not yet known, the TET2 mutation  is detectable in the 
early stages of MDS and so is classified as a favourable prognostic marker in 
contrast to mutations in NRAS (Paquette et al., 1993) and TP53 (Christiansen et al., 
2001) or hypermethylation of p15
INK4B
 (Christiansen et al., 2003) which are viewed 
as late-stage mutations and offer poor prognosis. 
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FLT3 mutations 
The FMS-like tyrosine kinase 3 (FLT3), also known as foetal liver kinase 2 
(FLK2) and human stem cell kinase 1 (STK1) (Small et al., 1994), is a membrane-
bound receptor tyrosine kinase (RTK) and member of the RTK subclass III which 
also includes macrophage-colony stimulating factor (M-CSF) receptor (FMS), KIT 
and platelet-derived growth factor (PDGF) (Nolte and Hofmann, 2011, Stirewalt and 
Radich, 2003). This subclass regulates the survival, apoptosis, differentiation and 
proliferation of haematopoietic cells, and FLT3 is mostly expressed on early 
progenitor cells of the myeloid and lymphoid lineages which are CD34
+
 (Nolte and 
Hofmann, 2011, Stirewalt and Radich, 2003).  RTK III members contain five 
immunoglobin-like extracellular domains, a transmembrane domain, a 
juxtamembrane domain and two intracellular tyrosine kinase domains (TKD) linked 
by a kinase insert domain (Stirewalt and Radich, 2003). There are two forms of the 
FLT3 receptor, a 160 kDa mature glycosylated form which is membrane-bound  and 
a 130 kDa non-glycosylated form which is cytoplasmic (Carow et al., 1996; Lyman 
et al., 1993). Glycosylation signals the maturation of the receptor and its 
translocation to the membrane. The inactive receptor exists in monomeric form at the 
membrane until it is bound by the FLT3 ligand (FL), a cell surface transmembrane 
protein  type I which undergoes proteolytic processing or alternative splicing to 
become a secreted polypeptide (Wodnar-Filipowicz, 2003). FL is produced by 
marrow stromal fibroblasts and T lymphocytes and displays synergy with other 
growth factors and interleukins to stimulate proliferation of early progenitor or stem 
cells (Lyman, 1995). When FL binds FLT3 it induces dimerisation of the receptor 
and autophosphorylation of its TKDs, this stimulates phosphorylation of downstream 
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effectors, following which the dimerised receptors become internalised and degraded 
within the cell (Stirewalt and Radich, 2003). 
Dosil et al. (1993) first investigated the signalling pathways stimulated by 
FLT3 by generating a chimeric receptor composed of the extracellular domain of 
FMS and the transmembrane and cytoplasmic domains of murine FLK2/FLT3.  
They demonstrated that FLT3 signalling in interleukin 3 (IL-3)-dependent Ba/F3 
lymphoid cells removed the requirement for IL-3, promoted and maintained cell 
proliferation. They also showed that PLCγ1, Ras GTPase-activating protein 
(RasGAP), the p85 subunit of phosphatidylinositol 3'-kinase (PI3K), the adaptor 
proteins Shc and the growth factor receptor-bound protein 2 (Grb2), the guanine 
nucleotide exchange factor Vav, and the proto-oncogenic tyrosine-protein kinases 
Fyn and Src are components of theFLK2/FLT3 signal transduction pathway. Of 
those components, PLCγ1, p85, Shc, Grb2, and Src family TKs, physically associate 
with the FLK2/FLT3 cytoplasmic domain. More recently, FLT3 signalling was also 
shown to result in the activation of Akt and MAPK further downstream (Hayakawa 
et al., 2000; Takahashi, 2006). 
FLT3 is also one of the most commonly mutated genes in haematological 
malignancies and can be detected in 1-3% of patients with ALL, 5-10% of MDS 
patients and  in 15-35% of AML patients (Nakao et al., 1996; Stirewalt and Radich, 
2003) and confers a poor prognosis (Pratz and Levis, 2008).  The two most common 
types of FLT3 mutations are internal tandem duplications of exons 14 and 15 of the 
juxtamembrane domain (FLT3-ITD), which are detectable in about 15% of AML 
patients, commonly in patients with translocations t(15;17) but also in AML-CN 
patients with NPM1  mutations (Takahashi, 2011), and missense point mutations in 
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exon 20 of the TK domain (FLT3-TKD) which are found in 5-10% of AML cases 
(Stirewalt and Radich, 2003).  In both instances the mutations result in the 
constitutive activation and autophosphorylation of the receptor  in the absence of the 
FL, though reports indicate that stimulation with FL can result in increased abnormal 
blast proliferation in patients who have the FLT3-ITD mutation as well as those who 
have wild type FLT3 (FLT3-WT) (Bruserud et al., 2003), suggesting that the mutant 
receptor may still be responsive to the ligand and stimulation with the ligand can 
further increase signalling from the already constitutively active receptor if it 
positioned correctly at the membrane. However, when the receptor is mutated it can 
become retained in biosynthetic compartments such as the endoplasmic reticulum 
(ER) instead of being trafficked to the membrane (Schmidt-Arras et al., 2009). 
Choudhary et al. (2009) showed that this mis-localisation results in altered signalling 
from the constitutively active receptor with aberrant activation of STAT5 and its 
transcriptional targets Pim-1/2 but no activation of PI3K or MAPK pathways which 
are usually triggered by constitutive signalling from the mutant receptor at the 
membrane.  
1.3  Mechanisms of FLT3-ITD pathogenesis 
Oncogenic FLT3-ITD signalling is thought to contribute to AML progression 
in two ways. Firstly via direct activation of the pro-survival Ras/MEK/Erk and 
PI3K/Akt pathways (Gilliland and Griffin, 2002), which are also stimulated by wild 
type FLT3 but only in response to appropriate growth factor stimulation by FL 
binding. In addition to this and in contrast to FLT3-WT signalling, FLT3-ITD 
activates STAT5, especially when the receptor is localised to the ER as mentioned 
above. This results in up-regulation of STAT5 target gene SOCS which alters 
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cytokine signalling (Choudhary et al., 2007), proto-oncogenes Pim-1/2 
serine/threonine kinases which promote cell cycle 
progression, apoptosis and transcriptional activation (Bachmann and Moroy, 2005; 
Choudhary et al., 2009), cyclin D1, c-myc and the anti-apoptotic gene p21 (Calo et 
al., 2003; Takahashi et al., 2004). As well as STAT5, FLT3-ITD influences several 
myeloid transcription factors such as PU.1 (Rosenbauer et al., 2004)and C/EBPα 
(Radomska et al., 2006) both of which are inhibited by FLT3-ITD activity causing a 
block in differentiation of myeloid precursor cells and an accumulation of immature 
blasts (Zheng and Small, 2005). Through activating the PI3K/Akt pathway FLT3-
ITD indirectly negatively regulates the FOXO family of forkhead transcription 
factors, specifically FOXO3a and its target genes pro-apoptotic Bim1 and cyclin-
dependent kinase inhibitor P27KIP1 (Takahashi, 2011). 
FLT3 signalling has also been associated with the increased production of 
reactive oxygen species (ROS) which can cause double-stranded breaks in DNA, 
contributing to the genomic instability so frequently observed in AML (Sallmyr et 
al., 2008b).  As well causing DNA damage, increased ROS levels can have a 
transforming effect on the cell by functioning as signalling molecules and 
stimulating abnormal proliferation and survival (Naughton et al., 2009). The 
recognition of ROS as signalling molecules in their own right has been prompted by 
the emergence of evidence for ROS playing a role in a diverse range of cellular 
processes including cell survival (Naughton et al., 2009), regulation of transcription 
factors (Tothova et al., 2007), and migration (Diaz et al., 2009; Ferraro et al., 2006).  
Increased  levels of ROS production, driven by the activity of oncogenes and growth 
factors, have been detected in a number of tumour types (Hole et al., 2012, 
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Mitsushita et al., 2004; Weinberg and Chandel, 2009; Wu, 2006) leading to aberrant 
oxidant signalling and contributing to a tumourigenic phenotype. Specifically with 
regard to haematopoietic tumours, oxidative stress triggered by excessive production 
of ROS can be found in myeloid leukaemias including chronic myeloid leukaemia 
(CML) and AML as well as acute lymphoblastic leukaemia (ALL) and MDS 
(Battisti et al., 2008; Farquhar and Bowen, 2003; Hole et al., 2012). It is thought that 
FLT3 signalling triggers ROS generation by activating the NADPH oxidase (Nox) 
family of ROS producers, via STAT5a and Rac1 in AML cells (Reddy et al., 2011; 
Sallmyr et al., 2008a).         
1.4  Treatment of AML 
AML treatment is divided into two phases, chemotherapeutic induction of 
remission and post-remission consolidation therapy which consists of additional 
chemotherapy and/or allogenic or autologous stem cell transplantation. The average 
complete response  rate, when the cancer disappears after treatment, with this mode 
of treatment is between 60% to 70% with long-term survival rates from 25% to 35% 
(Kantarjian et al., 2008). The induction of remission phase aims to reduce the 
amount of abnormal cells to an undetectable level, however despite this intervention, 
some leukaemic cells can remain in number too low to be detected and if the initial 
induction phase is not followed by a consolidation phase then the patient is likely to 
relapse (Abeloff, 2004). The consolidation treatment options are considered based on 
the genetic basis for the disease and can therefore vary from patient to patient 
depending on the karyotype and mutation profile of the affected cells (Estey, 2001).  
Patients with karyotypes that are considered favourable, such as those with inv(16), 
t(8;21), and t(15;17), are given a further dose of intensive chemotherapy 
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(Appelbaum et al., 2000; Mayer et al., 1994). Whereas patients with high-risk 
cytogenetics, underlying MDS, or therapy-related AML are classified as being at 
high risk of relapse and for these patients allogenic stem cell transplantation from a 
suitable donor is usually attempted (Appelbaum et al., 2000).  
FLT3 mutations are one of the more common molecular abnormalities found 
in AML, and so FLT3 has become the focus of worldwide research in an attempt to 
develop a targeted therapy. In general AML patients with FLT3-ITD mutations have 
pronounced leukocytosis, a hypercellular bone marrow and intermediate risk 
cytogenetics. The complete remission rate after induction is similar to that of patients 
with wild type FLT3 but there is a much greater risk of relapse (Levis and Small, 
2003). It is thought that targeting FLT3-ITD alone will not significantly improve the 
outcome for patients with the mutation, but that in combination with chemotherapy 
may generate synergistic effects which will improve upon results seen with 
chemotherapy alone (Pratz and Levis, 2008).  To date, more than 20 compounds 
have been reported in the literature to function as FLT3-ITD inhibitors (Pratz and 
Levis, 2008, Wiernik, 2010), and several of these have been taken to clinical trials 
(DeAngelo et al., 2006; Fischer et al., 2010; Giles et al., 2003; Kindler et al., 2010, 
O'Farrell et al., 2003; Smith et al., 2004; Stone et al., 2005; Weisberg et al., 2002). 
The compounds are heterocyclic and either function as ATP competitors or are 
structurally analogous to the intermediary complex of a tyrosine covalently bound to 
ATP, so that they fit into the ATP-binding compartment of FLT3-ITD, as well as 
that of other RTKs. This prevents ATP binding, which is necessary to initiate the 
FLT3-ITD auto-phosphorylation signalling cascade (Pratz and Levis, 2008). Clinical 
trials have shown that the FLT3-ITD inhibitors Lestaurtinib (CEP-701), Midostaurin 
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(PKC412), Sunitinib (SU11248) and Tandutinib (MLN518) inhibit FLT3-ITD 
autophosphorylation in vivo, resulting in the clearance of peripheral blood leukaemia 
cells, yet only very rarely affecting the bone marrow population (Weisberg et al., 
2009).This means that the effects were short-lived, as the leukaemic stem cells in the 
bone marrow re-populated the peripheral blood with resistant blasts, highlighting the 
limits of the FLT3-ITD inhibitors as a monotherapy. However, several FLT3-ITD 
inhibitors have been tested in combination with conventional chemotherapeutics 
(Stone et al., 2012) and are hoped to provide a viable treatment opportunity, 
especially to patients for whom transplantation is not an option. Similar approaches 
in ALL patients who carry Bcr-Abl, the chimeric oncogenic TK, have yielded very 
positive results in clinical trials which combined the TK inhibitor Imatinib with 
chemotherapeutic agents (Thomas et al., 2004). 
2. ROS Signalling 
2.1  ROS 
ROS refers to the highly reactive derivatives of oxygen including radicals 
such the oxygen ions superoxide (O2
•−
), hydroxyl (
•
OH), peroxyl (RO2
•
), and alkoxyl 
(RO·), possessing unpaired valence shell electrons, as well as the non-radical 
peroxides hypochlorous acid (HOCl), ozone (O3), singlet oxygen (
1
O2), and 
hydrogen peroxide (H2O2) (Bedard and Krause, 2007) which, because of their un-
stable O-O linkage, are volatile sources of further radicals (Nic et al., 2006). In cell 
biology, ROS have been long regarded as by-products of a cascade of reactions, 
stemming from cellular oxygen metabolism. Aerobic respiration results in the 
production of ROS as a side effect of the activity of the electron transport chain 
(Figure 1). In this situation, O2
•−
 is formed when oxygen is prematurely reduced by a 
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single electron, but the free radical is quickly neutralised by the mitochondrion‟s 
own antioxidant defence system of mitochondrial superoxide dismutase (SOD) and 
peroxidases. Conditions of hypoxia, damage to the mitochondria itself, or reduced 
levels of these free radical scavenging enzymes result in increased „leakage‟ of ROS 
from the mitochondria, leading to an intracellular environment of oxidative stress 
which triggers apoptosis (Simon et al., 2000). 
These ROS, if permitted to accumulate to toxic levels, can have detrimental effects 
on cellular biomolecules, such as proteins and lipids, leading to apoptosis. In 
addition to this, exposure of DNA to ROS results in the formation of double stranded 
breaks and oxidatively modified bases. These lesions can interfere with the coding 
sequences, as in the case of cytosine deamination events causing G-C to T-A 
transition mutations, as well as disrupting DNA structure or RNA polymerase 
activity. These lesions, if not repaired, can also trigger apoptosis or may even prove 
oncogenic (Cooke et al., 2003). It has been shown that many different tumour types 
produce ROS at levels higher than in their normal counterparts (Hole et al., 2012; 
Mitsushita et al., 2004; Weinberg and Chandel, 2009; Wu, 2006), stimulating pro-
mutagenic lesions which contribute to the tumourigenic phenotype.  
 
Other molecules prone to oxidative damage include lipids. Lipid peroxidation, 
particularly of the polyunsaturated fatty acids which compose the plasma membrane 
and internal cellular compartmental membranes, results in the formation of fatty acid 
radical and lipid peroxides, leading to deterioration and eventual rupturing of the cell 
membrane (Mylonas and Kouretas, 1999). 
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Figure 1. ROS production by the mitochondrial respiratory chain 
The inner mitochondrial membrane bound-respiratory chain consists of Complex I- 
NADH dehydrogenase complex, II- succinate-dehydrogenase coenzyme Q 
reductase, III- cytochrome b-c1 complex, IV- cytochrome oxidase complex and V- 
ATP synthase. During the transfer of electrons from NADH to oxygen (O2) and the 
concurrent production of ATP, the relationship between the pool of available NADH 
electron donors,  local O2 concentration and the efficiency of ATP synthase 
determines the amount of superoxide (O2
•-
) which is produced. Mitochondrial 
antioxidants manganese superoxide dismutase (MnSOD) in the matrix, and 
copper/zinc SOD (CuZnSOD), localised to the intermembrane space, convert the 
O2
•-
 into the membrane permeable hydrogen peroxide (H2O2). 
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Proteins are the main targets of ROS within the cell, accounting for 
approximately 69% of oxidation events, due to their abundance and high rate 
constants for oxidation-reactions compared to lipids (18%) and nucleic acids (15%) 
(Davies, 2005; Sheehan, 2006). Thus, it is possible that proteins evolved to act as a 
form of buffer, by absorbing oxidants and preventing oxidation-induced DNA 
mutation, or oxidation and rupture of lipid membranes. This trade-off would have 
resulted in oxidative-modifications to proteins. The consequences of protein-
oxidation depend on the concentration and species of ROS involved, but also vary 
hugely from protein to protein depending on their individual biochemical and 
structural characteristics. Oxidation-induced changes in the charge, size, 
hydrophobicity or polarity of the amino acids in a polypeptide can affect its 
secondary and tertiary structure, dictating the stability and activity of the whole 
protein. Oxidation of amino acid side chains causes inter- and intra-molecular cross-
linkages while the polypeptide backbone is prone to 
•
OH attack resulting in protein 
fragmentation and degradation (Berlett and Stadtman, 1997). Sulfur-containing 
amino acids such as cysteine and methionine are the most easily oxidized (Janssen-
Heininger et al., 2008), and also the most relevant, from a physiological perspective, 
as these oxidation events can be reversible (Hoshi and Heinemann, 2001). 
Also warranting a mention at this point is the analogous process of s-
nitrosylation. This system of the covalent attachment of a nitrogen monoxide group 
to a cysteine residue, has been extensively reviewed (Hess et al., 2005), and occurs 
as a result of exposure to reactive nitrogen species (RNS). An „acid-base‟ motif is 
thought to signify s-nitrosylation-susceptible sites on proteins, which is based on the 
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relative placement of charged amino acids in order to facilitate a low pKa (Stamler et 
al., 1997). 
Hess et al., (2005) comment on the potential cross-talk between oxidation 
and s-nitrosylation, as dual systems of cysteine modification, and propose a redox-
signalling model whereby s-nitrosylation functions as the „primary effector‟, and 
oxidation as a form of allosteric moderator, affecting the ability of a target to 
respond to s-nitrosylation.  As outlined by Hess et al. (2005), this model applies 
readily to the ryanodine receptor/Ca2+ channel and erythrocytic haemoglobin.  
Antioxidants 
Cells have evolved a variety of methods of coping with and reducing 
oxidative stress because of the potentially devastating effects which intracellular 
oxidants can inflict. Oxidation of methionine within proteins is thought to represent a 
form of antioxidant system, by readily scavenging oxidant species and thereby 
limiting the exposure of other residues (Luo and Levine, 2009). The oxidation of 
methionine results in the generation of methionine-sulfoxide and can be reversed by 
the activity of methionine sulfoxide reductase (MsrA/B) utilising a thioredoxin (Trx) 
co-factor (Lee and Gladyshev, 2011). This suggests that the cycling of methionine 
between oxidized and reduced states is an enzymatically-regulated mechanism which 
has evolved to buffer against the presence of ROS. Methionine oxidation can also 
proceed past the formation of methionine sulfoxide, to the hyperoxidized form 
methionine sulfone, which cannot be reversed (Stadtman et al. 2003).  
Endogenous cellular antioxidant enzymes are also expressed in virtually 
every cell type and efficiently scavenge and neutralise free radicals to prevent toxic 
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accumulation. Amongst the most active and widespread antioxidants is the 
glutathione (GSH) system.  GSH can reduce disulfide bonds formed as a result of 
cysteine oxidation, crucial for the regeneration of other anti-oxidants such as 
glutaredoxins (Grx) which rely on GSH as a co-factor.  This reaction requires the 
oxidation of GSH to oxidized-GSH (GSSG), before it is reduced back to GSH by 
GSH reductases. GSH has such a prominent role in ROS defence that  its own redox 
state is an important indicator of the redox state of the cell, so much so that the 
oxidised form is frequently used as a biomarker for oxidative stress (Pastore et al., 
2001). 
The process of s-glutathionylation, the reversible formation of a mixed 
disulfide between an oxidized cysteine residue and GSH, occurs as a result of both 
oxidative and nitrosative stress and is thought to protect proteins from further 
oxidation as well as modulating their function to facilitate the relaying of signals 
(Dalle-Donne et al., 2009; Giustarini et al., 2005). Cysteines which are s-
glutathionylated, in order to prevent hyperoxidation, are likely to be crucial to the 
stability or activity of the protein, though their modification may temporarily 
inactivate the enzyme, or alter its signalling capacity. This modification is reversed 
under reducing conditions by the actions of Grx or Trx (Shelton et al., 2005). 
Another important antioxidant  is Trx, part of  a group of interacting 
molecules in the Trx system, The system refers to Trx, which catalyses the reduction 
of proteins through cysteine thiol-disulfide exchange, as well as Trx-reductase 
(TrxR) which regenerates Trx, and its co-factor and electron donor NADPH 
(Nordberg and Arner, 2001).  Other ubiquitous antioxidants include SOD, which 
catalyses the conversion of O2
•−
 to H2O2 (McCord and Fridovich, 1988), GSH 
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peroxidases, which convert  lipid hydroperoxides to alcohols and H2O2  to H2O 
(Arthur, 2000), and catalase which also neutralises H2O2 (Chelikani et al., 2004).  
Peroxiredoxins 
More recently another class of cellular redox scavengers have emerged, the 
peroxiredoxins (Prx). These enzymes are defined by their ability to reduce 
hydroperoxides and peroxynitrite (Rhee et al., 2012) . Similarly to GSH, the redox 
reaction catalysed by Prx involves the oxidation of Prx molecules themselves, and a 
thiol-dependent cycling back to the reduced state. Prx appear to be unique amongst 
cysteine-containing proteins, in that they are able to recover from hyper-oxidation of 
their cysteine residues to sulfinic acids. A slow reduction of sulfinic acid-containing 
Prx requires ATP-dependent activity of sulfiredoxins (Srx) and is thought to be an 
adaptation unique to eukaryotic cells to facilitate the temporary, localised 
accumulation of high levels of H2O2 for signalling purposes (Cordray et al., 2007). 
This so called „Floodgate‟ hypothesis with regard to Prx oxidation describes a dual 
role for Prx as general antioxidant defence enzymes, the „ancestral role‟, as well as 
regulators of spatially defined redox signalling (Poole et al., 2004; Wood et al., 
2003; Choi et al., 2005; Rhee et al., 2005).  
The tight control of ROS levels within the cell highlights the potentially 
devastating effects that de-regulation of these molecules can have on the cellular 
integrity, genetic material and other crucial molecular components.  However, more 
recently the recognition of ROS as mediators of cellular communications has 
prompted their classification as signalling mediators in their own right. Even prior to 
this role being identified, it was known that production of ROS was not always a 
side effect of cellular respiration. Aside from the incidental generation of ROS as by-
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products of metabolism, the professional production of ROS is becomingly 
increasingly recognised as an important source of intercellular oxidants. The 
lipoxygenase (Lox) and cyclooxygenase (Cox) families of enzymes are responsible 
for ROS production for the purposes of fatty acid metabolism and the biosynthesis of 
hormones and inflammatory mediators (Figure 2). Lipid peroxide intermediates, 
such as hydroperoxyeicosatetraenoic acids (HPETEs), are formed initially which are 
highly reactive oxidising molecules themselves and have been shown to inactivate 
PTPs (Conrad et al., 2010). In addition to this, 12-Hydroxyeicosatetraenoic acid 
(12(S)-HETE), and 15-S-Hydroxyeicosatetraenoic acid (15(S)-HETE), the end 
products of the Lox pathway, can stimulate ROS production by the Noxs (Serezani 
et al., 2005). 
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Figure 2. The production of ROS by the Lox and Cox 
Eicosanoid biosynthesis proceeds via the oxidation of fatty acids, such as 
arachadonic acid, catalysed by the Lox enzymes, resulting in the formation of 
leukotrienes, or the Cox enzymes which produce prostaglandins. Both pathways 
require the addition of molecular oxygen (O2) to arachadonic acid and involve the 
production of ROS as a by-product of this oxidative step. 
 
 
 
23 
 
2.2 Nox 
The generation of ROS is known to be the primary function of the Nox 
family of enzymes (Figure 3). The ROS generated by the Nox in the phagosomes of 
professional phagocytic cells such as  the neutrophils, monocytes, macrophages, 
dendritic cells, and mast cells were initially shown to be responsible for the killing of 
endocytosed bacterial pathogens (Robinson and Badwey, 1995). The subsequent 
discoveries of Nox enzymes in cells other than phagocytes, such as vascular smooth 
muscle cells (Griendling et al., 1994), fibroblasts (Meier et al., 1991), thyroid cells 
(De Deken et al., 2000), neurons (Serrano et al., 2003), hepatocytes (Reinehr et al., 
2005) and endothelial cells (Gorlach et al., 2000) amongst others, prompted the 
question of what functions are being fulfilled by Nox enzymes in non-phagocytic 
cells.  
The Nox family of professional ROS producers consists of 7 isoforms of the 
catalytic subunit of the Nox holoenzyme complex; Nox 1-5, as well as the Dual 
oxidases (Duox) 1 and 2. Nox 2, or gp91phox as it was originally called, is the 
prototypic Nox first identified in phagocytes as being required for oxidant-dependent 
microbial killing (Lambeth, 2004).The Nox isoforms share several conserved 
structural features. The catalytic subunit is a transmembrane protein containing 
electron-transferring FAD and heme groups capable of removing an electron from 
the preferential donor substrate, cytosolic NADPH, and using this electron to reduce 
molecular oxygen in the extracellular or phagosomal space, resulting in the 
generation of  (Bedard and Krause, 2007). The  generated can be transported across 
the plasma membrane through ion channels, but more frequently is rapidly converted 
into H2O2,, which may then diffuse back across the membrane with the aid of 
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aquaporin channel proteins (Bienert et al., 2007). The Nox isoforms differ in terms 
of additional domains of the catalytic subunit. Nox 1, 2, 3 and 4 share the most 
homology (Bedard and Krause, 2007) and have very similar catalytic core domain 
structure, whereas Nox 5 contains an additional intracellular amino-terminal calcium 
binding domain (Banfi et al., 2001). The Duox 1 and 2 possess this domain as well 
as a further transmembrane amino-terminal peroxidase-like domain, which faces into 
the extracellular space (Edens et al., 2001). 
The isoforms also vary in their requirements for the several Nox activator and 
regulatory subunits. These subunits were originally identified as being necessary for 
the formation of the active Nox2 enzyme complex but as further Nox isoforms were 
investigated, it appeared that these subunits were not always required for catalytic 
activity of individual Nox.  Possibly the most crucial regulatory subunit is the small 
transmembrane protein p22phox, which functions as both a stabilising presence for 
the catalytic subunit, as well as an anchor for the other regulatory subunits which are 
not membrane bound. Originally isolated in complex with Nox 2, a complex titled 
flavocytochrome b558 (Parkos et al., 1987), p22phox is necessary for the stability of 
Nox 1-4 (DeLeo et al., 2000), whereas Nox 5 and Duox 1 and 2 appear to not require 
p22phox (Kawahara et al., 2005).  
Three cytosolic subunits are required for Nox 2 activation and must be 
recruited to the membrane in order to fulfil their functions. p47phox is termed the 
organiser subunit of Nox 2, as its binding to p22phox facilitates the assembly of the 
other subunits. In the cytosol, p47phox is bound to p67phox, the Nox 2 activator, so 
upon p47phox translocation to the membrane, p67phox is also brought into contact 
with the Nox 2 subunit. Another small subunit, p40phox, is bound to p47phox and 
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p67phox in the cytosol and is recruited to the membrane with p47phox, however it is 
unclear as to the precise function of p40phox, though studies seem to suggest that its 
presence enhances Nox 2 activity (Cross, 2000; Kuribayashi et al., 2002; Tsunawaki 
et al., 1996).  Phosphorylation of cytosolic p47phox  has been reported to occur via a 
range of kinase, including PKCα, βII, δ(Fontayne et al., 2002) δ (Bey et al., 2004) 
Src (Chowdhury et al., 2005), MAPK (Dang et al., 2006) and Akt (Hoyal et al., 
2003) and appears to be one of the signals which triggers the translocation of 
p47phox to the membrane, but another requirement is phosphorylation of membrane 
phospholipids, by PI3K and phospholipase D, to which p47phox  binds (Kanai et al., 
2001) . 
Nox 1 differs from Nox 2 in that it uses its own unique organiser and 
regulatory subunits, NoxO1 ( a p47phox homolog) and NoxA1(a p67phox homolog)  
respectively (Bedard and Krause, 2007). These subunits also appear to be employed 
preferentially by Nox 3, though there is evidence to suggest that Nox 3 can also be 
activated by p67phox (Banfi et al., 2004a; Ueno et al., 2005).  In contrast, Nox 4  
(Martyn et al., 2006), Nox 5 (Banfi et al., 2001) and Duox 1, 2 (Bedard and Krause, 
2007) have no requirements for activator or organiser subunits, with Nox 5 (Banfi et 
al., 2004b), and Duox1 and 2 activity  being subject solely to Ca
2+
 levels (Ameziane-
El-Hassani et al., 2005). In addition to the phox subunits, another cytosolic factor 
required for Nox 1, 2, and possibly 3 (Ueyama et al., 2006) and 4 (Gorin et al., 
2003)  activity is the small GTPase Rac1, which when in its active GTP-bound state 
binds p67phox  (Lapouge et al., 2000) The exchange of GDP for GTP in Rac1, as 
catalysed by guanine exchange factors (GEFs) causes the release of Rac1 from its 
inhibitory RhoGDI partner and allows it to bind the Nox holoenzyme, forming an 
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active complex (Knaus et al., 1991). In summary there are three separate events 
which trigger activation of Nox 1, 2 and 3; the phosphorylation of its cytosolic 
organiser subunits preceding their translocation to the membrane; the 
phosphorylation of membrane inositides to facilitate binding of the subunits, and the 
release of Rac1GTP from its inhibitory partner.  
Nox 4 was long thought to be the only constitutively active member of the 
Nox family, under regulation  by transcription factors  at the level of mRNA rather 
than relying on cytosolic organiser and activator subunits (Von Löhneysen  et al., 
2012; Serrander et al., 2007). However, it has recently been proposed that Nox 4 
requires the stabilising presence of p22phox with which it forms a heterodimer at the 
plasma membrane (Ambasta et al., 2004), and that this association is dependent on 
the polymerase delta-interacting protein (Poldip2) (Lyle et al., 2009).  
The Nox are responsible for the generation of ROS in response to a variety of 
stimuli. These stimuli range from LPS and inflammatory mediators, a reminder of 
the original microbiocidal role of Nox, to B and T cell receptors (Richards and Clark, 
2009; Jackson et al., 2004) and growth factors such as PDGF, Thrombin, TNF- α, 
TGF-β, Angiotensin II  (Brown and Griendling, 2009) and Bcr-Abl (Naughton et al., 
2009). The ability of Nox to produce ROS in the context of growth factor binding 
and receptor activation, and not exclusively as a host defence mechanism, suggests 
that the role of Nox enzymes has expanded to include the generation of oxidants for 
the purposes of signalling.           
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2.3  Redox signalling                  
There has been a recent emergence of evidence for ROS playing a role in a 
diverse range of cellular processes including cell survival (Naughton et al., 2009), 
regulation of transcription factors and gene expression (Li et al., 2009), cell 
senescence (Colavitti and Finkel, 2005), angiogenesis  (Ushio-Fukai, 2006b), 
differentiation (Xiao et al., 2009), cell death (Kim et al., 2007), migration (Meng et 
al., 2008) , cytoskeletal remodelling  (Lyle et al., 2009), proliferation (Jay et al., 
2008; Arnold et al., 2001), transformation (Laurent et al., 2008), insulin signalling 
(Mahadev et al., 2004), oxygen sensing  (Lee et al., 2006), hormone synthesis   
(Pfarr et al., 2006), invasion  (Deem and Cook-Mills, 2004), regulation of cellular 
redox potential (Bedard and Krause, 2007), and protein folding and cross-linking 
(Santos et al., 2009) . 
The ability of Nox derived-ROS to regulate discrete signalling pathways and 
influence specific molecules and processes, lies in the compartmentalisation of the 
oxidant production. Individual Nox isoforms are localised to different sub-cellular 
compartments, allowing for co-localisation with specific ROS targets, thus reducing 
the likelihood of off-target redox signalling and insulating the local accumulation of 
ROS to prevent toxic side-effects (Terada, 2006). An example of this 
sequesterisation of Nox ROS production is the localisation of Nox 4 to the ER. 
Proteins regularly undergo redox processing as part of their maturation within the 
ER, resulting in modifications essential to their tertiary structure and function such 
as disulfide bond formation and protein folding (Appenzeller-Herzog et al., 2010; 
Zito et al., 2010).  It has been recently demonstrated by Chen et al. (2008a) that ER-
resident protein PTP1B, is subject to redox modification by Nox 4 focally activated 
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in the ER, but in this situation the oxidation transiently inhibits PTP1B to facilitate 
endocytosed EGFR signalling . The specificity of the redox signal was highlighted 
by the failure of Nox 4 to oxidise a cytosolic, mutant form of the phosphatase. 
Similarly, Nox localisation to endosomes, lipid rafts and caveolae confers the same 
type of sequesterisation of oxidants for precise signalling purposes (Ushio-Fukai, 
2006a). 
The availability of regulatory subunits, or co-factors such as Ca
2+ 
in the case 
of Nox 5 and the Duox, also ensures that the production of ROS is spatially and 
temporally regulated. The recent identification and characterisation of two novel 
adaptor proteins for Nox1 and 3, Tks4 and Tks5   (Gianni et al., 2009), highlights the 
role of Nox regulatory molecules in dictating the specificity of the redox signalling 
and tailoring it to the physiological needs of the cell. The Tks proteins function in a 
similar manner to p47 phox, i.e.as organiser subunits controlling the recruitment of 
other subunits to the membrane, but appear to operate only within the invadopodia 
and podosomes of migrating cells, ensuring that Nox activation occurs within the 
confines of these actin-rich invading structures, which seem to require ROS for their 
stabilisation. This mode of spatial regulation of Nox activity is also evident also in 
the case of PTP-PEST susceptibility to p47phox-dependent production of ROS at 
sites of focal adhesions (Wu et al., 2005). 
The compartmentalisation of the redox signal is also regulated in part by the 
ROS-scavenging systems discussed earlier. The specificity of these enzymes for 
particular ROS, their proximity to individual Nox as well as their ability to become 
variably oxidised all contribute to the formation of discrete redox circuits within the 
cell, ensuring the temporal and spatial production and activity of ROS is tightly 
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controlled.  Despite this, de-regulated and aberrant production of ROS by Nox does 
occur and can have detrimental phenotypic effects on the cell. Nox have been 
implicated in a range of pathologies including neurodegenerative disorders (Gao et 
al., 2012), asthma (Henricks and Nijkamp, 2001), cardiovascular disease (Heymes et 
al., 2003), hypertension  (Rey et al., 2002) , photo-ageing (Valencia et al., 2006), 
male infertility (Aitken and Baker, 2004) , pre-eclampsia (Brodsky et al., 2004), 
cerebral and myocardial infarction (Hong et al., 2006; Meischl et al., 2006), septic 
shock and multi-organ failure  (Abdelrahman et al., 2005) , diabetes (Etoh et al., 
2003), acute renal failure (Nath and Norby, 2000) and  retinal degeneration (Usui et 
al., 2009).  
In addition to this, the role of Nox as effectors of growth factors signalling 
means that their activity is subject to de-regulation in situations of oncogenic RTK 
signalling, constitutively active receptors or aberrant production of growth factors or 
ligands. Indeed a number of tumour types have been shown to produce higher levels 
of ROS than is physiologically normal (Hole et al., 2012; Mitsushita et al., 2004; 
Weinberg and Chandel, 2009; Wu, 2006), due to oncogenic RTK signalling, over-
expression  of the Nox enzymes themselves (Bedard and Krause, 2007; Cheng et al., 
2001), down-regulation of antioxidant scavenging enzymes (Yuzhalin and Kutikhin, 
2012),  or co-occurrence of all three of these situations.  Increased ROS production 
proves tumourigenic through direct oxidation and damage of DNA, as discussed 
earlier, as well as through aberrant oxidant signalling, both contributing to a 
tumourigenic phenotype.  
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3. Objectives 
As this project is concerned with AML, it is important to note that in 
haematopoietic tumours excessive production of ROS can be found in myeloid 
leukaemias including CML and AML as well as ALL and MDS (Battisti et al., 2008; 
Farquhar and Bowen, 2003). It was recently shown that, in CML, the oncogenic 
RTK Bcr-Abl stimulates tumourigenic redox survival signalling via Nox (Naughton 
et al., 2009). Given the established role for FLT3-ITD in driving AML progression, 
as well as recent evidence for both ROS production downstream of FLT3-ITD 
signalling (Sallmyr et al., 2008b), and a link between FLT3-ITD and Nox (Reddy et 
al., 2011; Sallmyr et al., 2008a), we are confident that there is similar mechanism of 
oncogenic RTK-driven Nox activity operating in AML. Our hypothesis is that FLT3-
ITD signals to one or more Nox isoforms, and that the ROS produced by Nox 
contributes to the phenotype of AML through aberrant redox signalling.  The 
objectives of this project are three-fold. 1) To investigate signalling from FLT3 to 
Nox, 2) to identify the target pathways and proteins downstream of Nox-derived 
ROS in AML and the mechanisms whereby they are redox regulated and 3) to 
evaluate the contribution that this FLT3-driven redox signalling makes to the AML 
phenotype.  
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Figure 3. Nox production of ROS 
The Nox family consists of 7 isoforms, Nox1-5 and Duox 1 and 2. Upon stimulation, 
the catalytic subunit removes an electron from cytosolic NADPH, and uses this 
electron to reduce O2 generating O2
·-
. A) p22phox is required by Nox1-3, and 
possibly 4, and functions as both a stabilising presence as well as an anchor for the 
other regulatory subunits. Nox 1-3 activation also requires recruitment of cytosolic 
subunits and Rac1-GTP. B) Nox 4 is thought to require Poldip2 to facilitate its 
binding to p22phox.C) Nox 5 and the Duox appear to require only Ca
2+
 for which 
they contain an additional binding domain. Duox also possess a further 
transmembrane peroxidase-like domain, although this is thought to be non-
functional. 
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Unless otherwise stated all reagents were purchased from Sigma Aldrich (Dublin, 
Ireland). 
Antibodies 
Primary antibodies used for immunoblotting were Ubiquitin (MAB1510) from EMD 
Millipore Corporation (MA, USA), Rac1 (Arc03) from Cytoskeleton Inc., PP6C (07-
1224), Nox 2 (07-024) and PTP1B (07-088) from Upstate Biotechnology (Milton 
Keynes, UK). Nox 4 (ab61248), Rac2 (ab2244), Duox 2 (ab65813) and p-Ser PSR-
45 (ab6639) from Abcam (Cambridge, UK). p-Tyr (610000) from BD Transduction 
Laboratories (Oxford, UK), β-Actin (A5441) from Sigma-Aldrich (Dublin, Ireland). 
PP2Cα (3549), p-FLT3 Tyr591 (3461), FLT3 8F2 (3462), Src (L4A1) (2110), p-Src 
Y416 (2101), Ezrin (3145), p-Ezrin Y353 (3144), p-Thr 42H4 (9386) all from Cell 
Signalling Technology (Boston, USA). Nox 1 (sc-25545), Nox 5 (sc-67006), Duox 1 
(sc-48858), p47phox (sc-14015), p-Ezrin Y146 (sc-12941), Nox3 (sc-34699), 
p67phox (sc-15342), SHP-1 (sc-287), and p22phox (sc-20781) all from Santa Cruz 
Biotechnology Inc. (CA, USA). The Nox 4 antibody was a gift from Dr JD Lambeth 
(Emory University School of Medicine, Atlanta, GA). Horseradish peroxidise-
conjugated secondary antibodies (Dako, Stockport, UK) were used for detection with 
enhanced chemiluminescence and Li-Cor IRDye secondary antibodies (Li-Cor 
Biosciences, Nebraska, USA) were used for detection with the Odyssey System.   
Cell Culture 
The human AML cell lines, MOLM-13, which is heterozygous for the FLT3-ITD 
mutation (Quentmeier et al., 2003) and MV4-11 which is homozygous for the FLT3-
ITD mutation (Quentmeier et al., 2003), as well as the acute promyelocytic 
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leukaemia (APL) cell line HL-60 which is homozygous for FLT3-WT (Levis et al., 
2004), were all maintained in RPMI-1640 supplemented with 10% FBS, 1% 
penicillin/streptomycin and 2 mM l-glutamine in a humidified incubator at 37°C 
with 5% CO2. For Nox inhibition, cells were treated with Apocynin, Rac1inhibitor 
NSC23766, Bapta-AM and the flavoprotein inhibitor diphenyleneiodonium chloride 
(DPI) at the indicated concentrations and times. Cells were also treated with Src 
family inhibitor PP2 (Calbiochem, Nottingham, UK), the FLT3-ITD inhibitor 
PKC412 (Tocris, Bristol, UK), FLT3 ligand (FL) (PeproTech EC Ltd., London, UK) 
and H2O2 at the indicated concentrations for the indicated times. Dimethylsulfoxide 
(DMSO) was used as a vehicle. 
Flow Cytometric Analysis / Measurement of Intracellular ROS levels 
Flow cytometry was carried out as previously described (Naughton et al., 2009). 
Following treatments, ROS levels were determined by incubating the cells with 50 
µM of the cell-permeable fluorescent probe 2,7-dichlorodihydrofluorescein diacetate 
(H2DCFDA) (Invitrogen, Biosciences Ltd., Ireland) for 15 minutes in the dark. Cells 
were then analysed for mean fluorescent intensity of 10 000 events counted in the 
FL-1 channel on a FACSCalibur (BD Biosciences, Europe) using Cellquest Pro 
software (Becton Dickinson).  
Western Blot analysis 
Western Blotting was carried out as previously described (Naughton et al., 2009). 
Briefly, whole cell lysates were prepared by harvesting cells from culture, washing 
in PBS and solubilising in RIPA lysis buffer (50 mM Tris-HCl pH7.4, 1% NP-40, 
0.25% sodium deoxycholate, 150 mM sodium chloride, 1 mM EGTA, 1 mM sodium 
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orthovanadate, 1 mM sodium fluoride, 200 µM  4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride and cocktail protease inhibitors (Roche, Welwyn, 
Hertforshire, UK) for 30 minutes at 4°C, followed by centrifugation at 14 000 g for 
15 minutes at 4°C to remove cell debris. Protein concentrations were determined by 
Bio-Rad Protein Assay (Hemel, Hempstead, UK) and equal amounts (50 µg per 
lane) were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) 
before incubating with the appropriate antibodies. Membranes were developed using 
enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK) or the 
Odyssey Infrared Imager system and Odyssey software (version 2.1.12, Li-Cor 
Biosciences, USA). Densitometric analysis was carried out using ImageJ software 
(version 1.44, NIH, USA). 
Myeloperoxidase stain  
Cytospins were prepared using a Shandon Cytospin 2 Cytocentrifuge. MOLM-13 
cell suspensions containing 1 x 10
5
 cells were spun onto glass slides for 2 minutes at 
an Rcf of 17 x g. Cytospins were allowed to air dry for 1 hour and then fixed using 
ice cold 100% methanol for 2 minutes. Diaminobenzidine (DAB) solution consisting 
of 0.05% 3,3- DAB, 0.015% H2O2, and 0.01 M PBS was prepared and incubated 
with the cytospins for 20 minutes in the dark. Excess DAB solution was washed off 
with PBS and a counter stain of 1 µg/ml Hoescht (Thermo Fisher Scientific, Dublin, 
Ireland) was added for 1 hour and then cytospins were washed again with PBS. 
Slides were mounted with coverslips using Mowiol and dried at 37ºC for 1 hour 
before visualisation under 40X using a Leica DM LB2 microscope (Leica, Milton 
Keynes, UK). Light mode was used to visualise the DAB stain and fluorescent mode 
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was used to visualise the nuclear stain Hoescht. Whole blood sample, containing 
neutrophils, taken from a C57BL/6 mouse of age P8 was used as a positive control 
for myeloperoxidase.  
Two-Dimensional SDS-PAGE  
Samples containing 250 µg of total protein in RIPA lysis buffer were 
resuspended in 10% TCA and acetone to remove residual salts. The samples were 
incubated overnight at -20°C and then centrifuged at an Rcf of 15 000 x g for 30 
minutes (4°C). The resulting pellet was resuspended in 125 µl rehydration buffer [5 
M urea, 2 M thiourea, 2% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) (Anachem), 4% carrier ampholytes (GE Healthcare), 
1.5% 2-hydrooxyethyl disulfide (DeStreak, Sigma), and trace bromophenol blue] and 
loaded onto 7 cm pH 3-10 non linear immobilised pH gradient (IPG) strips 
(Immobiline
™
 DryStrip, GE Healthcare). The strip was allowed to passively 
rehydrate at room temperature for 16 hours. Isoelectric focusing was carried out  on 
a Protean isoelectric focusing cell (Bio-Rad) using a rapid voltage increase 
procedure: 250 V for 15 min then increased to a maximum of 4000 V within 2 hours 
and kept at 4000 V for 20000 min. After isoelectric focusing, the strips were 
subjected to two-step equilibration in equilibration buffers (6 M Urea, 0.375M Tris-
HCl pH 8.8, 2% SDS and 10% Glycerol) with 2% dithiothreitol (DTT) for the first 
step, and 2.5% iodoacetamide for the second step. The strips were then transferred 
on to the second-dimensional SDS-PAGE that was run on 12% polyacrylamide gels. 
Proteins were transferred and immunoblotted as for Western Blotting analysis. Gels 
used for spot-picking were stained with Instant Blue (Expedeon, Cambridgeshire, 
UK) for 1 hour followed by incubation in Brilliant Blue Colloidal Coomassie (0.02%  
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Colloidal Coomassie, 5% aluminium sulphate-14-18-hydrate, 10%  ethanol and 2% 
orthophosphoric acid) overnight and de-stained in 10% ethanol and 2% 
orthophosphoric acid prior to excision. Protein spots of interest were excised using 
OMX-S device (OMX GmbH, Wessling, Germany). 
Identification of Proteins by Peptide Fragment Fingerprinting (PFF) 
PFF was performed at Aberdeen Proteomics Facility, University of Aberdeen, 
Scotland. 
In gel digestion 
Proteins in the gel pieces were digested with trypsin (sequencing grade, modified; 
Promega UK, Southampton, UK) using an Investigator ProGest robotic workstation 
(Genomic Solutions Ltd., Huntingdon, UK). Briefly, proteins were reduced with 
DTT (60°C, 20 minutes), s-alkylated with iodoacetamide (25°C, 10 minutes) then 
digested with trypsin (37°C, 8 hours). The resulting tryptic peptide extract was dried 
by rotary evaporation (SC110 SpeedVac; Savant Instruments, Holbrook, NY, USA) 
and dissolved in 0.1% formic acid for LC-MS/MS analysis.  
Liquid Chromatography – Tandem Mass Spectrometry (LC-MS/MS) 
Peptide solutions were analysed using an HCTultra PTM Discovery System (Bruker 
Daltonics Ltd., Coventry, UK) coupled to an UltiMate 3000 LC System (Dionex 
(UK) Ltd., Camberley, Surrey, UK). Peptides were separated on a Monolithic 
Capillary Column (200 μm i.d. x 5 cm; Dionex) at a flow rate of 2.5 μL/minute using 
a gradient of acetonitrile (6 – 38% over 12 minutes) in 0.04% (aq.) formic acid. 
Peptide fragment mass spectra were acquired in data-dependent AutoMS (2) mode 
with a scan range of 300 – 1500 m/z, 3 averages, and up to 3 precursor ions selected 
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from the MS scan (100 – 2200 m/z). Precursors were actively excluded within a 1.0 
minute window, and all singly-charged ions were excluded. Peptide peaks were 
detected and deconvoluted automatically using DataAnalysis software (Bruker). 
Mass lists in the form of Mascot Generic Files were created automatically and used 
as the input for Mascot MS/MS Ions searches of the NCBInr database using the 
Matrix Science web server. The default search parameters used were: Enzyme = 
Trypsin;Max. missed cleavages = 1; Fixed modifications = Carbamidomethyl (C); 
Variable modifications = Oxidation (M); Peptide tolerance ± 1.5 Da; MS/MS 
tolerance ± 0.5 Da; Peptide charge = 2+and 3+; Instrument = ESI-TRAP. 
Immunofluorescence  
Glass coverslips were coated with 0.01% 70-150 kDa poly-l-lysine solution (Sigma 
Aldrich, Dublin Ireland) and UV sterilised. Cells were seeded onto coated coverslips 
at a density of 0.8 x 10
6
 cells per ml and allowed to adhere overnight. Following 24 
hour treatment, cells were fixed with 3% paraformaldehyde and permeabilised in 
PBS containing 0.2% BSA and 0.05% Saponin. Coverslips were then incubated with 
anti-Ezrin antibody (#3145, Cell Signalling Technologies, Boston, USA) at a 
dilution of 1:125 in 5% FBS/PBS for 2 hours at room temperature, washed in PBS 
three times and incubated with a secondary antibody goat anti-rabbit conjugated to 
Alexa fluor488 and nuclear stain Hoescht 1 µg/ml (Thermo Fisher Scientific, Dublin, 
Ireland) for 1 hour at room temperature. Following washes with PBS, the coverslips 
were mounted onto glass slides using Mowiol and dried overnight before imaging. 
Cells were visualised using a Leica DM LB2 microscope (Leica, Milton Keynes, 
UK). Images of the cells were acquired by Nikon Digital Sight DS-Fi1C camera 
(Nikon, Japan) using NIS-Elements software (version 3.0, Nikon, Japan).  
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Scanning Electron Microscopy 
Cells were seeded as for immunofluorescence and, following 24 hour treatment, 
were fixed in 2% glutaraldehyde in a 0.165 M PO4 buffer followed by a secondary 
fixation in osmium tetroxide (2% osmium tetroxide in 0.165 M PO4 ). Samples were 
dehydrated in ethanol and air-dried from tetramethylsilane. Samples were mounted 
on stubs using double-sided carbon tape, and sputter coated with ~28 nm layer of 
gold, using a Polaron E5150 Sputter Coating Unit, to prevent surface charging by the 
electron beam. Samples were then examined using a Jeol Scanning Electron 
Microscope (JSM-5510, Jeol Ltd., Tokyo, Japan).  
N-(biotinoyl)-N′-(iodoacetyl)ethylenediamine (BIAM)-labelling of reduced protein 
N-(biotinoyl)-N′-(iodoacetyl)ethylenediamine (BIAM) labelling of reduced protein 
was carried out as previously described (Giannoni et al., 2005). Briefly, whole cell 
lysates were prepared by harvesting cells from culture, washing in PBS and rapid 
freezing of cell pellet in liquid nitrogen. RIPA lysis buffer containing 100 µM 
BIAM(Invitrogen, Biosciences Ltd., Ireland) was also exposed to liquid nitrogen for 
20 minutes to remove oxygen. The frozen cell pellet was then solubilised in the 
BIAM-containing RIPA buffer, sonicated in a bath sonicator for three periods of 1 
minute each separated by 30 second intervals and incubated for 15 minutes at room 
temperature. Lysates were then centrifuged at an Rcf of 20 817 x g for 15 minutes at 
4°C to remove cell debris and the clarified lysate was then separated by SDS-PAGE 
and transferred to nitrocellulose membranes, to detect the reduced portion of the total 
lysate, or subjected to immunoprecipitation with Src specific antibody prior to SDS-
PAGE to detect reduced Src. In both cases the BIAM-labelled protein was detected 
with HRP-conjugated to streptavidin (HRP-SA) and ECL. 
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Immunoprecipitation 
Immunoprecipitation was carried out using the Crosslink IP Kit (Thermo Fisher 
Scientific, Dublin, Ireland) according to the manufacturers‟ instructions. Briefly, 
1mg of lysate was immunoprecipitated overnight with 10 µg of the appropriate 
antibody crosslinked to Protein A/G agarose using disuccinmidyl suberate (DSS). 
The immunocomplexes were separated by SDS-PAGE, transferred to nitrocellulose 
membrane and probed with the appropriate antibodies. 
siRNA  
For p22phox knockdown experiments, 2.5 x 10
6
 cells were transfected with 50 ng 
scrambled siRNA or 50 ng siRNA targeting p22phox (Ambion Silencer Select, 
Applied Biosystems, Warrington, U.K.). The transfection of siRNA used the Amaxa 
Nucleofactor technology with the Amaxa cell optimisation kit V (Amaxa, Cologne, 
Germany) and followed the Amaxa guidelines using program D-023 for MOLM-13 
and T-019 for HL60. Cells were lysed 24 hours post-transfection. HL60 cells were 
treated with 50 ng/ml FL for 30 minutes prior to lysis. 
Chemotaxis assay 
The chemotaxis assay was carried out as previously described by Zhou et al. 
(2010b), in 24-transwell chambers (Corning Costar, Cambridge, MA, USA). Briefly, 
cells (100 µl, 1 x 10
6 
cells ml
-1
) were treated as indicated in RPMI 1640 with FBS for 
20 hours, serum starved in the same treatments for the final 4 hours of the 24 hour 
incubation and then added to the upper chamber which was separated from the lower 
well by a 5 µm pore-size polycarbonate membrane. RPMI 1640 containing 10% FBS 
was placed in the lower wells (600 µl) as a chemoattractant. Cells were allowed to 
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migrate for 4 hours at 37°C and 5% CO2 atmosphere. The transwell was then fixed 
with methanol and stained for 5 minutes with 0.1% crystal violet. Cells were counted 
in five randomly selected fields per well under 20 X magnification on a Nikon 
Eclipse TS100 (Nikon, Japan). 
Statistical analysis 
Statistical analysis was performed using Student‟s t-test to evaluate the difference 
between experimental and control groups. Significance was defined at the level of 
P<0.05. 
Kinexus
TM 
Phosphatase Expression Screen 
20 x 10
6 
cells were centrifuged at an Rcf of 500 x g for 2 minutes at 4°C in swinging 
bucket benchtop centrifuge. Media was removed and cell pellet was resuspended 
gently in ice-cold PBS followed by centrifugation as above. This was repeated to 
ensure complete removal of serum. Pellet was then homogenised in 200 μl of ice-
cold lysis buffer (20 mM 3-(N-morpholino)propanesulfonic acid, 2 mM ethylene 
glycol tetraacetic acid, 5 mM ethylenediaminetetraacetic acid, 30 mM sodium 
fluoride, 60 mM β-glycerophosphate pH 7.2, 20 mM sodium pyrophosphate, 1 mM 
sodium orthovanadate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 5 
µM pepstatin A, cocktail protease inhibitors [Roche, Welwyn, Hertforshire, UK], 1 
mM DTT, distilled water). Sample was sonicated using a water bath sonicator four 
times for 10 seconds each time with 10-15 second intervals on ice to rupture the cells 
and to shear nuclear DNA. The homogenate was then centrifuged at an Rcf of 90 000 
x g for 30 minutes at 4°C in a Beckman Table Top TL-100 ultracentrifuge. The 
supernatant fraction was removed and the protein concentration was determined 
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using the Bradford Protein Assay (Bio-Rad, Hemel, Hempstead, UK) with bovine 
serum albumin used as a protein standard. The Kinexus
TM
 Protein Phosphatase 
Screening Service (KPPS 1.2)  to determine the expression level of 30 phosphatases 
requires 500 μg of protein and this was diluted to 1 mg/ml in 4X SDS-PAGE sample 
buffer (50% glycerol, 125 mM Tris-HCl pH 6.8, 4% SDS, 0.08% Bromophenol blue, 
5% β-mercaptoethanol, distilled water). The samples were then boiled for 4 minutes 
at 95°C and shipped in a 1.5 ml Eppendorf screw-cap vial to Kinetworks Screening 
Services, Kinexus
TM
 Bioinformatics Corporation, Vancouver, CA. KPPS 1.2 then 
utilised multi-immunoblotting, which generated a unique identification pattern for 
each sample analysed and provided information about the quantitative expression 
level for each phosphatase detected. The identification and detection of each target 
protein was based on its immunoreactivity and apparent molecular mass. 
BIAM-labelling and depletion prior to Kinexus
TM 
Phosphatase Expression Screen 
To determine the effect of PKC412 on phosphatase oxidation, BIAM-labelling was 
carried out as previously described in section titled „N-(biotinoyl)-N′-
(iodoacetyl)ethylenediamine (BIAM)-labelling of reduced protein‟, samples were 
then sonicated and ultracentrifuged as described in section titled „KinexusTM 
Phosphatase Expression Screen‟. The supernatant fraction was removed and the 
protein concentration was determined using the Bradford Protein Assay (Bio-Rad, 
Hemel, Hempstead, UK) with bovine serum albumin used as a protein standard. 30 
µg of total lysate was reserved at this point for comparison. 2 mg of lysate was 
incubated overnight in spin columns (Thermo Fisher Scientific, Dublin, Ireland) 
containing streptavidin-sepharose bead conjugate to bind the biotin-labelled portion 
of lysate. Flow-through was collected and designated biotin-depleted, and the biotin-
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labelled portion was eluted. Biotin-labelled total lysate, biotin-labelled flow-through 
and biotin-depleted samples were separated using 12% SDS-PAGE, and Coomassie-
stained to confirm changes in protein quantity. Replicate gels were transferred to 
nitrocellulose membranes and probed for biotin using HRP-conjugated streptavidin 
(HRP-SA) and ECL, with Ponceau used to confirm loading. When depletion was 
confirmed, depleted samples were diluted in 4X SDS-PAGE sample buffer as 
previously described, boiled for 4 minutes at 95°C and shipped in a 1.5 ml 
Eppendorf screw-cap vial to Kinetworks Screening Services, Kinexus
TM
 
Bioinformatics Corporation, Vancouver, CA. 
Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) 
Following a 24 hour treatment 5x 10
6
 cells were harvested from each sample. Media 
was removed and total cellular RNA was isolated using the Isolate RNA mini kit 
(Bioline Ltd, UK), according to the manufacturer‟s protocol for eukaryotic cells.  
The concentration of RNA in each sample was determined in triplicate by 
spectrophotometric analysis using a Biophotometer (Amersham Biosciences). 500 ng 
of RNA was then run on a 1% agarose gel to check integrity. RNA was treated to 
remove any contaminating DNA using DNase 1 amplification grade kit (Sigma-
Aldrich) according to manufacturers‟ instructions. 
cDNA was then synthesised from 2 µg RNA using 1x Moloney Murine Leukaemia 
Virus Reverse Transcriptase (M-MLV RT) buffer, 25 mM MgCl2, 40 U/µl RNAse 
inhibitor, 200 U/µl M-MLV Reverse Transcriptase, 50 mM oligo dTs and 10 mM 
dNTPs (all from Promega, UK) or the equivalent volume of RNAse-free water for 
the non-reverse transcriptase control (NRT). The final volume of each replicate was 
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made up to 20 µl with RNAse free water and the reaction was run at 42ºC for 1 hour, 
99ºC for 10 minutes, followed by overnight storage at 4ºC.  
The real-time reverse transcriptase PCR reaction was used to amplify cDNA from 4 
genes of interest; PTPN1/SHP-1, PP2Cα, PP6C and PTPN6/PTP1B, with GAPDH 
as a housekeeping gene for normalisation. Three technical replicates and one NRT 
control were used per sample for each gene. The qRT-PCR reaction was carried out 
on a DNA Engine Opticon 2.0 (MJ Research Inc., Waltham, USA), using Quantittect 
SYBR Green Sensimix kit and Quantitect Primer Assays (Qiagen, West Sussex, 
UK).  Qiagen pre-designed primers were used for human PTPN1/SHP-1 
(Hs_PTPN1_2_SG QT01006978), PP2Cα (Hs_PPP2CA_1_SG QT00085603), PP6C 
(Hs_PPP6C_1_SG QT00083433), PTPN6/PTP1B (Hs_PTPN6_1_SG QT00011725) 
and GAPDH (Hs_GAPDH_2_SG QT01192646).  Briefly, 50 ng cDNA template 
was combined with 10 µl of 20X SYBR Green Sensimix and 2 µl 10X primer in 20 
µl total reaction volume in a 96 well plate (Bio-Rad) and the PCR reaction was 
carried out as follows: 95ºC for 15 minutes followed by 44 cycles of 94ºC for 15 
seconds, 56ºC for 30 minutes and 72ºC for 30 minutes. Relative mRNA levels for 
each gene were calculated from relative C(t) values and normalised against GAPDH.  
Ubiquitination assay 
10 x10
6
MOLM-13 cells were treated with 5 µM proteasome inhibitor Lactacystin for 
24 hours prior to lysis to prevent the degradation of ubiquitinated proteins. Cells 
were lysed in 1% SDS lysis buffer containing 10 mM N-Ethylmaleimide (NEM), a 
de-ubiquitinating enzyme inhibitor and vortexed, boiled for 10 minutes and 
sonicated for 3-4 seconds. Lysates were clarified by centrifugation at an Rcf  of 20 
817 g at 4°C for 10 minutes. The supernatants were transferred to a cold eppendorf 
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tube and protein concentration was determined using the Bradford reagent. 1 mg of 
lysate was immunoprecipitated overnight using Crosslink IP Kit (Thermo Fisher 
Scientific, Dublin, Ireland) according to the manufacturers‟ instructions, with 10 µg 
of SHP-1 antibody crosslinked to Protein A/G agarose using DSS. 10 mM NEM was 
included at all washing steps. The immunocomplexes were separated by 10% SDS-
PAGE, transferred to nitrocellulose membrane, which was pre-soaked in transfer 
buffer containing 20% methanol and transferred in the same buffer.  Membranes 
were autoclaved for 15 minutes prior to blocking to expose further ubiquitin moieties 
for detection, blocked in 5% BSA and probed with anti-ubiquitin and anti-SHP-1 
antibodies.  
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Chapter 3 
 
Regulation of tyrosine phosphorylation by Nox-derived 
reactive oxygen species in a FLT3-ITD cell line 
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Abstract 
The emergence of evidence implicating reactive oxygen species as signalling 
mediators in their own right has been accompanied by the use of inhibitors of the 
NADPH oxidase enzymes in order to determine the functional significance of redox-
signalling.  The purpose of this chapter was to identify downstream targets of 
NADPH oxidase-derived reactive oxygen species signalling in AML cells which 
contain the constitutively active form of the receptor tyrosine kinase FLT3. This was 
achieved by performing a proteomic analysis utilising two-dimensional 
phosphotyrosine immunoblotting. The majority of the targets identified were 
cytoskeletal-associated proteins including Ezrin, a known regulator of the 
cytoskeleton, which was selected for further examination. The study demonstrated 
that inhibition of NADPH oxidase enzymes, using diphenyleneiodonium chloride in 
the AML cell line MOLM-13, resulted in a decrease in Ezrin tyrosine 
phosphorylation.  
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Introduction 
The role played by tyrosine phosphorylation cascades in intracellular signal 
transduction, cannot be overstated. This ancient form of relaying information is 
thought to have evolved just before the appearance of multicellular organisms, about 
600 million years ago  (Pincus et al., 2008) , and proved so beneficial and efficient in 
evolutionary terms that it formed the basis for a multitude of complex diverging and 
converging signalling networks underlying every aspect of cellular function (Mayer, 
2008). From gene expression, differentiation, apoptosis, proliferation and bio-
synthesis, there is barely a pathway or area of cellular activity which does not utilise 
this mechanism to some extent.  
Although crucial to cellular functions, the amount of tyrosine 
phosphorylation occurring in the cell is actually relatively small compared to the 
frequency of threonine and serine phosphorylation. Chou et al. (2010) estimates that 
approximately one third of all cellular proteins become phosphorylated at a serine or 
threonine residue, compared with just 0.05-0.1% becoming tyrosine phosphorylated. 
Serine and threonine phosphorylation are important post-translational modifications 
necessary for the functioning of many proteins and, as Lim and Pawson (2010) point 
out, the emergence of serine/threonine kinases in very primitive eukaryotic single-
celled organisms preceded that of TKs. However, the evolution of PTPs from a dual- 
specificity phosphatase ancestor (Alonso et al., 2004) also preceded the appearance 
of TKs, highlighting the necessity of maintaining tight control over the 
phosphorylation of  functionally important tyrosine residues which were 
occasionally phosphorylated by some serine/threonine kinases (Lim and Pawson, 
2010).  
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The requirement for close regulation of tyrosine phosphorylation becomes 
apparent when one considers the degree to which this post-translational modification 
is utilised as a signalling mechanism within the cell. Many cell activities require 
tyrosine phosphorylation, including but not limited to proliferation, host immune 
defence, survival, apoptosis, cell cycle, senescence, gene expression, differentiation, 
metabolism, motility, adhesion and hormone response (Hunter, 2009). De-regulation 
of these core cellular processes can disrupt the correct functioning of the cell, with 
especially detrimental, oncogenic consequences in the case of aberrant cellular p-
Tyr-mediated survival signalling within multi-celled organisms.  
Tyrosine phosphorylation is a dynamic circuit subject to the activity of TKs, 
which phosphorylate substrates at tyrosine residues, and PTPs which negatively 
regulate the phosphorylation signal by removing the phosphate group. The regulation 
of these two families of enzymes is crucial to maintain their synergy, which in turn 
affects the integrity, duration and effectiveness of the signal. Regulation at the level 
of gene expression is crucial, as can be inferred from the many tumour types which 
display gene amplification or de-regulated transcription of proto-oncogenic TKs and 
receptor TKs (RTKs)  (Little et al., 2012;  Mimae et al., 2012), as well as tumours in 
which crucial tumour suppressive PTP genes have been deleted, silenced or 
otherwise transcriptionally repressed (Julien et al., 2011;Tonks, 2006).  
In addition to the regulation of gene expression, post-translational 
modifications of both TKs and PTPs allow for rapid, efficient responses at the level 
of protein activity and turnover. Modifications such as ubiquitination (Hicke, 2001)   
and sumolyation (Yang and Sharrocks, 2006), as well as proteolytic cleavage 
(Hunter, 2009) and dimerisation (Julien et al., 2011) affect both RTKs and PTPs. 
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However, one of the most common mechanisms for TK and PTP regulation 
is phosphorylation. TKs and PTPs are positively and negatively regulated by 
phosphorylation themselves, the nature of the phosphorylated residue (serine, 
threonine or tyrosine) and its effect (i.e. inhibitory or stimulatory) is specific to the 
individual enzyme. An example of the complex nature of phosphorylation as a 
regulatory mechanism can be observed in the activation of Src kinase which requires 
both the removal of an inhibitory C-terminal tyrosine phosphorylation at Y527 by a 
phosphatase as well as autophosphorylation at Y416 before it can become active 
(Roskoski, 2005). As well as these phosphorylation events, recent evidence suggests 
that Src also requires oxidative activation, as will be discussed in more detail in 
Chapter 4.  
In addition to phosphorylation, oxidation of PTPs is a very common mode of 
regulating these enzymes,  the dual processes of phosphorylation and oxidation are 
often co-ordinated for fine-tuning of PTP activity during p-Tyr signalling which 
involves the production of ROS (Chiarugi and Buricchi, 2007). It can be said that the 
PTP family are the prototypic intermediary target in redox signalling. At 
physiological pH, the low pKa of a crucial cysteine residue in the highly conserved 
active site motif, C(X)5R, of these proteins ensures that they are extremely 
vulnerable to oxidation, which disrupts the nucleophilic potential of the active site 
and renders the enzyme inactive (Denu and Tanner, 1998; Leslie et al., 2004).  
Oxidation results in the formation of sulfenic acid (SOH) which, on the 
occasion of close proximity of another cysteine, can form a disulfide bond (S-S).  
The oxidation of cysteine to sulfenic acid is reversible and sulfenic-acid or disulfide- 
containing PTPs can be reduced by Trx, Grx, or GSH (Denu and Tanner, 1998), 
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allowing for a dynamic switch in PTP activity to facilitate the propagation of a signal 
accompanied by oxidant production. The duration or intensity of the signal can also 
be fine-tuned by the degree of PTP oxidation. At higher ROS concentrations, further 
oxidation of the sulfenic acid intermediate results in the formation of the more stable 
sulfinic (SO2H) or sulfonic (SO3H) acids. These hyper-oxidised PTPs are 
permanently inactivated, thus allowing for an increased period of signalling 
uninterrupted by phosphatase activity (Ray et al., 2012).  
Under normal physiological situations, PTPs are regenerated by endogenous 
antioxidants and the ROS level is carefully regulated to ensure that hyper-oxidation 
of PTPs is kept to minimum so that PTP inhibition by ROS serves to facilitate the 
necessary and temporary passage of a signal (Leslie et al., 2004).  
In conditions of de-regulated and constitutively active TK and RTK 
signalling involving ROS production, the phenomenon of redox regulation of PTPs 
can compound any pro-survival signalling effects of the constitutive phosphorylation 
and contribute to the development of an oncogenic phenotype. By inhibiting, either 
transiently or permanently, the negative regulators of the pathway, oxidants as 
signalling mediators shift the balance further in favour of the proliferative and anti-
apoptotic message which is being propagated continuously by the phosphorylation 
cascade. The down regulation of antioxidant enzymes in tumourigenesis, as 
discussed earlier, can exacerbate this situation by removing the means of transiently-
inhibited PTP regeneration and leading to the formation of an oxidative environment 
within the cell, not conducive to PTP activity. The subject of PTP regulation both at 
the level of gene transcription and post-translational modification will be discussed 
further in Chapter 5.  
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As an oncogenic RTK, FLT3-ITD can be expected to drive de-regulated 
tyrosine phosphorylation within the AML cell, through a variety of pathways which 
it stimulates. It has also been shown that the FLT3-ITD signalling pathway invokes 
the production of ROS (Sallmyr et al., 2008a). Though the source of these ROS is 
not yet confirmed, it is suspected to be Nox-derived. In a situation analogous to that 
of Bcr-Abl-positive CML (Naughton et al., 2009), it is likely that these ROS 
contribute in some way to the oncogenic phenotype of the AML cell, via oxidation 
of target proteins. Thus, the focus of this study is on the targets of redox regulation 
by Nox in an AML cell driven by the FLT3-ITD mutated receptor. It was decided 
to focus initially on changes in tyrosine phosphorylation in response to Nox 
signalling because of the prominent role of tyrosine phosphorylation in the FLT3-
ITD context and the vulnerability of this signalling device to redox regulation. Also 
taken into consideration at this point was the relative scarcity of p-Tyr 
modifications in comparison to phosphothreonine (p-Thr) and phosphoserine (p-
Ser), which was seen to be advantageous in a proposed search for meaningful 
protein targets against a background of phosphorylation “noise”.  
To identify p-Tyr changes downstream of Nox, an effective inhibitor of Nox 
activity is required, as is a means of detecting p-Tyr residues. The latter requirement 
is easily met by using a pan p-Tyr antibody to probe for proteins with 
phosphorylated tyrosine residues within a whole cell lysate. Antibodies such as this 
are broad in terms of specificity and will bind p-Tyr regardless of the surrounding 
amino acid sequence, ensuring an even coverage of the proteome.  
The choice of an effective method of inhibiting Nox, however, poses more 
problems. With regard to the available Nox inhibitors, there is much difference in 
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opinion with regard to the most specific and efficient, and the choice is also limited 
by suitability to a particular cell type as well as the nature of the downstream effect 
of interest. Some compounds branded as Nox inhibitors, appear to function more 
preferentially as an anti-oxidant or free-radical scavenger (Heumuller et al., 2008), 
rather than interacting with the Nox enzymes themselves, while for others the 
inhibition of Nox seems to be almost a by-product of the more general mode of 
action of the compound as a calcium chelator, in the case of Bapta-AM, or as a Rac-
1 inhibitor. At the time of writing, several new compounds marketed as Nox 
inhibitors are emerging and becoming more visible in the literature (Cifuentes-
Pagano et al., 2012; Kim et al., 2012)   such as VAS 2870 (Ten Freyhaus et al., 
2006), GKT136901 (Page P et al., 2008), ML171 (Gianni et al., 2010), ebselen and 
its analogs (Smith et al., 2012). It is possible that one or several of these, will be 
shown to demonstrate definitive, specific Nox inhibition. However, with regard to 
this study, it can be concluded that, after much analysis, the most suitable Nox 
inhibitor was selected for this cell type from the limited range available at the time. 
The importance of this selection and the consideration it entailed cannot be 
overlooked, as this initial exploratory step into tyrosine phosphorylation influenced 
by Nox activity would come to form the basis for the entire study. 
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Results 
Expression of Nox isoforms, regulatory and organiser subunits in MOLM-13 
cells 
To investigate Nox-derived ROS targets in FLT3-ITD driven AML, we used an 
AML cell line which is heterozygous for the FLT3-ITD mutation, MOLM-13 
(Quentmeier et al., 2003). This cell line is classified as AML-M5a and was 
established at a period of relapse from the peripheral blood of a 20 year old male 
patient suffering from acute monocytic leukaemia which had originally developed 
from MDS (Matsuo et al., 1997). The selection of a cell line heterozygous for the 
FLT3-ITD mutation rather than a cell line which carries two FLT3-ITD alleles, such 
as MV4-11 (Quentmeier et al., 2003), was made based on the requirement for a cell 
line which would respond to stimulation with the FLT3 ligand (FL), i.e. one which 
contains a copy of the wild type FLT3 receptor and in which the FLT3 signalling 
pathways are not saturated by constitutive FLT3-ITD signalling driven by bi-allelic 
expression of the mutant. 
MOLM-13 cells were examined, using western blotting, for expression of the 
individual Nox isoforms as well as Nox regulatory and organiser subunits. This was 
carried out to inform future decisions regarding choices of Nox inhibitors and siRNA 
targeting. The western blotting data revealed that MOLM-13 cells express Nox1, 2, 
4, 5, p22phox, p47 phox and p67phox (Figure 4). There was no signal detected for 
Nox 3, which is known have a very limited expression pattern, primarily in the 
spleen, foetal kidney, liver, lung and inner ear (Cheng et al., 2001). Additionally, 
there was no expression of Duox 1 or Duox 2 detected, but these proteins are thought 
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to be expressed pre-dominantly in the thyroid, salivary gland and gastrointestinal 
tract (De Deken et al., 2000). 
 
 
 
 
 
Figure 4.  Nox expression in MOLM-13 cells  
Western blot analysis of Nox isoforms 1, 2, 4 and 5, as well as transmembrane 
protein p22phox, organiser subunit p47phox and activator subunit p67phox, as 
expressed in the FLT3-ITD cell line MOLM-13. Nox 3 and Duox 1 and 2 were not 
detected.  β-Actin is shown as a loading control.  
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Incubation of MOLM-13 cells with Nox inhibitor Apocynin does not reduce 
ROS and p-Tyr levels  
Ideally, in order to determine the effects of Nox activity, the individual Nox 
subunits would be knocked down using short interfering RNA (siRNA) and the 
effects on the p-Tyr levels of the cell observed, allowing attribution of specific 
downstream  targets to specific Nox. However, myeloid leukaemia cells have been 
widely classified as „difficult to transfect‟ (Esendagli et al., 2009; Marit et al., 2000; 
Roddie et al., 2000; Schakowski et al., 2004; Uchida et al., 2002), meaning that they 
are not amenable to the conventional lipid or amine-based  reagents used as a 
vehicles for transfection. Instead, electroporation is often employed to deliver the 
nucleic acid into the cell (Schakowski et al., 2004). This relatively harsh procedure is 
accompanied by a decrease in cell viability which creates problems for subsequent 
assays using the transfected cells (Crawley et al., 1997). In addition to this 
drawback, the nature of the nucleic acid itself also causes difficulties for efficient 
transfection. The introduction of double stranded nucleic acids into macrophage-
derived leukaemic cells, whose normal physiological role involves the phagocytosis 
of viral nucleic acids, prompts the haematopoietic interferon-inducible nuclear 
protein (Hin) 200 family of proteins to instigate a pro-apoptotic caspase cascade 
(Roberts et al., 2009), again reducing the amount of viable transfected cells available 
for subsequent functional experiments.  
Therefore, it was decided that the best course of action for the initial 
exploratory experiments into Nox activity, because of the hurdles presented by 
transfection of leukaemic cells, would be to use a chemical rather than genetic 
method of Nox inhibition. 
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The first Nox inhibitor which was investigated for its suitability was 
Apocynin. Named after the plant from which it was first isolated, Apocynum 
cannabinum, the methoxy-substituted catechol also known as acetovanillon, has 
been widely used to treat inflammatory conditions such as asthma, fever and 
rheumatism (Palmen et al., 1995). Subsequent to its pharmacological isolation, the 
mode of action of Apocynin was discovered to be via inhibition of  production by 
Nox (Hart et al., 1990). This prompted the use of Apocynin in a wide range of 
studies into Nox activity (Gill and Wilcox, 2006; Stolk et al., 1994; Williams and 
Griendling, 2007), as well as some controversy over the precise molecular 
mechanism by which Apocynin inhibits the  burst by Nox. Some literature points to 
a role for Apocynin as a scavenger of free radicals and attribute its ROS-reducing 
effects to its antioxidant properties rather than any direct interaction with Nox 
enzymes (Heumuller et al., 2008). Other studies suggest that it functions as an 
intracellular inhibitor of Nox holoenzyme assembly (Stolk et al., 1994), while 
additional studies question the ability of Apocynin to inhibit Nox in systems other 
than phagocytic cells (Vejrazka et al., 2005).  
As MOLM-13 cells are monocyte-derived, it was assumed that Apocynin 
would inhibit Nox activity but fluorescence assisted cytometry (FACS), using the 
H2DCFDA probe to detect oxidants, demonstrated no decrease in ROS levels in 
these cells upon treatment with increasing concentrations of Apocynin (Figure 5A). 
In addition to this, western blot analysis of whole MOLM-13 cell lysates, probed 
with a pan p-Tyr antibody showed no change in p-Tyr levels in MOLM-13 cells 
upon treatment with Apocynin at increasing concentrations (Figure 5B).  
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Figure 5. Effects of Nox inhibitor Apocynin on the ROS and p-Tyr levels of 
MOLM-13 cells. A) Intracellular ROS levels measured by relative DCF 
fluorescence (FL1-H) in untreated MOLM-13 cells overlaid with cells treated with 
the DMSO vehicle only or 1, 2, 3 or 4 mM Nox inhibitor Apocynin, for 24 hours. B) 
Western blot analysis of the p-Tyr profile of untreated MOLM-13 cells, cells treated 
with the DMSO vehicle only or with 1, 2, 3 or 4 mM Apocynin for 24 hours. β-Actin 
is shown as a loading control.  
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MOLM-13 cells do not express the Myeloperoxidase enzyme necessary for 
activation of Apocynin 
It has been previously demonstrated that the monomeric form of Apocynin 
requires oxidative activation by myeloperoxidase (MPO) before it can form active 
Apocynin dimers (Ximenes et al., 2007). MPO is a haemo-peroxidase found 
abundantly in the cytoplasmic granules of neutrophils, which when activated use the 
enzyme to produce microbiocidal hypochlorous acid. Circulating monocytes and 
macrophages have been shown to produce MPO (Loria et al., 2008), however MPO-
deficient monocytes and macrophages have also been observed in patients who 
suffer from hereditary MPO deficiency or acquired MPO deficiency (Locksley et al., 
1983), the latter frequently occurring as a result of AML, CML and MDS (Lanza, 
1998). In addition to this, MOLM-13 cells, although of the myelomonocytic lineage, 
have clearly deviated from normal development pathway of this lineage and so 
cannot be assumed to express the same profile of enzymes as would be produced by 
normal monocytes. It was hypothesised at this point that the failure of Apocynin to 
decrease the ROS levels of MOLM-13 cells was due to an absence of the MPO 
enzyme. This was confirmed by a MPO histochemical stain (Figure 6), which used 
diaminobenzidine (DAB) as a target for H2O2 in the presence of MPO. The oxidation 
of DAB resulted in a brown chromogenic product visible in the control whole blood 
sample (Figure 6A), but the addition of DAB failed to elicit any colour change in the 
MOLM-13 cell sample (Figure 6B). This effectively eliminated Apocynin from the 
category of Nox inhibitors suitable for use our system.  
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Figure 6. Myeloperoxidase stain performed on MOLM-13 cells  
3,3'-Diaminobenzidine (DAB)-oxidation  reaction for the detection of 
myeloperoxidase in cytospin preparations of A)  whole blood sample, containing 
neutrophils indicated with arrows, taken from a C57BL/6 mouse of age P8 and 
imaged  using a light microscope,  B) MOLM-13 cells, counterstained with 
fluorescent  nuclear probe Dapi and  imaged under a fluorescent microscope i) and 
light microscope ii), with a merged image iii) to confirm  presence of cells.  
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Incubation of MOLM-13 cells with calcium chelator Bapta-AM causes a slight 
decrease in ROS but does not affect p-Tyr levels 
Another compound which has been used as a Nox inhibitor, is the calcium 
chelator 1,2- bis(o-aminophenoxy)ethane-N,N,N,N-tetraacetic acid (Bapta-AM) 
(Reistad and Mariussen, 2005; Yu et al., 2005). The mode of action of this 
compound dictates its role as an inhibitor of Ca
2+ 
-dependent Nox only, that is Nox 5 
and the Duox. By determining the effect of Bapta-AM on p-Tyr levels, it would be 
possible to either narrow down the focus of this study to Nox 5 or rule it out as being 
involved in p-Tyr signalling in this system. Indeed the treatment of MOLM-13 cells 
with Bapta-AM resulted in a decrease in ROS levels (Figure 7A), but did not have a 
negative effect on the p-Tyr profile (Figure 7B). The decrease in ROS seemed to 
plateau after 1 µM and did not further decrease with increasing concentrations of 
Bapta-AM, suggesting that the Ca
2+ 
-dependent Nox was fully inhibited at 1 µM. 
Western blot analysis showed that Bapta-AM slightly increased the level of p-Tyr in 
the cells, an effect attributable to the broad spectrum activity of the compound and 
its possible inhibitory effect on Ca
2+ 
-dependent phosphatases  (Maloney et al., 
1999). At this point it was concluded that Bapta-AM inhibits Nox 5 in MOLM-13 
cells, and either this isoform is not involved in p-Tyr signalling or the broad 
targeting of Bapta-AM is masking any p-Tyr decrease which is occurring due to Nox 
5 inhibition. Both possible explanations prompted us to cease using Bapta-AM as a 
Nox inhibitor for the purposes of this study.  
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Figure 7. Effects of calcium chelator Bapta-AM on the ROS and p-Tyr levels of 
MOLM-13 cells.  A) Intracellular ROS levels measured by relative DCF 
fluorescence (FL1-H) in untreated MOLM-13 cells overlaid with cells treated with 
the DMSO vehicle only or 1, 5 or 10 µM Bapta-AM, for 24 hours. B) Western blot 
analysis of the p-Tyr profile of untreated MOLM-13 cells, cells treated with the 
DMSO vehicle only or with 1, 5, 10 µM Bapta-AM for 24 hours. β-Actin is shown 
as a loading control. 
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Incubation of MOLM-13 cells with an inhibitor of Rac 1 GTPase does not result 
in a decrease in p-Tyr or ROS levels 
The requirement of Rac 1-GTP for activation of Nox 1, 2 and possibly 3 and 
4, provides an opportunity for effective inhibition of the activity of these Nox 
through inhibition of Rac 1. N6-[2-[[4-(diethylamino)-1-methylbutyl]amino]-6-
methyl-4-pyrimidinyl]-2-methyl-4,6-quinolinediamine,trihydrochloride (NSC23766) 
inhibits Rac 1 by impairing its interaction with Rac-specific guanine nucleotide 
exchange factors (GEFs) TrioN and Tiam1 (Gao et al., 2004). GEFs regulate the 
availability of Rac 1-GTP by substituting GTP for the GDP which is bound to Rac 1 
(Ugolev et al., 2008). The obvious pleiotrophic effects of inhibiting a molecule such 
as Rac 1, with its role as central node in a variety of signalling pathways   (Pai et al., 
2010)  have not prevented Rac 1 inhibitors such as NSC23766 from being widely 
used to implicate Nox activity in a range of systems (Gao et al., 2004; Godfrey et al., 
2012). However, incubation of MOLM-13 cells with increasing concentrations of 
NSC23766 failed to reduce the levels of ROS being produced (Figure 8A), similarly 
there was no decrease in p-Tyr levels but instead a slight increase, likely due a stress 
response within the cell upon inhibition of such a crucial molecule (Figure 8B). The 
lack of any changes in cellular ROS suggests that the inhibitor is not effectively 
inhibiting Nox activity. There is some ambiguity in the literature with regard to the 
Rac isoform capable of activating Nox in haematopoietic systems. While some 
studies propose that the ubiquitous Rac 1 is the pre-dominant isoform associated 
with Nox in monocytic cells (Zhao et al., 2003) others maintain that Rac 2 is solely 
responsible for Nox activation in haematopoietic cells (Hordijk, 2006). Further 
evidence points to the importance of the Rac effector domain, which is 100% 
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homologous between Rac 1 and Rac  2, in the Rac-p67phox interaction and cites this 
to suggests a redundancy between the two isoforms (Lapouge et al., 2000; Kwong et 
al., 1995) .This would explain the failure of a Rac 1 inhibitor to block Nox activity 
in cells which also express Rac 2.      
MOLM-13 cells express Rac 1 and Rac 2  
Indeed, western blot analysis of MOLM-13 cells, as well as another FLT3-
ITD AML cell line MV4-11 showed that both Rac 1 and Rac 2 isoforms are highly 
expressed in these cells (Figure 9), providing evidence that some element of 
redundancy may account for the lack of effectiveness of the Rac 1 inhibitor. HeLa 
cells were used as both a positive control for Rac 1 expression (Burnham et al., 
2007) and a negative control for Rac 2 expression (Hordijk, 2006).  
Nox inhibitor DPI causes a decrease in ROS and p-Tyr levels in MOLM-13 cells 
 Perhaps the most commonly used Nox inhibitor is diphenyleneiodonium 
chloride (DPI) (Cifuentes-Pagano et al., 2012). DPI operates as a non-competitive 
inhibitor of flavin-containing enzymes, such as Nox, by abstracting an electron from 
the nucleophilic FAD group and generating a phenylated adduct which prevents 
electron transfer to the flavin site (O'Donnell et al., 1993). While Bapta-AM or a Rac 
1 inhibitor are thought to selectively inhibit specific Nox isoforms, the mode of 
action of DPI means that it is effective against all Nox and Duox family members, 
providing a broad basis from which to begin examining general Nox activity. 
Treatment of MOLM-13 cells with increasing concentrations of DPI for 24 hours 
resulted in a dose-dependent decrease in ROS (Figure 10A).  
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Figure 8. Effects of the Rac1 inhibitor NSC23766 on the ROS and p-Tyr levels 
of MOLM-13 cells.  A) Intracellular ROS levels measured by relative DCF 
fluorescence (FL1-H) in MOLM-13 cells treated with the DMSO vehicle only and 
overlaid with cells treated with 200 or 400 µM NSC23766, for 24 hours. B) Western 
blot analysis of the p-Tyr profile of untreated MOLM-13 cells, cells treated with the 
DMSO vehicle only or with 200 or 400 µM NSC23766 for 24 hours. β-Actin is 
shown as a loading control. 
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Figure 9. Rac 1 and Rac 2 expression in AML cell lines MOLM-13 and MV4-11 
Western blot analysis of Rac 1 GTPase and Rac 2 GTPase in the AML cell lines 
MOLM-13 and MV4-11. The HeLa cell line is shown as positive control for the 
expression of Rac 1 GTPase and as a negative control for Rac 2 GTPase.  β-Actin is 
shown as a loading control.  
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Although the greatest decrease was observed with 50 µM DPI, it was decided not to 
continue with this dose after Trypan Blue staining revealed a significant decrease in 
viability with this concentration of the compound, which was not observed for doses 
of 20 µM DPI and lower (Figure 10C). A concurrent decrease in p-Tyr occurred with 
increasing concentrations of DPI (Figure 10B) which was quantified by densitometry 
(Figure 10D).  
To ensure that these effects on tyrosine phosphorylation were not unique to the 
MOLM-13 cells, the MV4-11 cell line was treated with 20 µM DPI for 24 hours, 
which resulted in a similar decrease in ROS (Figure 11A) and in p-Tyr (Figure 11B). 
A dose of 20 µM was selected to progress with at this point, because of the decrease 
in p-Tyr and ROS observed without the viability of the cells becoming significantly 
compromised. A timecourse confirmed that 20 µM DPI gradually reduced both the 
ROS and p-Tyr levels from 1 to 24 hours (Figure 12A, 12B). To further confirm that 
DPI was indeed affecting the redox state of the cell, BIAM-labelling of MOLM-13 
whole cell lysate was used to show that treatment of the cells with DPI was altering 
the amount of reduced proteins within the cell (Figure 12C). 
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Figure 10. The effects of the Nox inhibitor DPI on the ROS, viability and p-Tyr 
levels of MOLM-13 cells.  A) Intracellular ROS levels measured by DCF 
fluorescence (FL1-H) in untreated MOLM-13 cells overlaid with cells treated with 
the DMSO vehicle only or 5, 20 or 50 µM Nox inhibitor DPI, for 24 hours. B) 
Western blot analysis of the p-Tyr profile of MOLM-13 cells treated with 5, 10 or 20 
µM DPI for 24 hours. β-Actin is shown as a loading control. C) Histogram 
represents the viability of MOLM-13 cells after 24 hour incubation with 5, 10, 20 or 
50 µM DPI as determined by Trypan Blue staining. Statistical analysis was 
performed using Student‟s t-test to evaluate the difference between untreated and 
treated samples. Significance was defined at the level of P<0.05. D) Histogram 
represents the densitometric analysis carried out the p-Tyr western blot profiles of 
three individual biological replicates of MOLM-13 cells treated with 5, 10 or 20 µM 
DPI or with the DMSO vehicle only for 24 hours. Statistical analysis was performed 
using Student‟s t-test to evaluate the difference between untreated and treated 
samples for each of three p-Tyr bands of 52, 38 and 31 kDa in size.  
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Figure 10. The effects of the Nox inhibitor DPI on the ROS, viability and p-Tyr 
levels of MOLM-13 cells (legend on facing page). 
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Figure 11. Effects of the Nox inhibitor DPI on the ROS and p-Tyr levels of 
MV4-11 cells.  A) Intracellular ROS levels measured by relative DCF fluorescence 
(FL1-H) in MV4-11 cells treated with the DMSO vehicle only and overlaid with 
cells treated with 20 µM DPI, for 24 hours. B) Western blot analysis of the p-Tyr 
profile of untreated MV4-11 cells, cells treated with the DMSO vehicle only or with 
20 µM DPI for 24 hours. β-Actin is shown as a loading control. 
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Figure 12. Optimisation of DPI incubation in MOLM-13 cells. 
A) Intracellular ROS levels measured by relative DCF fluorescence (FL1-H) in 
MOLM-13 cells treated with the DMSO vehicle only and overlaid with cells treated 
with 20 µM DPI, for 1, 8, or 24 hours. B) Western blot analysis of the p-Tyr profile 
of untreated MOLM-13 cells, cells treated with the DMSO vehicle only or with 20 
µM DPI for 1, 8 or 24 hours. C) HRP-SA detection of BIAM- labelled (reduced) 
protein content of  MOLM-13 cells treated with 20 µM DPI for 24 hours. β-Actin is 
shown as a loading control. 
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The effect of the Nox inhibitor DPI on the p-Ser and p-Thr levels in MOLM-13 
cells 
 The results generated thus far using DPI prompted exploration of whether 
this was an effect specific to phosphorylation at tyrosine residues or if the Nox 
inhibitor also affected serine and threonine phosphorylation. As phosphorylation of 
these residues is a far more common occurrence within the cell that tyrosine 
phosphorylation, should DPI also show an effect on p-Ser or p-Thr it would broaden 
the spectrum of Nox influence. However 20 µM DPI did not reduce levels of p-Ser 
within the MOLM-13 cells when used over a period of 1-24 hours (Figure 13A). In 
contrast, there appears to be an increase in p-Thr with DPI treatment at 1 hour and 8 
hours before a dramatic decrease at 24 hours (Figure 13B). This pattern is different 
to p-Ser and does not align with the stepwise decrease seen in p-Tyr. Although there 
is no doubt that this result may be of interest, it fell beyond the scope of this study, 
which is focused on p-Tyr signalling, to investigate this angle any further.  
Two-dimensional (2D) p-Tyr immunoblotting 
The discrete p-Tyr bands observed in one-dimensional (1D) western blotting of a 
whole cell lysate with the pan p-Tyr antibody represented groups of proteins of 
similar molecular weights whose tyrosine phosphorylation was affected by DPI. In 
order to identify the specific proteins affected, the lysate would need to be further 
separated, providing a degree of resolution that would enable the visualisation of 
individual proteins. Two-dimensional SDS-PAGE is a process which was developed 
to fulfil this requirement. 
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Figure 13.  Effects of DPI on p-Ser and p-Thr levels of MOLM-13 cells  
Western blot analysis of the A) phosphoserine (p-Ser) and B) phosphothreonine (p-
Thr) profiles of MOLM-13 cells treated with 20 µM DPI for 1, 8 and 24 hours. β-
Actin is shown as a loading control 
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 This technique involves the separation of proteins firstly on the basis of their 
pH-dependent charge, through isoelectric focusing, and subsequently according to 
their size, on an SDS polyacrylamide gel. While many proteins may have a similar 
isoelectric point (pI) or molecular weight (mW) to another protein, it is less likely 
that they will share both distinct physiochemical characteristics, thus enabling the 
separation of up to 10 000 individual protein spots (O'Farrell, 1975). In combination 
with p-Tyr immunoblotting, 2D-SDS-PAGE allows the visualisation of discrete 
protein spots corresponding to individual proteins with phosphorylated tyrosine 
residues. Differences observed in samples treated with DPI can be used to identify 
the specific proteins affected.  
Optimisation of two-dimensional gel p-Tyr immunoblotting 
 Appropriate sample preparation is crucial to the success of a 2D 
electrophoresis experiment. The method of preparation of protein samples for 
separation by 2D gel electrophoresis varies according to the nature of the material 
from which the protein is being extracted and often requires some optimisation to 
determine the correct protocol for the sample in question. Generally speaking, cell 
culture yields a cleaner sample than, for example, proteins extracted from animal 
tissue or other biological material which may contain albumin, IgG, lipids and other 
contaminating agents which may interfere with protein solubilisation and/or 
isoelectric focusing. It is advisable to keep the sample preparation as simple as 
possible as additional washing, precipitation and lyophilisation steps may not be 
necessary for the sample in question and may result in loss of protein.  
 Therefore, when considering how to prepare the protein samples extracted 
from MOLM-13 cells in culture it was decided to use the minimum amount of steps 
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necessary in order to maximise protein yield. The initial procedure involved simply 
washing the pellet in a wash buffer (250 mM sucrose, 10 mM Tris-HCl), 
resuspending the pelleted cells in a 2D lysis buffer (8 M urea, 4% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate, 2% IPG buffer (GE 
Healthcare, UK), 40 mM dithiothreitol, 200 μM 4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride and cocktail protease inhibitors (Roche, Welwyn, 
Hertforshire, UK ) and once the protein concentration has been determined using the 
Bradford Bio-Rad Assay (see Materials and Methods), the protein sample was added 
to the rehydration buffer and vortexed for 2 minutes to mix, then loaded onto the IPG 
strips as described in the Materials and Methods section.  
 The 2D lysis buffer was shown to be almost as effective as conventional 
RIPA lysis buffer in terms of protein yield (Figure 14A) and, as it did not contain 
any charged detergents, it was more suitable for the subsequent focusing steps.  
 The selection of IPG strips with a pH range of 3-10 came after comparison of 
both the 3-10 (Figure 14B) and 7-10 (Figure 14C) strips. It appeared that 7-10 was 
too narrow a range for broad examination of the total protein content of these cells 
and would be better suited to an investigation where a specific protein with an 
isoelectric point from 7-10 was of interest. Separation of MOLM-13 cell lysate with 
these strips resulted in a band of proteins forming at the pH 7 end of the gel, 
representing proteins with pIs of less than 7 which could not be separated and 
aggregated at this terminal of the IPG strip.  
However, overall this method was yielding variable results with „Erratic Resistance‟ 
frequently being recorded by the focuser and often resulting in an almost  
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Figure 14. Optimisation of experimental conditions for 2D SDS-PAGE I. 
A) Ponceau-stained nitrocellulose membranes showing result of SDS-PAGE carried 
out using MOLM-13 cells lysates prepared using RIPA lysis buffer or 2D lysis 
buffer. B) Coomassie-stained 2D gels, separated using IPG strips of pH range 3-10 
or C) 7-10. 
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complete lack of protein in the second dimension SDS gels and p-Tyr blots except 
for a vertical smearing of aggregated, un-focused protein sample (Figure 15A). 
   
 This suggested that contaminants such as salts or other small ionic molecules, 
nucleic acids, polysaccharides, lipids or phenolic compounds, may have been present 
in the sample, interfering with the solubilisation and focusing of the proteins within 
the sample and preventing adequate first-dimension separation. The sucrose wash 
buffer was suspected as being a possible source of contaminating polysaccharides 
but removal of this washing step still resulted in poor focusing (15B). Washing of 
the cell pellet with PBS post harvesting was another possible source of contaminants, 
specifically salts, but again substitution of this wash with a sterilised water wash did 
not prevent the problem of inadequate focusing (15C). Accumulation of 
contaminants or precipitation of components of the lysis, wash or rehydration buffers 
over time while in storage was ruled out as being an issue when fresh buffers failed 
to improve the protein yield in the second dimension (15D). 
Finally, in order to remove these contaminants the sample was precipitated with 
trichloroacetic acid (TCA) and ice-cold acetone, and then re-solubilised in the 
rehydration solution. TCA limits proteolysis, removes impurities and precipitates the 
protein, and acetone then removes the excess TCA as well as salts, lipids, nucleic 
acids and detergents (Jiang et al., 2004; Méchin et al., 2007). As TCA and acetone 
remove charged detergents, this precipitation step allowed us to use RIPA lysis 
buffer instead of 2D lysis buffer. RIPA lysis is known to result in a better protein 
yield of membrane proteins, lower background and minimal interference with 
proteins immunoreactivity (Gilbert et al., 2002) but, because it contains charged 
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detergents (sodium deoxycholate) and salts (Tris-HCl, NaCl) which can also 
interfere with isoelectric focusing, removal of these is required prior to the first-
dimension of separation. The combination of RIPA lysis buffer and TCA acetone 
precipitation results in protein spots becoming visible in the second- dimension SDS- 
PAGE upon staining with Colloidal Coomassie (Figure 16A). Addition of 2-
Hydroxyethyl disulfide (De-Streak reagent) prior to focusing (Olsson et al., 2002) 
also greatly improved the appearance of the SD- PAGE gel by preventing horizontal 
streaking of oxidised proteins (Figure 16B).  
Figure 15. Optimisation of experimental conditions for 2D SDS-PAGE II.  
A) 2D p-Tyr immunoblot result of „Erratic Resistance‟ during the isoelectric 
focusing step. B) Coomassie-stained 2D gel after removal of sucrose wash step prior 
to focusing. C) Ponceau-stained nitrocellulose membrane of 2D SDS-PAGE after 
substitution of PBS wash with ddH2O wash. D) Coomassie-stained 2D gel carried 
out using fresh rehydration and equilibration buffer stocks.  
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Figure 16. Effect of TCA/acetone precipitation on the isoelectric focusing of 
MOLM-13 cell lysates. A) Coomassie stained 2D gels prepared using 
trichloroacetic acid (TCA) acetone precipitation to remove contaminants prior to 
rehydration and B) the effects of addition of 2-hydroxyethyl disulfide (De-Streak 
reagent) to the rehydration buffer prior to focusing.  
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Identification of individual proteins whose tyrosine phosphorylation is affected 
by Nox activity 
 By comparing the 2D p-Tyr immunoblots of untreated MOLM-13 cells to 
those treated with 20 µM DPI for 24 hours, it was possible to select specific p-Tyr 
protein spots which were present in the untreated but absent in the DPI-treated 
samples, corresponding to proteins whose tyrosine phosphorylation state is 
dependent on Nox activity. Use of Fast Stain as a form of loading control to compare 
the whole protein profiles present on the membranes prior to incubation with the p-
Tyr antibody, allowed the selection of proteins, from the corresponding Coomassie-
stained 2D gel, which were differentially phosphorylated due to DPI and not 
differentially expressed or simply differentially loaded. 20 Protein spots were cut 
from the 2D Coomassie-stained gel replicates of the 2D p-Tyr immunoblots, which 
were run in parallel, and sent to Aberdeen Proteomics Facility for sequencing by 
tandem liquid chromatography mass spectrometry, and annotation using the National 
Centre for Biotechnology Information nr (NCBInr) database with the Matrix Science 
web server (Figure 17). The NCBInr is a protein database for Blast searches which 
contains frequently updated non-redundant sequences from GenBank coding 
sequence (CDS) translations, Protein Data Bank (PDB), Swiss-Prot, Protein 
Information Resource (PIR), and Protein Research Foundation (PRF). Of the 20 
spots which were analysed, two did not return any significant hits. Spot no. 3 was 
identified as an un-named protein product (gi89054178). Table 1 represents the 
annotated spots which returned significant hits. In the case of more than one 
significant hit being returned for a single spot, the most significant as determined by 
Mascot and % coverage, is shown. 
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The protein products annotated from the screen were grouped according to their 
published functionality, as defined by the Universal Protein Resource (UniProt), in 
order to determine what category of proteins was most affected by Nox activity. The 
category of cytoskeletal or cytoskeletal-associated proteins was the largest (Figure 
18), reflecting the emerging role for Nox in cell migration dynamics (Kim et al., 
2010; Schroder et al., 2007). Ezrin, a member of the Ezrin/Radixin/Moesin family of 
cytoskeletal regulatory proteins was selected for further study, as a protein 
representative of the largest category of functionally annotated targets of Nox. Also 
contributing to this decision was the established role of Ezrin in tumourigenesis 
(Brambilla and Fais, 2009; Fais, 2004; Lugini et al., 2003; Zhou et al., 2010a) and 
the commercial availability of antibodies to two tyrosine phosphorylation sites on 
Ezrin Y146 and Y353, making Ezrin both a relevant and practical candidate for 
further investigation.  
 
Ezrin tyrosine phosphorylation is affected by Nox inhibitor DPI 
 In order to confirm the results obtained through 2D p-Tyr immunoblotting, 
the phosphorylation of two tyrosine residues on Ezrin was examined by western 
blotting. Upon incubation of MOLM-13 cells with 20 µM DPI for 24 hours, a 
decrease in phosphorylation was observed at both Y146 and Y353 in Ezrin (Figure 
19A), reflecting the pan p-Tyr western blot data, corresponding to a decrease in ROS 
and confirming the identification of Ezrin by 2D p-Tyr immunoblotting. A similar 
result was observed for the MV4-11 cell line (Figure 19B) suggesting that this effect 
may be more generally applicable to FLT3 mutated leukaemia cell lines, not just the 
unique cell line, MOLM-13.  
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Figure 17. Annotation of tyrosine phosphorylated proteins affected by Nox 
activity.  Protein spots taken from  A) Coomassie stained gel replicates of  B) 2D p-
Tyr immunoblots of untreated MOLM-13 cells and cells treated with 20 µM DPI for 
24 hours. Spots indicated, numbered and annotated C) represent tyrosine 
phosphorylated proteins which are present in the untreated sample and absent in the 
DPI-treated sample. 
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Spot no. Most significant hit NCBI 
Accession no. 
% Coverage  Mascot Score** 
1 Moesin  gi4505257 17 95 
2 RDX protein (Radixin) gi33990951 15 130 
3 Cytovillin 2 (Ezrin) gi6457378 35 77 
4 Unknown protein 
product 
gi89054178 20 232 
5 Carbonic Anhydrase II gi4557395 44 214 
6 Fructose Bisphosphate 
Aldolase A 
gi4557305 45 525 
7 Heterogenous Nuclear 
Ribonucleoprotein H1 
gi48145673 17 104 
8 Heterogenous Nuclear 
Ribonucleoprotein K4 
gi73946435 28 194 
9 Fatty acid binding 
protein 
gi4557581 82 334 
10 High Mobility Group 
Protein B2 
gi11321591 39 133 
11 High Mobility Group 
Protein B1 
gi4504425 17 198 
12 Peptidylprolyl isomerase 
A (cyclophilin A) 
gi13937981 72 335 
13 Stathmin A gi5031851 45 132 
14 Heat Shock Protein 
B1/HSP 27 
gi4504517 62 313 
15 Heterogenous Nuclear 
Ribonucleoprotein C 
gi306875 14 99 
16 Alpha Enolase gi4503571 58 686 
17 Alpha-Actin gi4501881 49 706 
18 Elongation factor 1B gi4503477 45 279 
 
*Defined as unambiguous if ≥ 15% 
**Defined as significantly identical/extensively homologous if >44, P<0.05 
 
Table 1. 2D p-Tyr sample submission protein identification report. 
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Figure 18. Categories of proteins affected by Nox activity. 
Pie chart illustrating the proteins annotated from the 2D p-Tyr immunoblot samples 
submitted to Aberdeen Proteomic Facility, grouped according to function as defined 
by Universal Protein Resource (UniProt). 
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Figure 19. Ezrin tyrosine phosphorylation decreases upon Nox inhibition in 
MOLM-13 and MV4-11 cells.  Western blot analysis of p-Ezrin Y146 and Y353 in 
A) MOLM-13 cells and B) MV4-11 cells treated with the DMSO vehicle only or 
with 20 µM DPI for 24 hours.  
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Discussion 
 The initial results detailed in this chapter relied upon the trial of a panel of 
Nox inhibitors in order to determine which provided the most efficient inhibition in 
our cell system. However, rather than finding ourselves in the position of having to 
choose between several highly suitable candidate compounds, the selection process, 
though lengthy, was easy. This was due to the failure of Apocynin and Rac1 
inhibitor NSC23766 to affect the ROS levels of the MOLM-13 cells, which can be 
attributed to the lack of activating myeloperoxidase enzyme in the case of Apocynin 
and the presence of a compensating Rac isoform to overcome Rac1 inhibition.  
 The importance of exploring the reasons behind the failure of these inhibitors 
to elicit an ROS response is crucial to the interpretation of the result. It is important 
to distinguish between the possibility of simply an inefficient or inactive compound 
and the more profound situation of undetectable Nox involvement in the generation 
of ROS in these cells.  The ROS reduction resulting from incubation with the 
calcium chelator Bapta-AM has implications for Ca
2+
-dependent Nox only, Nox 5 
and the Duox. The reduction in ROS plateaued at 1 µM suggesting that the Nox in 
question was fully inhibited, yet was not accompanied by a reduction in p-Tyr levels, 
the parameter chosen to represent a contribution to growth factor signalling. This can 
be interpreted to signify that the inhibited Nox does not influence p-Tyr within the 
cell, but of course this simply eliminates a single member of the Nox family and in 
no way informs us about the contribution of the Ca
2+
-independent Nox. Thus, as 
useful as Bapta-AM may be in reducing ROS levels and facilitating research into 
Nox 5 and Duox 1 and 2 activities, it is limited in terms of attributing effects to 
broad Nox inhibition which is of more interest to this study. In fact the slight 
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increase in p-Tyr levels observed upon incubation with Bapta-AM, suggests that by 
chelating Ca
2+
 the compound is also causing some degree of stress to the cell, and 
providing further reason to avoid using such an inhibitor.  
 Western blotting using a pan antibody allowed visualisation of the p-Tyr 
signalling profile of the MOLM-13 cells, and observation of any global changes to 
the p-Tyr trend in order to judge the merit of using this readout as an indicator of the 
role of Nox. This broad-scale approach demonstrated that Nox activity positively 
influences the level of tyrosine phosphorylation within this cell line, phosphorylation 
which is strongly stimulated by the constitutively active RTK FLT3-ITD. As Nox 
enzymes do not have any kinase activity themselves, it can be concluded that they 
exert their effects on p-Tyr by regulation of redox-sensitive kinases or phosphatases.  
 The global profile of tyrosine phosphorylated proteins was translated into 
observable changes at an individual protein level through separation of lysates by 2D 
SDS-PAGE followed by p-Tyr immunoblotting. This technique requires a great deal 
of optimisation in order to meet the requirements of the specific experiment, with 
both the starting material and subsequent staining, blotting or sequencing steps 
affecting the way in which the samples are prepared. In general, lysates produced 
from cultured mammalian cells do not require precipitation or purification as would 
be required for samples of bodily fluids or homogenised animal or plant tissue. The 
relative lack of contaminants and non-protein impurities such as inorganic salts or 
minerals, connective tissue, extracellular matrix polysaccharides, bacteria, fungal or 
viral particles within the rigorously controlled cell culture environment means that, 
in theory, the cells can simply be lysed and used. However, in this instance we began 
to encounter erratic resistance readings on the isoelectric focuser during the focusing 
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step, accompanied by poor resolution of protein spots on the resulting 
polyacrylamide gel (Figure 15). The gels contained very few protein spots detectable 
by Coomassie staining and when transferred to the nitrocellulose membrane and 
stained with Fast-Stain similarly poor spot representation was observed. Probing 
with the p-Tyr antibody resulted in almost no detectable p-Tyr signal. A vertical 
smear was often observed towards the bottom of the stained gel and membrane and 
seemed to represent a condensed area of unfocused proteins which had migrated 
from the IPG strip into the polyacrylamide gel. This, in addition to the erratic 
resistance readings on the focuser, led us to conclude that the problem lay in the 
focusing step rather than the second dimension of separation.  
 Poor solubilisation of the protein sample in the rehydration buffer could 
result in loss of proteins either prior to the focusing, by simply remaining 
unsolubilised and not transferring to the IPG strip, or during the focusing step as 
some proteins have been shown to precipitate out of solution as they approach their 
isoelectric point (Rabilloud, 2009).This would result in under-representation of these 
proteins in the final polyacrylamide gel but does not account for the erratic resistance 
recorded on the focuser which indicates a high current flowing within the IPG strip. 
This can be explained by a high ampholyte concentration, low resistance water being 
used to dampen the electrode wicks or the presence of charged detergents in the 
rehydration buffer. As the rehydration buffer that was used did not contain any 
charged detergents this latter explanation was ruled out, similarly the water that was 
used to moisten the electrode wicks was double distilled and de-ionised resulting in 
an electrical conductivity of not more than 10 µS/cm (according to the Mili-Q water 
purification system specifications) enough to facilitate conductivity between the 
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electrode and the IPG strip but unlikely to be a rich source of charge-carrying 
molecules to contaminate the IPG strip. As carrier ampholytes are charged molecules 
themselves, their inclusion in the rehydration solution is necessary, to create 
equilibrium between the IPG strip and the buffer thus preventing the ampholytes 
within the IPG strip from leaching out into the buffer as well as to prevent isoelectric 
precipitation. However, carrier ampholytes are also potentially problematic as an 
excess of zwitterions could allow too much current to flow resulting in the erratic 
resistance reading. The rehydration solution which was used contained 4% (v/v) 
carrier ampholytes, and as 2-4% is generally recommended (Garfin, 2003) and this 
particular rehydration buffer composition had been previously used successfully by 
members of our laboratory (Tedesco et al., 2010) we were satisfied that it was not 
the source of the erratic resistance. However, charged contaminants such as 
conductive salt ions within the sample itself would result in an effect similar to 
excessive carrier ampholytes, i.e. causing the target current (in this case 50 µA) to be 
reached prematurely during the initial low voltage steps and preventing further 
focusing (Rabilloud and Chevallet, 2000). In addition to this, uncharged 
contaminants within the sample, such as polysaccharides, can physically block the 
pores of the IPG strip, preventing the sample from entering and indirectly preventing 
focusing (Berkelman et al., 2000). 
 A common problem in 2D SDS-PAGE, charged contaminants can be 
removed to some extent by the presence of electrode wicks which collect salts from 
the sample, preventing their accumulation at the anode and cathode which can create 
high conductivity and interfere with the pH gradient. But the wicks used here did not 
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seem to be efficiently removing the contaminants so the next option was to eliminate 
the contaminants from the lysate prior to solubilisation in the rehydration buffer.  
 Trichloroacetic acid (TCA) acetone precipitation is a method of removing 
substances such as salts, lipids and nucleic acids from protein lysates and is widely 
used in the preparation of samples for 2D SDS-PAGE (Link and LaBaer, 2011). 
Unfortunately this procedure can also reduce the protein content of the lysate as 
some proteins are insoluble in TCA or acetone, so a trade-off is required between 
improving the purity of the sample and the concomitant loss of proteins from it. In 
our situation, the presence of impurities was becoming such a problem that it was 
completely preventing successful 2D SDS-PAGE, so the TCA acetone precipitation 
was considered to be a worthwhile option. Including this step resulted in faultless 
isoelectric focusing and vastly improved the quality and quantity of the spot profile, 
allowing experiments to be carried out which resulted in annotation of individual 
protein targets.  So the somewhat time-consuming optimisation of the 2D SDS-
PAGE protocol was crucial to the quality of the final product and the quantity of data 
which could be extracted from it.   
 The grouping of the proteins identified by 2D SDS-PAGE was carried out 
based on functionality in order to identify cellular processes which are regulated by 
Nox in the FLT3-ITD cell line. Cytoskeletal regulation was the most highly 
represented function which tied in with the emerging role for both Nox and ROS in 
cellular motility and cytoskeletal dynamics. 
 However, the other categories of affected functions also proved interesting. 
Proteins which bind RNA such as hnRNPs featured strongly, and are known to play 
an important role in mRNA and pre-mRNA transport, processing and splicing. 
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Although there is a scarcity of data linking these proteins to Nox enzymes, there is 
evidence to suggest that they are subject to redox regulation (Stone and Collins, 
2002; Stone et al., 2003).  
Glycolytic-related proteins have repeatedly been shown to be redox-sensitive due to 
the extensive cross-talk between components of glycolysis and of the antioxidant 
defence system, which promotes redox homeostasis (Hamanaka and Chandel, 2011). 
It appears that one of the most immediate intracellular responses to oxidative stress, 
is a shift to the pentose phosphate pathway of carbon metabolism, which ensures 
increased production of NADPH reducing equivalents in order to cope with the 
perceived change in redox state (Kruger et al., 2011). Glycolysis is a process which 
is inherently valuable to cancer cells and recent data from Lu et al. (2012) implicates 
Nox enzymes as supporting the increased glycolysis observed in tumours.  
The DNA-binding high mobility group box (HMGB) proteins are known be redox 
sensitive proteins which operate at sites of oxidative DNA damage (Tang et al., 
2011), while proteins involved in stress responses such as heat shock protein 1 
(HSP1) can act as chaperones to prevent oxidative damage to proteins, and regulate 
the cellular redox homeostasis by influencing the levels of cellular antioxidants such 
as GSH (Papp et al., 2003).  There is clearly a wide range of redox-influence within 
the cell and a rich variety of Nox targets which future studies can explore. 
 Ezrin, a member of the Ezrin/Radixin/Moesin (ERM) family, was selected in 
this case as representative of the category of cytoskeletal regulatory proteins because 
it also represented a link between Nox-derived ROS and cellular motility, two 
themes which have been repeatedly connected but the molecular basis of their 
connection is yet to be clearly defined. Ezrin is also of interest from a cancer 
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perspective, with an established role in metastasis (Brambilla and Fais, 2009; Fais, 
2004;  Federici et al., 2009; Zhou et al., 2010a) and  an emerging role in proliferative 
signalling (Gautreau et al., 1999; Heiska et al., 2011; Kishore et al., 2005; Srivastava 
et al., 2005). Ezrin has been previously shown to be increased in leukaemic cells 
(Monni et al., 2008) and has been identified as a target of oncogenic signalling from 
extracellular signalling mediators PDGF, EGF and HGF as well as intracellular 
oncogenic kinases Src, Lck and Rho (Crepaldi et al., 1997; Fazioli et al., 1993; 
Monni et al., 2008). 
 Phosphorylation of Ezrin has been shown to regulate its activation and 
cytoskeletal associations (Chen et al., 1994; Kondo et al., 1997; Simons et al., 
1998), but much of the data favour a role for threonine phosphorylation in the 
structural organisation and localisation of Ezrin (Hayashi et al., 1999; Matsui, 1998) 
and propose a signalling role for the phosphorylation of its tyrosine residues at Y146 
and Y353 (Berryman et al., 1995; Gautreau et al., 1999; Heiska et al., 2011). Krieg 
and Hunter (1992) showed that Ezrin is phosphorylated at these sites in response to 
epidermal growth factor (EGF) signalling and Berryman et al. (1995) went on to link 
this tyrosine phosphorylation to Ezrin oligomerisation and the subsequent 
appearance of microvilli. In our FLT3-ITD cell line, Ezrin tyrosine phosphorylation 
at residues Y146 and Y353 is reduced upon 24 hours of Nox inhibition. This 
implicates tyrosine phosphorylated Ezrin as a possible propagator of the oncogenic 
signals originating from FLT3 in MOLM-13 cells.   
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Chapter 4 
 
 FLT3 regulation of p22phox drives redox-modulation of 
Src and Ezrin and influences leukaemic cell migration 
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Abstract 
The concept of reactive oxygen species being produced via the activation of specific 
oncogenes provides a basis for generating genomic instability and pro-survival 
signalling in tumour cells. This section demonstrates that oncogenic FLT3 signalling 
affects the activity of the NADPH oxidase enzymes through regulation of p22phox 
protein expression. FLT3 activity also affects the tyrosine phosphorylation of Ezrin, 
the downstream target of NADPH oxidase-derived ROS, in a p22phox-dependent 
manner. Inhibition of FLT3-ITD, using the staurosporine derivate PKC412, or of 
Nox, using diphenyleneiodonium chloride, also triggered a shift in Ezrin sub-cellular 
localisation as detected by immunofluorescence. The change in Ezrin localisation 
coincided with altered cell morphology, observed using scanning electron 
microscopy and a decreased ability to migrate through a polycarbonate transwell 
membrane. The results indicate that FLT3 drives production of ROS by Nox, which 
stimulates changes in Ezrin tyrosine phosphorylation and localisation via redox 
regulation of Src kinase. Furthermore, inhibition of FLT3-ITD signalling leads to 
alterations in MOLM-13 cell morphology and has a significant influence on cell 
motility.  
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Introduction 
 As an oncogenic RTK, FLT3-ITD is responsible for driving the molecular 
signalling events which ultimately contribute to the AML phenotype. The exact 
nature of these signal transduction events remains somewhat undefined apart from 
the established involvement of the Akt and MAPK (Hayakawa et al., 2000; 
Takahashi, 2006) pathways which drive proliferation of the FLT3-ITD immature 
blasts. An area which has received attention of late is the possibility of a redox 
element functioning within the FLT3-ITD signalling pathway. 
 This possibility was heralded by the elucidation of an analogous signalling 
pathway in CML by Naughton et al. (2009), whereby the oncogenic RTK Bcr-Abl 
stimulates proliferative ROS production via Nox 4. It had been previously shown 
that Bcr-Abl-transformed cells generate increased levels of ROS compared to their 
untransformed counterparts (Sattler et al., 2000), an observation echoed in FLT3-
ITD-transformed cells, as well as FLT3-ITD containing AML cell lines and primary 
cells taken from AML patients with the FLT3-ITD mutation (Sallmyr et al., 2008a). 
The increased ROS levels were thought to cause genomic instability, driving further 
oncogenic mutations (Sallmyr et al., 2008b). When contemplating the source of this 
ROS, it is tempting to attribute it to the upregulated mitochondrial activity needed to 
support the chronic proliferation of the tumour cells. However, as demonstrated by 
Piccoli et al. (2005), haematopoietic stem cells have a low mitochondrial O2 
consumption rate corresponding to a low number of mitochondrial respiratory chain 
complexes. Further examination showed that 50% of the total O2 consumption by 
these cells was due to Nox activity, making the Nox family very relevant to the 
redox profile of haematopoietic cells.  
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 Sallmyr et al. (2008a) went on to link FLT3-ITD and downstream ROS 
production via Nox by focusing on the established status of STAT5 as a FLT3-ITD 
substrate (Piloto et al., 2007). pSTAT5 has also been shown to interact with Rac 1-
GTP, which is a crucial component of the Nox holoenzyme complex for at least 3 of 
the Nox isoforms (Kawashima et al., 2006), and as a substrate for Bcr-Abl, has also 
been implicated as important factor in the initial transformation and maintenance of 
CML (Chatain et al., 2012) . Sallmyr et al. (2008a) demonstrated that the amount of 
pSTAT5 binding to active Rac 1-GTP was increased in 32D cells with the FLT3-
ITD mutation. They also used knockdown of STAT5 to reduce the ROS levels of 
32D cells transformed with FLT3-ITD and showed that inhibition of FLT3-ITD 
using CEP-701 prevented Rac 1-GTP binding to Nox. Altogether this indicated that 
an interaction between pSTAT5 and Rac 1-GTP resulted in Nox activation 
downstream of FLT3-ITD.  
 Recently, Reddy et al. (2011) expanded this model by showing that in a 
range of haematopoietic cell lines containing oncogenic RTKs, including the FLT3-
ITD cell line MOLM-13, the processes of growth and migration were heavily 
influenced by Nox isoforms 2 and 4 as well as p22phox. This again suggested a role 
for Nox in cellular functions driven by FLT3-ITD. However, in this situation the 
mode of FLT3-ITD driven regulation of Nox was concluded to be via control of the 
availability of the Nox substrate NADPH. 
 In contrast to this mechanism, it was demonstrated by Woolley et al. (2012) 
that in the FLT3-ITD cell line MV4-11, inhibition of FLT3-ITD signalling, using 
either PKC412 or CEP-701, resulted in a decrease in the protein levels of p22phox, 
suggesting a further scenario whereby FLT3 may regulate Nox activity. Woolley et 
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al. went on to clarify that the decrease in p22phox at a protein level did not 
correspond to a decrease in p22phox mRNA, but did correspond to post-translational 
regulation of p22phox through ubiquitination and proteasomal degradation.  
 The reported multi-layered regulation of Nox by FLT3-ITD, suggests at least 
that there is a connection between the two worth investigating. It also implies that 
Nox-derived ROS, produced in response to FLT3-ITD, function in a signalling 
capacity, mediating the FLT3-ITD-driven processes of growth and migration, as 
suggested by Reddy et al. (2011), and possibly proliferation,  if the CML model 
proposed by Naughton et al. (2009) is representative of the situation in other 
haematopoietic tumours driven by oncogenic RTKs. 
 In the previous chapter the regulatory role played by Nox in p-Tyr signalling 
was demonstrated using 1- and 2-D p-Tyr immunoblotting. The targets identified 
represent proteins which undergo a decrease in tyrosine phosphorylation upon Nox 
inhibition, prompting the question of what intermediary effector detects changes in 
ROS levels and translates these into changes at the level of p-Tyr of specific 
proteins, and to what end.  
 Effectors of redox signalling can be identified by their common 
structural characteristics which render them susceptible to oxidation by ROS. 
One such group of affected molecules and probably the most widely studied in 
terms of redox-regulated protein targets, is the PTPs (Figure 20). These enzymes 
contain a crucial cysteine residue in their highly conserved active site motif 
which, at physiological pH, has a very low pKa, resulting in a propensity to 
become easily oxidised. Oxidation of this cysteine leads to a sulfenic acid-
containing active site which is non-functional, creating a window of 
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phosphorylation signalling un-interrupted by phosphatase activity, until the 
enzyme is reduced and regenerated by Trx, Grx or GSH (Ostman et al., 2011). 
 Locally higher levels of ROS can cause further oxidation to sulfinic acid or 
even the hyper-oxidised sulfonic acid form which, being more stable than the 
sulfenic intermediate, are not as amenable to reduction by cellular antioxidants. In 
fact, sulfinic and sulfonic-state PTPs are permanently inactivated, providing the 
opportunity for sustained phosphorylation signalling, until the inactive PTPs are 
degraded and replaced (Ostman et al., 2011). Thus the duration of the 
phosphorylation signal can be modified by the levels of the accompanying oxidants. 
Many redox-sensitive PTPs are also regulated by phosphorylation, and it is 
becomingly increasingly obvious that these dual processes of PTP regulation do not 
occur in isolation but are tightly co-ordinated to temper the phosphorylation signal 
(Chiarugi and Buricchi, 2007). 
 The discrete targeting that can be achieved through the utilisation of oxidants 
as a signalling device has been demonstrated repeatedly by the PTP model (Choi et 
al., 2011; Juarez et al., 2008). The differential sensitivity of PTPs to both the nature 
of the oxidant species and the levels of ROS being produced, in addition the 
proximity of only the intended target PTP to the ROS source, confers a degree of 
specificity comparable to the enzyme-substrate „lock and key‟ paradigm, and 
prevents the kind of „collateral damage‟ which might compromise the integrity of the 
propagated signal. 
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Figure 20. Oxidation states of PTPs 
PTPs are highly susceptible to oxidation at physiological pH due to the low pKa of 
the catalytic cysteine residue located in the highly conserved PTP active site motif. 
Exposure of reduced PTPs (SH) to oxidants such as hydrogen peroxide (H2O2) 
results in the reversible formation of a sulfenic acid intermediate (SOH), which 
renders the enzyme inactive. Proximity to another cysteine at this stage favours the 
formation of a disulfide bond (S-S), or the formation of a mixed disulfide with GSH 
(PTP-SSG). Reduction of a disulfide or sulfenic acid-containing PTP by glutathione 
(GSH) returns the enzyme to its active state (SH), whereas further oxidation of the 
sulfenic acid intermediate results in the formation of the more stable sulfinic (SO2H) 
or sulfonic (SO3H) acids, hyper-oxidised and permanently inactivated. 
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While the redox-regulation of PTPs is an area which has been widely contributed to 
and acutely developed, it is reasonable to assume that PTPs are not the only 
molecules susceptible to oxidation for signalling purposes. Oxidation has been 
implicated as a signalling device in the regulation of GTPases (Heo, 2011), 
transcription factors (Li et al., 2010), proteases (Guttmann and Ghoshal, 2011) and 
protein disulfide isomerases (Chen et al., 2008b), amongst others.  
 The involvement of redox regulation of PTPs in p-Tyr signal transduction, 
prompts the question of whether the PTP counterpoint, the TKs, are similarly 
regulated by ROS. With a precedent set by the dual roles of phosphorylation as both 
a kinase-activating and phosphatase-inactivating mechanism, is there enough 
evidence to support the hypothesis that oxidation fulfils a similar function in the p-
Tyr signalling machine? 
 PTKs are the other half of the p-Tyr signalling dynamic, described as the 
„writer‟ to the PTPs „eraser‟ in the p-Tyr toolkit model proposed by Lim and Pawson 
(2010).  Such an interdependent system of signal transduction requires precise and 
co-ordinated regulation at every step, lest the powerful p-Tyr signal which features 
so prominently in almost every cellular function, become derailed.  
 The non-redox regulation of kinases through post-translational modifications 
such as phosphorylation as well as activator and inhibitor binding, has been 
extensively reviewed and can be summarised as a highly complex process with 
individual kinases and kinase families displaying idiosyncratic profiles of positive 
and negative regulatory modes. Similarly, the indirect redox regulation of kinases 
through the oxidative inactivation of inhibitory PTPs, has been widely documented 
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(Chiarugi and Cirri, 2003) and represents an important mechanism of redox-
mediated p-Tyr signalling.  
 Early evidence for the direct modification of kinases by ROS centred on the 
in vitro oxidation of Src kinase by nitric oxide (NO)-releasing agents resulting in 
enhanced catalytic activity (Akhand et al., 1999; Minetti et al., 2002).  Subsequent 
studies by Senga et al. (2000) identified a number of cysteine residues in Src 
necessary for the enzymes stability and transformative ability. Giannoni et al. (2005) 
focused on Cys245 and Cys487 which were demonstrated to undergo intramolecular 
disulfide bridge linkage upon exposure to ROS, leading to a level of Src activation 
not observed in the redox-insensitive Cys-Ala mutants. This collection of work was 
crucial in formulating the concept of phases of kinase activation through 
phosphorylation and de-phosphorylation steps, with a final super-activation state 
being achieved through oxidation. This concept and the supporting literature which 
has emerged since, demonstrating direct redox regulation of Src kinase in a variety 
of systems was recently and comprehensively reviewed by Giannoni et al. (2010). 
 Even in the two years since this review, further studies have emerged 
attesting to the direct redox regulation of Src kinase in different cell systems and 
with diverse signalling outcomes. Most recently, Xi et al. (2011) showed that, under 
conditions of hyperglycemia, IGF-1 signalling leads to enhanced Src activation 
through direct oxidation by Nox 4 in vascular smooth muscle cells. Lee et al. (2011)  
similarly demonstrates that vascular c-Src forms a signalling axis with VEGF-
derived ROS through the direct oxidation of cysteine residues on both c-Src and 
VEGFR, resulting in activation of the c-Src-PI3K-Akt pathway downstream of 
VEGFR but not the PLCγ1-Erk1/2 pathway, which is also downstream of the 
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receptor. The redox-specific activation of VEGFR appears to lead exclusively to 
redox activation of c-Src allowing the cell to sense the redox status of the 
endothelium and respond with specific pathway activation. 
 The vulnerability of cells to de-regulated kinase activity and the subsequent 
risks of tumourigenesis have been widely documented, with an emphasis on the 
activation of kinases such as Src, through constitutive phosphorylation or 
overexpression. However the ability of redox-regulated kinases such as Src to 
become activated through oxidation represents another potential avenue for pro-
tumourigenic activity, especially within the oxidising environment of many cancer 
cells which display higher levels of ROS than their non-cancer counterparts (Hole et 
al., 2012; Mitsushita et al., 2004; Weinberg and Chandel, 2009; Wu, 2006).   
 One of Hanahan and Weinberg‟s (2000) hallmark tumourigenic 
characteristics  is the focus of a recent paper by Zhu et al. (2011), in which the 
authors demonstrate a role for redox-regulation of Src in conferring anoikis-
resistance to tumours. Oxidative activation of Src is triggered by a high ratio of 
O2
−·
:H2O2, caused by Nox activation downstream of integrin stimulation, echoing the 
findings of Giannoni et al.(2005). However in the situation described by Zhu and 
colleagues, cell attachment to the ECM via integrins is mimicked by angiopoietin-
like 4 protein (ANGPTL4) engagement of integrins of cells in suspension, 
stimulating the ROS production, activation of Src and subsequent pro-survival 
signalling normally associated with cell adhesion and eliminating the dependence of 
tumour cells on ECM or cell-cell contact. 
 Although these studies support a model whereby Src is activated in response 
to ROS, data consistent with an inhibitory role for ROS in Src activity has also been 
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proffered by Kemble et al. (2009). In contrast to the majority of published studies, 
yet echoing the earlier results of Cunnick et al. (1998), Kemble proposes that, upon 
oxidation, intermolecular disulfide bridges form between Cys277 residues on two 
Src molecules, resulting in inactive Src dimers. According to the authors this 
scenario is also applicable to FGFR1 because of its corresponding cysteine residue. 
 The contrast and seeming disparity between this work and other studies can 
be explained in part by the different conditions used by different groups. Kemble 
highlights two advantages of a cell-free assay over cellular techniques when 
examining redox-regulation of proteins. Firstly, in a cell-free system the absence of 
any Src-regulatory proteins, which may be the legitimate targets of oxidants, ensures 
that any effects on Src observed can be attributed to direct oxidation of the kinase 
itself and not to indirect effects via oxidation of mediators.  Secondly, great care 
must be taken during the processes of lysis and immunoprecipitation, used to isolate 
Src from cells, in order to preserve the intracellular redox state of the kinase, by 
minimising both exposure to environmental oxygen as well as the release of cellular 
oxidants during lysis. However, cell-free assays alone cannot faithfully replicate the 
physiological scenario of localised ROS production in proximity to relevant protein 
targets, nor do they address the issue of oxidant concentration carefully tempered by 
the presence of cellular antioxidants and Prxs. In addition to this, it is likely that the 
physiological redox regulation of Src is complex enough to involve both the redox-
activation and inactivation of Src depending on the ROS concentration as well as the 
sensitivity and accessibility of individual cysteine residues. As argued by Giannoni 
et al. (2010), oxidation of Cys277 might well be an artefact of the process of 
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isolating Src, and may not occur within intact cells due to the native conformation of 
the enzyme. 
 It is interesting at this point to note that Tang et al. (2005)  also observed 
redox-inactivation of Src kinase but in live cells, through the addition of H2O2 to 
primary HUVECs, HAECs, and E6 fibroblasts. This is in contrast to the cell-free 
assays used by Kemble et al. (2009), in which a redox-inactivation of Src was also 
observed. However Tang et al. reported that Src activity was not affected in cell free 
assays, clearly demonstrating a disconnect between the two systems. 
 In order to address the conflict between their results and the earlier studies 
supporting redox-activation of Src, Tang et al. propose an elegant compromise by 
outlining a scenario whereby both the localisation of the kinase, as well as the dose 
of H2O2 used, affect the outcome in terms of positive or negative regulation. The 
immunofluorescence data of Tang et al. appear to demonstrate that Src kinases 
residing in focal adhesion complexes or at the plasma membrane become inactivated 
after addition of H2O2, whereas those localised to the cytoplasm and compartments 
such as endosomes become activated. Tang et al. also comment on the importance of 
the dose of H2O2 used, they choose to use a relatively low dose (50-250 µM), 
describing how very high concentrations in the mM range, which cannot be claimed 
to be physiologically relevant, may eclipse the natural regulation of the kinase, 
producing highly artificial results. The addition of high doses of exogenous H2O2 is 
often used to demonstrate both the redox-activation and inactivation of Src but 
cannot accurately reproduce the temporally and spatially regulated cellular 
production of H2O2. Another alternative, the induction of ROS-producing enzymes 
would allow the concentration, proximity, duration and nature of the species 
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produced to more closely reflect that of the physiological situation, and is one 
method of introducing a much-needed cellular context into the debate on redox 
regulation of Src. 
 Irrespective of its consequence for Src kinase activity, the susceptibility of 
Src to redox regulation is a characteristic shared by other members of the Src family 
kinases (SFK). The first kinase determined to be redox regulated was the 
lymphocyte-specific tyrosine protein kinase p56lck (Lck) (Nakamura et al., 1993). 
Nakamura and colleagues examined the tyrosine phosphorylation profile of T-cells 
after exposure to oxidative stress, in the form of the thiol-oxidising agent diamide, 
and discovered that Lck was phosphorylated at its autophosphorylation site Tyr394 
after exposure to the oxidant. They also detected increased activity of Lck 
presumably as a consequence of this phosphorylation event, while other similar 
kinases such as p59fyn did not become activated.  
 More recently the SFK Lyn was demonstrated by Yoo et al. (2011) to be a 
„redox sensor‟ in zebrafish neutrophils. In this elegant model of wound healing, 
neutrophilic Lyn undergoes oxidation at Cys466 upon exposure to extracellular H2O2 
produced at the site of the wound, resulting in the autophosphorylation and 
activation of the kinase and selective stimulation of its downstream pathways. In this 
case Erk is activated whereas JNK and p38 remain un-stimulated. The redox 
activation of Lyn appears to be the dominant factor driving the directional migration 
of the neutrophils towards the wounded area. Although the paracrine signalling 
properties of H2O2 in wound healing have been well described (Niethammer et al., 
2009), Yoo et al. are the first to demonstrate a molecular connection between the 
redox signal and the neutrophil recruitment response. 
106 
 
 The Src family are not the only kinases susceptible to redox-regulation. 
RTKs such as the insulin receptor (IR), epidermal growth factor receptor (EGFR), 
platelet-derived growth factor receptor (PDGFR) and c-Ret have all been reported to 
undergo direct oxidation (Nakashima et al., 2002). In addition to this and as 
documented by Kemble et al. (2009) there is evidence to suggest that FGFR1 is 
negatively redox regulated while Lee et al. (2011) report that VEGFR undergoes 
oxidative activation.  
 Close investigation of the redox-regulation of proto-oncogenic RTK c-Ret by 
Kato et al.(2000) has revealed that oxidative activation of the kinase occurs via 
disulfide bond formation between cysteine residues on two different c-Ret 
molecules, resulting in dimerisation. The cysteine residue in question, Cys376, is 
necessary for the basal activity of the kinase, as well as its up-regulation in response 
to UV irradiation. As the authors point out, this cysteine is highly conserved in a 
number of receptor and non-RTKs such as Ros, c-Abl, Src, Fms, Fps, HIR, HER, 
and Lck, implying that a similar mechanism for oxidative regulation may operate 
with regard to all of these kinases. Interestingly, the corresponding residue in Src to 
c-Ret Cys376 is Cys498, which was not implicated in previously mentioned 
literature discussing Src redox regulation but was recently demonstrated by Rahman 
et al. (2010) to undergo S-nitrosylation upon exposure to NO leading to kinase 
activation. This development introduces the possibility that reactive nitrogen species 
(RNS) may also play a role in kinase regulation through cysteine modification. 
 In addition to Src, the range of redox-sensitive targets is broadening and 
diversifying to include a variety of kinases operating in a wide range of systems. 
Recent evidence has identified a redox element in the direct regulation of c-Abl 
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(Leonberg and Chai, 2007), Akt (Wani et al., 2011), c-AMP-dependent protein 
kinase (Humphries et al., 2005), Erk (Galli et al., 2008), Ca(2+)/calmodulin-
dependent protein kinase (Erickson et al., 2008), cGMP–dependent protein kinase 
(PKG) Iα (Burgoyne et al., 2007), ataxia–telangiectasia mutated (ATM) protein 
kinase (Guo et al., 2010) and apoptosis signal-regulated kinase-1 (ASK-1) (Nadeau 
et al., 2007). Additionally, evidence to support a role for direct redox regulation of 
several components of the MAPK signalling pathway (Greene et al.,2000 ; Galli et 
al., 2008), re-inforces the early work of Adler et al. (1999), who demonstrated the 
redox-dependent activation of JNK via the oxidative inactivation of its inhibitor 
GSH-S-transferase Pi.  
This emerging body of literature adds to the ongoing shift in the redox-signalling 
paradigm by presenting evidence to support the hypothesis that redox signalling, 
particularly in the context of phosphorylation signal transduction, does not simply 
operate via the inhibition of phosphatases but also involves the direct regulation of 
redox-sensitive kinases.   
 One of the objectives of this chapter is to contribute to that shift in paradigm 
by providing evidence to support a role for the redox regulation of Src kinase in 
mediating the Nox-Ezrin communication which was elucidated in the previous 
chapter. This chapter will also clarify the nature of the relationship between FLT3 
and Nox in the MOLM-13 AML cell and demonstrate the relevance of the FLT3-
Nox-Src-Ezrin signalling pathway to the AML cell phenotype.  
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Figure 21. Models of Src kinase redox regulation 
Contrasting models of the outcome of Src oxidation as proposed by Giannoni et al. 
(2005) (left) and Kemble et al. (2009) (right). The model of redox-activation of Src 
involves phases of Src activation, from the generally accepted inactive conformation 
due to inhibitory phosphorylation at C-terminal Y527, to the first phase of activation 
via relief of this inhibitory phosphate and autophosphorylation at Y416 of the 
catalytic domain. The final stage of activation requires oxidation of Cys245 of the 
SH2 domain and Cys487 of the catalytic domain resulting in intramolecular disulfide 
bond formation and an increase in kinase activity. Kemble et al. support the 
conflicting theory of redox inactivation of Src via oxidation of Cys277 on different 
Src molecules resulting in intermolecular disulfide bond formation, producing an 
inactive dimer. 
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Results                
FLT3 signalling affects the redox state of MOLM-13 cells 
 The production of ROS downstream of FLT3 signalling has been reported by 
Sallmyr et al. (2008a) and Reddy et al. (2011), and  recent work from our own 
laboratory (Woolley et al., 2012) has shown that inhibition of FLT3-ITD by the 
staurosporine derivate PKC412 (Midostaurin) , which is currently in clinical trials 
for the treatment of AML (Kindler et al., 2010), reduces the ROS levels of the FLT3-
ITD containing MV4-11 cell line. A similar effect was observed in MOLM-13 cells 
(Figure 22A), corresponding to an increase in BIAM-labelled protein (Figure 22B) 
and a decrease in p-FLT3 (Figure 22C) with no significant decrease in cell viability 
at this concentration (Figure 22D). This suggests that PKC412 inhibits FLT3-ITD in 
the MOLM-13 cells and is affecting the redox state of the cell.  
Inhibition of FLT3-ITD results in a decrease in p22phox protein levels in 
MOLM-13 
 Evidence in the literature strongly implicates FLT3 as being an upstream 
regulator of Nox with much of the data focusing on the oncogenic signalling by the 
constitutively active FLT3-ITD through STAT5 phosphorylation and NAPDH 
availability (Reddy et al., 2011; Sallmyr et al., 2008a).  According to the findings of 
Reddy et al. (2011) FLT3-ITD inhibition via PKC412 does not reduce the mRNA 
levels of Nox components in MOLM-13 cells, however the authors did not examine 
the changes in the amount of Nox isoforms and regulatory subunits at the protein 
level. Treatment of MOLM-13 cells with PKC412 for up to 24 hours had  
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Figure 22. FLT3-driven redox signalling in MOLM-13 cells  
A) Intracellular ROS levels measured by DCF fluorescence (FL1-H) in untreated 
MOLM-13 cells, overlaid with cells treated with 250 nM PKC412 for 8 hours and 24 
hours. B) HRP-SA detection of BIAM-labelled (reduced) protein content of MOLM-
13 cells treated with 250 nM PKC412 for 24 hours. C) Western blot analysis of the 
p-FLT3 levels of untreated MOLM-13 cells and cells treated with 250 nM PKC412 
for 24 hours. Total FLT3 levels are shown as a loading control. D) Histogram 
represents the viability of MOLM-13 cells after 24 hour incubation with 250 nM 
PKC412 as determined by Trypan Blue staining. Samples were not found to be 
statistically significant. Statistical analysis was performed using Student‟s t-test to 
evaluate the difference between untreated and PKC412-treated samples. Significance 
was defined at the level of P<0.05. 
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no effect on the protein levels of the majority of Nox proteins, did slightly reduce the 
levels of Nox 4 and p67phox, however it is the dramatic reduction in the levels of 
p22phox which is most striking (Figure 23).  The decrease in p22phox protein is also 
observed by Woolley et al. (2012) in MV4-11 cells but similarly to Reddy et al., 
Woolley et al. noted that there was no change in p22phox mRNA levels. In fact, 
Woolley et al. went on to show that FLT3 affects the levels of p22phox through 
regulation of its ubiquitination and degradation.   
 
 
 
Figure 23. Effects of FLT3-ITD inhibitor PKC412 on Nox expression 
Western blot analysis of Nox isoforms 1, 2, 4 and 5, as well as transmembrane 
protein p22phox, organiser subunit p47phox and activator subunit p67phox, in 
untreated MOLM-13 cells, cells treated with the DMSO vehicle only for 24 hours, or 
cells treated with 250 nM FLT3-ITD inhibitor PKC412 for 8 or 24 hours. β-Actin is 
shown as a loading control.  
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Redox effects of PKC412 are specifically due to its inhibition of FLT3-ITD 
 Although it has been shown in Figure 22C that PKC412 does reduce the 
amount of actively signalling p-FLT3 in MOLM-13 cells, the alterations in cellular 
redox state observed could be explained by off-target effects of the drug which are 
unrelated to its FLT3-ITD inhibition. For this reason, the HL60 cell line was 
employed to demonstrate that the redox effects of PKC412 are caused by inhibition 
of FLT3-ITD signalling. The HL60 cell line expresses only the wild type FLT3 
receptor which becomes activated only upon stimulation by the FLT3 ligand (FL). 
As PKC412 has a higher affinity for the mutated version of the receptor, the HL60 
cells are frequently used as negative control for the drug (Levis et al., 2004; 
Seedhouse et al., 2006; Woolley et al., 2012). Indeed,  in this case there was no 
effect on ROS or BIAM-labelled protein levels in the HL60 cells treated with 250 
nM PKC412, nor was there any effect on the p22phox protein levels (Figure 24), a 
result also noted by Woolley et al. (2012). However, it must be noted that at higher 
concentrations of this drug, an inhibition of the wild type receptor is likely to occur. 
Stimulation with the FLT3 ligand induces redox changes in HL60 cells 
 There are reported differences between the signalling pathways of the wild 
type FLT3 and the constitutively active mutant. This is attributed to the occasional 
prolonged retention of the mutant receptor in the ER, due to folding defects and 
impaired trafficking to the membrane (Choudhary et al., 2009; Schmidt-Arras et al., 
2009), leading to a proximity to novel substrates and interacting partners that the 
wild type receptor is not exposed to in its location at the membrane. However, there 
is some overlap between the mutant and wild type FLT3 when both are localised to  
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Figure 24. Effect of FLT3-ITD inhibitor PKC412 on the HL60 cell line 
A) Intracellular ROS levels measured by DCF fluorescence (FL1-H) in untreated 
HL60 cells, overlaid with cells treated with 250 nM PKC412 for 24 hours. B) HRP-
SA detection of BIAM-labelled (reduced) protein content of HL60 cells treated with 
the DMSO vehicle only and cells treated with 250 nM PKC412 for 24 hours. C) 
Western blot analyses of p22phox expression in HL60 cells treated with the DMSO 
vehicle only and in cells treated with 250 nM PKC412 for 24 hours. β-Actin is 
shown as a loading control. 
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the membrane, including stimulation of the Ras-MAPK and  JAK-STAT pathways, 
PI3K, Src, and phospholipase C-gamma (PLCγ), so the spheres of influence of the 
two versions of the FLT3 receptor are clearly not mutually exclusive (Choudhary et 
al., 2005; Gu et al., 2011).  
 In order to determine if the FLT3-Nox-ROS sequence being investigated here 
is unique to the FLT3-ITD mutant, or is common to both the mutated and wild type 
forms, the FLT3 ligand (FL) was used to stimulate the wild type FLT3 receptor in 
HL60 cells and the redox readout of the cells was examined. Based on unpublished 
data from within our laboratory, which previously established the optimal dose for 
stimulation of the wild type HL60 cell receptor with the FL, 50 ng/ml of FL was 
used to stimulate the HL60 cells. Figure 25 shows that stimulation resulted in an 
increase in ROS levels corresponding to a decrease in BIAM-labelled protein and an 
increase in p-FLT3. Although the ROS burst induced by FLT3 ligand in HL60 cells 
appears modest when represented on the log scale of the FACS histogram, it is likely 
that as a physiologically relevant signalling event it is localised and concentrated in 
order to stimulate a specific target rather than triggering cell-wide oxidative stress. It 
appears that the FL-induced ROS burst is relative to the FLT3 status of the cell, as 
the MOLM-13 cells, heterozygous for the wild type receptor displayed less of an 
ROS increase and a smaller p-FLT3 induction (Figure 26).  
 Similarly, the MV4-11 cells which do not express the wild type receptor at 
all showed no change in ROS or p-FLT3 levels (Figure 26), thus acting as a negative 
control for the FLT3 ligand and demonstrating that the effects on the redox profile of 
the cells is related to ability of the ligand to stimulate the receptor and not due to off-
target effects of the ligand itself.  
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Figure 25. Effect of the FLT3 ligand (FL) on the HL60 cell line.  
A) Intracellular ROS levels measured by DCF fluorescence (FL1-H) in untreated 
HL60 cells overlaid with cells stimulated with 50 ng/ml FL for 30 minutes. B) HRP-
SA detection of BIAM-labelled (reduced) protein content of HL-60 cells stimulated 
with 50 ng/ml FL for 30 minutes. β-Actin is shown as a loading control. C) Western 
blot analysis of the p-FLT3 levels of untreated HL60 cells and cells stimulated with 
50 ng/ml FL for 15 and 30 minutes. Total FLT3 levels are shown as a loading 
control. 
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Figure 26. Effect of the FLT3 ligand (FL) on the MOLM-13 and MV4-11 cell 
lines. A) Intracellular ROS levels measured by DCF fluorescence (FL1-H) in 
untreated MOLM-13 cells overlaid with cells stimulated with 50 ng/ml FL for 30 
minutes. B) Western blot analysis of the p-FLT3 levels of untreated MOLM-1 3 cells 
and cells stimulated with 50 ng/ml FL for 15 or 30 minutes. Total FLT3 levels are 
shown as a loading control. C) Intracellular ROS levels measured by DCF 
fluorescence (FL1-H) untreated MV4-11 cells overlaid with cells stimulated with 50 
ng/ml FL for 30 minutes. D) Western blot analysis of the p-FLT3 levels of untreated 
MV4-11 cells and cells stimulated with 50 ng/ml FL for 15 or 30 minutes. Total 
FLT3 levels are shown as a loading control. 
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Stimulation of the wild type FLT3 receptor with the FLT3 ligand results in an 
increase in p22phox protein levels  
 Having observed that both FLT3-ITD and wild type activity are connected to 
the ROS levels of the AML cells, and that inhibition of the mutant receptor caused a 
decrease in p22phox levels in MOLM-13 cells, the next step was to determine if 
stimulation of the wild type receptor resulted in an increase in p22phox protein. 
Correlating well with the effects on the ROS levels, the ability of the ligand to 
increase p22phox levels appears to correspond to the FLT3 receptor status of the cell 
line in question and the ability to respond to the ligand. In this way HL60 cells 
showed the largest induction of p22phox, the same treatments in MOLM-13 cells 
induces a much smaller increase in p22phox levels, but the basal p22phox levels in 
MOLM-13 are higher than those in HL60 cells, and there was no effect on the 
p22phox levels of MV4-11 cells (Figure 27).  
 
 
Figure 27.  Effect of FLT3 ligand stimulation on the expression of p22phox in 
AML cell lines.  Western blot analysis of the levels of p22phox protein expression 
in the untreated HL60, MOLM13 and MV4-11 cell lines, and cells stimulated with 
50 ng/ml FL for 15 and 30 minutes. β-Actin is shown as a loading control. 
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FLT3 signals to Ezrin, a downstream target of Nox 
 To further probe the relationship between FLT3 and Nox, the ability of FLT3 
to signal to Ezrin, the downstream target of Nox mediated p-Tyr signalling, was 
tested using both PKC412 and the FL. As FLT3 is a RTK, it is reasonable to assume 
that interfering with its activity; either positively or negatively, will affect the p-Tyr 
levels of the cell. This was demonstrated for MV4-11 and MOLM-13 cells treated 
with PKC412 (Figure 28A and B), and while the inhibitor again had no effect on the 
p-Tyr levels of HL60 cells (Figure 28C), the FL induced tyrosine phosphorylation 
(Figure 28D).  In agreement with the general p-Tyr effects, tyrosine phosphorylation 
specifically of Ezrin was also affected by FLT3 signalling. PKC412 reduced the 
levels of p-Ezrin at the two tyrosine residues also regulated by Nox activity, Y146 
and Y353, in both MOLM-13 (Figure 29A) and MV4-11 cells (Figure 29B). Again 
there was no effect of PKC412 on the p-Ezrin levels of HL60 cells (Figure 29C), but 
the FL did stimulate phosphorylation at both residues in this cell line (Figure 29D). 
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Figure 28. Effects of FLT3 signalling on the p-Tyr levels of AML cell lines. 
Western blot analyses of the p-Tyr profiles of A) MOLM-13 B) MV4-11 and C) 
HL60 cells treated with the DMSO vehicle only or with 250 nM PKC412 for 24 
hours, and D) HL60 cells stimulated with 50 ng/ml FL for 15 or 30 minutes. β-Actin 
is shown as a loading control.  
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Figure 29. Effects of FLT3 signalling on Ezrin tyrosine phosphorylation. 
Western blot analyses of p-Ezrin Y146 and Y353 in A) MOLM-13 B) MV4-11 and 
C) HL60 cells treated with the DMSO vehicle only or with 250 nM PKC412 for 24 
hours, and D) HL60 cells stimulated with 50 ng/ml FL for 30 minutes. β-Actin is 
shown as a loading control. 
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Inhibition of Src results in a decrease in p-Ezrin Y353 and Y146 
 Taken together, these results indicate that FLT3 signalling in MOLM-13, 
MV4-11 and HL60 cells, drives the production of ROS by Nox, and influences the 
phosphorylation of Ezrin at tyrosines Y146 and Y353. If Ezrin tyrosine 
phosphorylation is dependent on ROS then this presents the possibility that the 
phosphorylation process is carried out by a redox-sensitive kinase. Early indications 
were that Ezrin was phosphorylated on Y146 and Y353 after stimulation of the EGF 
receptor (Bretscher, 1989, Krieg and Hunter, 1992), and more recent evidence has 
narrowed this down to indicate that Src kinase phosphorylates Ezrin on Y146 
(Srivastava et al., 2005; Wang et al., 2003) and on another tyrosine residue Y477 
(Heiska and Carpen, 2005; Mak et al., 2012).  Y146 is a conserved residue amongst 
the Ezrin-related proteins Radixin and Moesin as well as band 4.1, Talin and 
phosphatases PTPH1 and PTPMEG which all share homology of the N-terminal 
domain where this residue is located (Krieg and Hunter, 1992). Y353 however is 
unique to Ezrin and has been shown to be phosphorylated downstream of Syk kinase 
in B cell lines, though the same study also demonstrated that inhibition of Src kinase 
in these cells influenced phosphorylation at Y353 (Coffey et al., 2009).  
 As Src is a kinase known to be redox regulated (Giannoni et al., 2010), its 
documented involvement with Ezrin serves to further strengthen the premise that it 
may play a role in the FLT3-Nox-Ezrin pathway. The ability of Src to phosphorylate 
Ezrin at both Y146 and Y353 was confirmed in MOLM-13 cells using western 
blotting to examine the phosphorylation status of both residues after treatment with 
the SFK inhibitor PP2 (Figure 30). 
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Figure 30. Effect of SFK inhibition on the tyrosine phosphorylation of Ezrin. 
Western blot analyses of p-Ezrin Y146 and Y353 in MOLM-13 cells treated with 20 
µM of the SFK inhibitor PP2 for 24 hours. β-Actin is shown as a loading control. 
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Src activity is redox regulated 
 Next the possibility of redox regulation of Src downstream of Nox was 
examined. Initially, the effect of Nox inhibition, via DPI, on Src activity was 
investigated using western blotting. Src phosphorylation on Y416, reflecting active 
Src, was shown to be reduced upon treatment with DPI similarly to the reduction 
observed using the Src inhibitor PP2 (Figure 31A). Interestingly, active Src was 
shown to increase upon incubation of MOLM-13 cells with H2O2 (Figure 31A, lane 
5), or of HL60 cells with FL (Figure 31B). Similar results were observed in MV4-11 
cells (Figure 31C).  
Src is reduced in response to inhibition of FLT3-ITD and Nox signalling 
 In order to confirm that these changes in p-Src Y416 correspond to changes 
in the redox state of Src, BIAM-labelling of MOLM-13 cell lysates followed by 
immunoprecipitation of Src and immunoblotting using HRP conjugated to 
streptavidin (HRP-SA) was carried out to determine the proportion of reduced Src 
(Figure 32) as in the procedure described by Giannoni et al. (2005). Compared to the 
untreated cells, an increase in reduced Src was observed upon treatment with either 
DPI or PKC412 (Figure 32A lanes 2 and 4), implying that the proportion of oxidised 
Src decreases after inhibition of ROS production either at the level of FLT3-
induction of Nox or inhibition of Nox activity itself. 
As expected, incubation with H2O2 (Figure 32A, lane 3) resulted in a decreased 
fraction of reduced Src, corresponding to an increase in oxidised Src. The reducing 
effect of DPI and PKC412 on Src also occurred in MV4-11 cells (Figure 32B), while 
PKC412 had no effect on the redox state of Src in HL60 cells (Figure 32C). 
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Comparison of the p-Src Y416 data with the results of the BIAM-labelling of Src, 
seems to align with the model of oxidative-activation of Src proposed by Giannoni et 
al. (2005) rather than the oxidative-inactivation of Src supported by Kemble et al. 
(2009). In this scenario, it appears that ROS production downstream of FLT3-ITD 
affect the activity of Src via alterations to its redox status.  
 
 
 
Figure 31. Effects of DPI, H2O2 and FLT3 ligand on Src activity. 
Western blot analysis of p-Src Y416 in A) untreated MOLM-13 cells, cells treated 
with the DMSO vehicle only, 20 µM DPI for 24 hours, 20 µM Src inhibitor PP2 for 
24 hours, or 100 µM H2O2 for 30 minutes, B) untreated HL60 cells and cells 
stimulated with 50 ng/ml FL for 30 minutes and C) MV4-11 cells treated with 
DMSO vehicle only or 20 µM DPI for 24 hours or 100 µM H2O2 for 30 minutes. β-
Actin is shown as a loading control. 
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Figure 32. Redox regulation of Src in AML cells. 
HRP-SA detection of BIAM-labelled (reduced) Src fraction of total Src 
immunoprecipitated from A) untreated MOLM-13 cells and cells treated with 20 µM 
DPI 24 hours, 100 µM H2O2 for 30 minutes or 250 nM PKC412 for 24 hours, B) 
untreated MV4-11 cells and cells treated with 20 µM DPI or 250 nM PKC412 for 24 
hours, C) untreated HL60 cells and cells treated with 250 nM PKC412 for 24 hours.  
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Tyrosine phosphorylation downstream of Nox occurs through redox regulation 
of Src  
 As a redox-sensitive kinase, Src is in a position to translate the upstream 
ROS signal induced by FLT3 and generated by Nox, into downstream tyrosine 
phosphorylation of protein targets. To investigate the extent to which Src mediates 
the redox-driven tyrosine phosphorylation observed in MOLM-13 cells, cells were 
treated with either Src inhibitor PP2 alone or prior to H2O2 incubation and the p-Tyr 
levels of cells were then examined. Incubation with H2O2 induced an increase in p-
Tyr levels in MOLM-13 (Figure 33A, lane 4) and in MV4-11 cells (Figure 33B). 
The Src inhibitor PP2 (Figure 33A, lane 5) prompted a decrease in p-Tyr to an extent 
similar to that of DPI (Figure 33A, lane 3). Furthermore, pre-incubation with PP2, 
prior to stimulation with H2O2, prevented the peroxide-induced increase in p-Tyr 
(Figure 33A, lane 6). This effect was also shown to apply specifically to Ezrin 
tyrosine phosphorylation, with both Y146 and Y353 showing increased 
phosphorylation in response to H2O2 and this increase being blocked upon pre-
treatment with PP2 in MOLM-13 cells (Figure 33C). The susceptibility of Ezrin 
tyrosine phosphorylation to H2O2 was also observed in MV4-11 cells (Figure 33D). 
Altogether, this suggests an intermediary role for Src in translating the redox status 
of the cell into modifications at the protein level.  
 
 
 
 
128 
 
 
Figure 33. Effects of Src inhibition on Nox-driven tyrosine phosphorylation. 
Western blot analyses of A) p-Tyr levels in untreated MOLM-13 cells, cells treated 
with DMSO vehicle or 20 µM DPI for 24 hours, 100 µM H2O2 for 30 minutes, 20 
µM PP2 for 24 hours, or pre-incubated with 20 µM PP2 for 24 hours prior to the 
introduction of 100 µM H2O2 for 30 minutes and B) p-Tyr levels in MV4-11 cells 
treated with DMSO vehicle for 24 hours, 100 µM H2O2 for 30 minutes or 20 µM 
DPI for 23 hours, C) p-Ezrin Y146 and Y353 in untreated MOLM-13 cells, cells 
treated with DMSO vehicle only or 100 µM H2O2 for 30 minutes, or pre-incubated 
with 20 µM PP2 for 24 hours prior to treatment with 100 µM H2O2 for 30 minutes, 
D) p-Ezrin Y146 and Y353 in MV4-11 cells treated with 100 µM H2O2 for 30 
minutes. β-Actin is shown as a loading control. 
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siRNA-mediated knockdown of p22phox results in a decrease in p-Ezrin and p-
Src 
 The effects of Nox inhibition via DPI on the downstream targets Src and 
subsequently Ezrin have been demonstrated. Given the mode of action of DPI and to 
eliminate the possibility that flavin-containing enzymes other than Nox may be 
responsible for these effects, MOLM-13 cells were transfected with siRNA targeting 
p22phox using the Amaxa Nucleofactor electroporation technology.
 
The initial 
experiments using the programme recommended by Amaxa for MOLM-13 cell 
transfection had such a detrimental effect on cell viability that protein yields were 
too low to use for SDS-PAGE. As discussed in the previous chapter myeloid 
leukaemia cells have been widely classified as „difficult to transfect‟ therefore some 
optimisation was required in order to find a programme which ensured transfection 
efficiency without compromising cell viability. As expected, very poor transfection 
efficiency was observed for the control 3486 bp maxGFP™ plasmid for all 
programmes tested, likely due to the size of the construct (Figure 34A), but upon 
transfection with the much smaller 21 bp siRNA targeting p22phox, an almost 
complete reduction in p22phox protein was observed for programme D023 (Figure 
34B), with protein yield remaining substantial. Therefore this programme was used 
for the subsequent MOLM-13 siRNA experiments. 
 In agreement with the results observed using DPI, p22phox knockdown using 
siRNA in MOLM-13 cells reduced phosphorylation of Ezrin at both Y146 and Y353 
and of Src at Y416 (Figure 35). This confirms that the effects previously observed 
using DPI may be attributable specifically to inhibition of Nox activity.  
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Figure 34. Optimisation of siRNA transfection of MOLM-13 cells. 
A) Green fluorescent protein (GFP) fluorescence as measured on the FL1-H channel 
in  untransfected MOLM-13 cells overlaid with cells transfected with 50 ng 
maxGFP™ plasmid, using three different Amaxa Nucleofactor electroporation 
programmes X001, D023 and Q017. B) Western blot analyses of p22phox protein 
levels from untransfected MOLM-13 cells, cells transfected with 50 ng scrambled 
siRNA control (Scr) or three different siRNAs targeting p22phox. 
 
 
 
 
131 
 
 
 
 
Figure 35. Effect of p22phox knockdown on downstream targets of Nox-driven 
ROS in MOLM-13 cells. Western blot analyses of p-Ezrin Y146, Y353, p-Src Y416 
and p22phox protein levels from MOLM-13 cells transfected with scrambled siRNA 
control (Scr) or siRNA targeting p22phox. β-Actin is shown as a loading control. 
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siRNA knockdown of p22phox in HL60 cells demonstrates reliance of FLT3 
signalling on p22phox 
 To clarify whether the increases in p-Ezrin and p-Src observed upon 
stimulation of HL60 cells with the FLT3 ligand are related to ROS levels, p22phox 
was knocked down using siRNA in HL60 cells and the cells were then stimulated 
with the FL. It was observed that levels of p-Ezrin Y353 and Y146 as well as p-Src 
416 decreased upon p22phox knockdown (Figure 36) despite stimulation with the 
same concentration of FLT3 ligand (50ng/ml) for the same period of time which, in 
un-transfected cells, provoked the increases observed in Figures 29 and 31. This 
demonstrates that p22phox specifically mediates the FLT3 signal of which Ezrin and 
Src are downstream targets. 
Inhibition of Nox, Src or FLT3 affects the localisation of Ezrin within MOLM-
13 cells 
 FLT3 and Nox activity affects Ezrin tyrosine phosphorylation but the 
significance of this effect to the function of Ezrin is hard to predict based on the 
relative scarcity of literature regarding Ezrin tyrosine phosphorylation. Threonine 
phosphorylation of Ezrin, by comparison, has received the majority of attention 
because of its role in activation of the protein via relief of the auto-inhibitory 
conformation (Matsui, 1998; Simons et al., 1998). Within the cell, activated Ezrin 
has been shown to localise to the cytoplasmic side of the plasma membrane 
(Turunen et al., 1989) where it forms a dynamic link between F-actin and the plasma 
membrane proteins (Fehon et al., 2010), and is significantly enriched in cell 
protrusions such as membrane ruffles and microvilli (Auvinen et al., 2007; Pakkanen 
et al., 1988). Immunofluorescence was carried out on MOLM-13 cells in order to 
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investigate whether the effect of FLT3, Nox or Src activity on Ezrin tyrosine 
phosphorylation also affects Ezrin localisation (Figure 37).  In untreated cells, Ezrin 
staining was punctate with some localisation to the periphery of the cell. 
 
 
 
Figure 36. Effect of p22phox knockdown on the FLT3 ligand (FL) stimulation 
of HL60 cells. Western blot analyses of the levels of p-Ezrin Y146, Y353, p-Src 
Y416 and p22phox after FL stimulation (50 ng/ml for 30 minutes) of HL60 cells 
transfected with scrambled siRNA control (Scr) or siRNA targeting p22phox. β-
Actin is shown as a loading control.  
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 After 24 hour incubation with DPI, PKC412 or PP2, Ezrin can be seen to lose 
the punctate staining, move from the membrane to the cytosol, and accumulate in a 
peri-nuclear pattern, showing some co-localisation with the nuclear stain Hoescht. 
The same effect was observed for PKC412 in MV4-11 cells (Figure 38), while no 
change in Ezrin sub-cellular localisation was seen in HL60 cells treated with 
PKC412 (Figure 39). Nucleolar and nuclear localisation of Ezrin, as well as another 
ERM family member Moesin, have been previously observed (Barret et al., 2000; 
Batchelor et al., 2004; Melendez-Vasquez et al., 2001) and Batchelor et al. have 
identified a nuclear localisation-sequence that is common to all three ERM proteins, 
but the consequences of this localisation are as yet undetermined.  
 
         
 
 
 
 
 
 
       
 
 
135 
 
 
 
 
 
 
 
 
Figure 37. Effects of inhibition of Nox, FLT3 or Src on Ezrin sub-cellular 
localisation in MOLM-13 cells. Immunofluorescence micrographs of Ezrin sub-
cellular localisation (green) showing punctate staining at the periphery of untreated 
MOLM-13 cells, and cytoplasmic staining pattern with some co-localisation with the 
nuclear stain Hoescht (blue) in cells treated with 20 µM DPI, 250 nM PKC412, 20 
µM PP2 for 24 hours. Ezrin/Hoescht denotes merged image. A representative 
micrograph is shown in each case. Scale bar represents 10 µm. 
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Figure 38. Effects of inhibition of FLT3-ITD on Ezrin sub-cellular localisation 
in MV4-11 cells. Immunofluorescence micrographs of Ezrin sub-cellular 
localisation (green) showing punctate staining at the periphery of untreated MV4-11 
cells, and cytoplasmic staining pattern with some co-localisation with the nuclear 
stain Hoescht (blue) in cells treated with 250 nM PKC412, for 24 hours. 
Ezrin/Hoescht denotes merged image. A representative micrograph is shown in each 
case. Scale bar represents 10 µm. 
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Figure 39. Effects of inhibition of FLT3-ITD on Ezrin sub-cellular localisation 
in HL60 cells. Immunofluorescence micrographs of Ezrin sub-cellular localisation 
(green) showing punctate staining at the periphery of untreated HL60 cells, and 
cytoplasmic staining pattern with some co-localisation with the nuclear stain Hoescht 
(blue) in cells treated with 250 nM PKC412, for 24 hours. Ezrin/Hoescht denotes 
merged image. A representative micrograph is shown in each case. Scale bar 
represents 10 µm. 
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Nox-driven changes in Ezrin localisation results in morphological changes in 
MOLM-13 cells 
 As a key regulator of the cytoskeleton, Ezrin has been shown to promote the 
formation of invasive and migratory features such as invadopodia, lammelipodia and 
ruffled edges (Brambilla and Fais, 2009; Martin et al., 1997). The changes in Ezrin 
localisation due to FLT3 or Nox inhibition, seen in Figures 37 and 38, could 
therefore affect the ability of the cell to form these membrane protrusions. Scanning 
electron microscopy (SEM) was used to examine the morphology of MOLM-13 cells 
adhering to poly-l-lysine-coated coverslips, and showed that, in contrast to the 
spread, flattened appearance of untreated cells, cells treated with DPI, PKC412 or 
PP2 for 24 hours displayed a more bulbous retracted morphology (Figure 40). This is 
consistent with previous reports of changes in cell morphology coinciding with 
alterations in Ezrin sub-cellular localisation (Auvinen et al., 2007; Bretscher, 1989; 
Krieg and Hunter, 1992). The untreated cells appear to be adhering to the poly-l-
lysine at multiple points on the basal cell surface, while the cells treated with DPI, 
PKC412 or PP2 seem less connected. Viewing adhesion as a precursory step to the 
process of migration, this prompted the question of whether FLT3 or Nox inhibition, 
and the resulting effects on Ezrin and cell morphology, would affect the ability of 
MOLM-13 cells to migrate.     
Inhibition of Nox or FLT3 results in a decreased ability of AML cells to migrate 
 As Ezrin expression has been associated with increased migration of tumour 
cells (Zhou et al., 2010b), a reduction in its tyrosine phosphorylation, changes to its 
sub-cellular localisation and alterations to MOLM-13 cell morphology due to FLT3, 
Src or Nox inhibition could negatively influence the motility of MOLM-13 cells.  
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Figure 40. Effect of Nox or FLT3-ITD inhibition on MOLM-13 cell 
morphology. Scanning electron micrographs of untreated MOLM-13 cells compared 
to cells treated with 20 µM DPI, 250 nM PKC412 or 20 µM PP2 for 24 hours. Scale 
and accelerating voltages are indicated. A representative micrograph is shown in 
each case. 
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A chemotaxis assay was carried out to assess the ability of MOLM-13 cells to 
migrate across a transwell membrane. Compared to the untreated control, cells 
treated with DPI (Figure 41A), PKC412 (Figure 41B) or PP2 (Figure 41C) displayed 
a very significant and concentration-dependent decrease in migration, reflected by 
similar results in MV4-11 cells (Figure 42A).  PKC412 had no effect on the 
migration of HL60 cells (Figure 42B). This demonstrated that the modulation of 
Ezrin tyrosine phosphorylation and sub-cellular localisation caused by FLT3 and 
Nox inhibition correlates with the effects of their inhibition on the motility of 
MOLM-13 cells and reflected the finding of Zhou et al. (2010) that Ezrin is a key 
mediator in the metastasis of another leukaemia cell line MOLT4.  
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Figure 41. Effect of Nox, FLT3 or Src inhibition on the migration of MOLM-13 
cells. Graphs depicting the migration, through a 5 µm polycarbonate membrane, of 
untreated MOLM-13 cells, cells treated with DMSO vehicle only and cells treated 
with increasing concentrations of DPI (A) PKC412 (B), or PP2 for 24 hours. 
Migration of untreated cells was used as a control (=1). Statistical analysis was 
performed using Student‟s t-test. *** denotes P<0.001. 
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Figure 42. Effect of Nox or FLT3-ITD inhibition on the migration of MV4-11 
and HL60 cells. Graph depicts the migration, through a 5 µm polycarbonate 
membrane, of A) untreated MV4-11 cells, cells treated with DMSO vehicle only and 
treated with 20 µM DPI or 250 nM PKC412 for 24 hours and B) untreated HL60 
cells, cells treated with DMSO vehicle only and cells treated with 250 nM PKC412 
for 24 hours. Migration of untreated cells was used as a control (=1). Statistical 
analysis was performed using Student‟s t-test.  *** denotes P<0.001. 
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Discussion 
 Aberrant migration of leukaemic cells followed by extramedullary infiltration 
into secondary sites of bone marrow and organs are major complicating factors for 
AML (Fukuda et al., 2005; Stefanidakis et al., 2009). The role of FLT3 in regulating 
both the normal migration of haematopoietic progenitors, as well as the subversive 
migration of leukaemic cells has been demonstrated (Fukuda and Pelus, 2006). There 
is evidence to suggest that FLT3 signalling involves downstream activation of Nox 
and subsequent increase in ROS levels (Reddy et al., 2011; Sallmyr et al., 2008a) 
and it has also been established that ROS produced by Nox can promote and stabilise 
the cell protrusions that facilitate migration and invasion (Diaz et al., 2009; Gianni et 
al., 2011). With regard to the mechanism whereby Nox-derived ROS exert their 
effects on the cytoskeletal machinery of the cell, much data support a role for Src 
kinase in translating the upstream oxidant generation to the downstream protein 
modifications and the resulting phenotypic effects. Src has been shown to undergo 
oxidative activation upon integrin engagement (Chiarugi, 2008), which facilitates its 
interaction with cytoskeletal mediators leading to alterations in cell morphology 
associated with adhesion and invasion (Giannoni et al., 2005).  
 Incorporation of a redox element into a signalling pathway appears to be 
fraught with difficulty, not least in terms of the perceived lack of specificity of 
oxidant targeting and the potentially detrimental effects such highly reactive 
molecules can cause to intracellular biomolecules such as DNA and lipids. Indeed 
the utilisation of ROS as signalling mediators in their own right has evolved to be 
tightly regulated spatially, temporally and in terms of substrate susceptibility. This 
regulation is facilitated by the discrete subcellular compartmentalisation of ROS 
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production (Chen et al., 2009), the restricted availability of Nox activating and 
regulatory subunits (Gianni et al., 2009;Terada, 2006) and the presence of cytosolic 
scavenging and neutralising enzymes such as Cu/Zn SODs, GSH peroxidase 
(Terada, 2006) and Prxs (Rhee and Woo, 2011; Rhee et al., 2012) to prevent escape 
or accumulation of ROS to toxic levels. Substrate specificity is also regulated 
through co-localisation of ROS producing enzymes and the intended target of the 
oxidants produced, to distinct insulated intracellular compartments. The redox 
regulation of Src in the scenario presented in this chapter must involve proximity of 
the kinase to a p22phox-dependent Nox isoform as demonstrated by the p22phox 
knockdown experiments. As Nox 3 has been shown not to be expressed in these 
cells, Nox 1, 2 and possibly 4 are the incumbent isoforms.  
 The direct oxidation of Src supported by results presented in this chapter, 
does not exclude the possibility that concomitant oxidative-inactivation of a PTP 
which de-phosphorylates Ezrin is also occurring, and contributing to the changes in 
Ezrin tyrosine phosphorylation. Although on the whole there is very little literature 
surrounding de-phosphorylation of Ezrin, it is worth noting at this point an 
interesting paper from Forte et al. (2008) which demonstrates that the overexpression 
of dual specificity phosphatase of regenerating liver-3 (PRL-3), which is implicated 
in a range of metastatic tumours, causes the de-phosphorylation of Ezrin Y146 and 
Y353. Separately, it has been shown that PRL-3 is downstream of FLT3-ITD 
signalling (Zhou et al., 2011) and is subject to redox regulation (Orsatti et al., 2009), 
making it a highly promising candidate for a position in the FLT3-Nox-Ezrin 
pathway.  
146 
 
 Similarly, the direct redox activation of Src does not prohibit the possibility 
that indirect redox activation of the kinase is also operating via oxidative-
inactivation of a phosphatase, or indeed a kinase such as Csk, which inhibits Src 
activity. In fact, this study aims to provide evidence to complement rather than 
confront the established model of redox regulation of tyrosine phosphorylation, with 
the objective of broadening the current redox signalling paradigm to include direct 
redox regulation of kinases as a crucial component. 
 Ezrin has previously been shown to play a key role in the metastasis of 
leukaemic cells (Zhou et al., 2010), as well as being associated with the migration 
and progression of a range of other cancers (Brambilla and Fais, 2009; Fais, 2004). 
Previously published data from Monni et al. (2008) has shown that Ezrin is 
phosphorylated downstream of another constitutively active FLT3 mutant, FLT3-
D835Y. As neither MOLM-13 nor MV4-11 cells contain this mutation, the results of 
this and the previous chapter demonstrate a novel link between FLT3-ITD signalling 
and modulation of Ezrin tyrosine phosphorylation. Since the publication of this data 
(Corcoran and Cotter, 2013), further evidence has emerged linking the 
phosphorylation of Ezrin to oncogenic FLT3-ITD signalling. Habif et al. (2013) used 
2D SDS-PAGE  to identify Ezrin as a downstream target of FLT3-ITD-driven 
phosphorylation and mediator of proliferative signalling in AML cells. 
 Our data showed that FLT3-ITD or Nox inhibition affected Ezrin by causing 
a shift in its localisation from the plasma membrane to the cytoplasm and possibly 
the nucleus. This shift coincides with de-phosphorylation of Ezrin at two tyrosine 
sites Y146 and Y353, though it is possible that additional, at present unknown, 
mechanisms of FLT3-driven regulation of Ezrin are also contributing. The changes 
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in sub-cellular localisation of Ezrin are likely to affect the established function of 
Ezrin as a cytoskeletal regulatory protein. Specifically as an intermediary between F-
actin and cell membrane proteins, its scaffolding function is inherently related to its 
location within the cell. The proximity of Ezrin to the cell membrane determines its 
ability to bind membrane-residing factors such as CD44 (Mori et al., 2008), 
PtdIns(4,5)P2 (Maniti et al., 2012),  ICAM-1 and 2 (Barreiro et al., 2002) and EBP50 
(LaLonde et al., 2010) amongst others, and  it is through these interactions that a link 
is formed between F-actin and the membrane leading to F-actin-rich membrane 
protrusions which facilitate cell motility (Arpin et al., 2011; Saleh et al., 2009). 
Although there is, to our knowledge, no evidence in the literature regarding the 
relevance of Ezrin tyrosine phosphorylation to its sub-cellular localisation, it is worth 
noting that inactive Ezrin has been repeatedly observed to be cytoplasmic rather than 
localising to the periphery of the cell and it is only upon activation that the protein 
shifts to the membrane (Bretscher et al., 2002; Gary and Bretscher, 1995).   
 However, rather than viewing the translocation observed here as negative 
regulation of Ezrin, it is possible that Ezrin plays a role in both the cytoplasm and 
nucleus, perhaps as a signalling molecule. While it is accepted that threonine 
phosphorylation of Ezrin facilitates its activation (Ng et al., 2001), less is known 
about the functional significance of Ezrin tyrosine phosphorylation. What data does 
exist seems to point towards a role for Ezrin tyrosine phosphorylation in signal 
transduction. Gautreau et al. (1999) have previously proposed that p-Ezrin Y353 
operates as a survival signalling molecule through interactions with the PI3K/Akt 
pathway. Further evidence links phosphorylation on Ezrin Y146 to Src-dependent 
adhesion signalling promoting cell proliferation (Srivastava et al., 2005) and 
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nominates another Src-phosphorylated residue Y477 as the effector of a malignant 
phenotype in Src-transformed cells (Heiska and Carpen, 2005; Heiska et al., 2011), 
supported again by a recent report from Mak et al. (2012) proposing a role for 
phosphorylation of Y477 in invasion and migration. 
 The shuttling of cytoskeletal proteins to the nucleus is being increasingly 
acknowledged as a direct and mechanical mode of communication between the 
plasma membrane, the interface for receiving extracellular stimuli, and the nucleus, 
where those signals are integrated and translated into necessary adaptive changes for 
the cell (Aplin, 2003; Aplin and Juliano, 2001). Proteins such as actin, paxillin, 
zymixin and ZO-1 have been shown to localise to the nucleus and participate in 
mRNA transcription (Balda et al., 2003; Chan et al., 2007; Hofmann et al., 2001; 
Woods et al., 2002). Band 4.1 has been shown to facilitate splicing (Lallena et al., 
1998)  as well as fulfilling its non-nuclear role in linking transmembrane proteins to 
the spectrin/actin cytoskeleton (Conboy, 1993) and both actin and band 4.1 play a 
role in maintaining the integrity of the nuclear matrix (Krauss et al., 1997; Rando et 
al., 2002).  
 Batchelor et al. (2004) also report the phenomenon of nuclear localisation of 
Ezrin, but in response to changes in cell density. They propose a structural role for 
Ezrin in the nucleus, similar to its role at the plasma membrane, and based on the 
affiliation that Ezrin has for actin, suggest that it could also facilitate transcription or 
export of mRNA from the nucleus as these are processes in which nuclear actin 
participates. The possible localisation of Ezrin to the nucleus in response to FLT3 or 
Nox inhibition could serve to communicate a signal of decreased FLT3 signalling at 
the cell membrane. This signal could trigger a response which, in its early stages, 
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manifests itself as a reduction in cell motility in order to conserve energy, but may 
later result in changes at the level of transcription of stress response genes as the cell 
attempts to adjust to and survive through the reduction in growth factor stimulation.  
 The effectiveness of the FLT3-ITD inhibitor PKC412, in impairing the 
migration of the AML cell line MOLM-13, highlights a potential mechanism 
whereby this inhibitor, currently in clinical trials for the treatment of AML, may 
prevent the spread of leukaemic blasts from the primary site of expansion to 
secondary extramedullary sites. The use of the HL60 cell line, which expresses only 
the wild type FLT3 receptor, as a negative control for PKC412 demonstrates that the 
observed effects of the drug are specific to FLT3-ITD signalling. 
 It is likely that FLT3 modulation of Ezrin tyrosine phosphorylation and sub-
cellular localisation are not the only mechanisms whereby FLT3 regulates leukaemic 
cell migration and this crucial aspect of FLT3 signalling deserves further 
investigation to clearly elucidate all of the contributing effectors.  
 The realisation that ROS may directly oxidise kinases in a signalling context 
allows the reviewing of previously published data with a view to identifying 
additional redox-regulated kinases. Articles which reported the sensitivity of a 
kinase-driven signal transduction pathway to ROS can be revisited and, by removing 
the assumption that another factor mediates the connection between the oxidant and 
the kinase, the hypothesis of a redox-sensitive kinase can be examined. Pourmahram 
et al. (2008) provides an example of such an opportunity, as the authors detected a 
shift in sub-cellular localisation in PKCα in intrapulmonary arteries upon exposure to 
low concentrations of H2O2. Similarly, Kato (2000) and colleagues‟ discovery of 
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redox-sensitive cysteine residues in c-Ret which are conserved across a range of 
kinases  should prompt investigation of the redox-sensitivity of those kinases. 
 Recently progress in the field of redox biology has been due to the 
development of methods for detection of redox-modifications, a subject which has 
been recently reviewed extensively in its own right (Butterfield and Dalle-Donne, 
2012). In this study, BIAM-labelling of reduced cysteine residues was used to 
examine the redox state of Src, adapted from a protocol outlined by Bovin et al. 
(2010, 2008) and although efficient for this purpose, is by no means the only option 
for analysing the redox state of individual proteins. A novel approach from Haque et 
al. (2011) uses an antibody raised to detect oxidised forms of PTPs, allowing the 
analysis of the redox state of specific phosphatases.   
 Recent advances in the development of fluorescent and affinity-labelled 
probes for the high throughput detection and  isolation of sulfenic acid modifications 
are described by Poole and Nelson (2008), and also recently covered by Paulsen and 
Carroll (2009). Concurrently, high throughput studies such as those conducted by 
Fomenko et al. (2007) and Weerapana et al. (2010) strive to quantify and 
characterise the reactive cysteine residues in native enzymes, with a view to 
predicting redox-relevant motifs. In addition to this, methodologies such as the 
carbonyl-based proteomics approach employed by Brioschi et al. (2012) are 
effective in identifying oxidative stress biomarkers which are invaluable from a 
prognostic and diagnostic perspective. 
 Redox regulation of signal transduction is a rapidly progressing field. The 
recent acceleration of research in this field has contributed to our understanding of 
the mechanisms whereby ROS exert their effects on target kinases and the 
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consequences of those effects both at the level of kinase activity and in terms of 
broader signalling and phenotypic implications. Data gleaned by analysing the 
physiological requirement for ROS production as a signalling device, can assist our 
understanding of the pathological situation which occurs when this system becomes 
deregulated. Implicating the redox regulation of kinases in the molecular basis of 
cancer and cardiovascular disease in particular, complements the established models 
of pathological oxidative stress but also provides new avenues and possibilities for 
targeted, antioxidant-based therapeutics. 
 In conclusion, we report a link between FLT3 signalling and Ezrin, mediated 
by Nox-derived ROS and the subsequent redox regulation of Src, which correlates 
with an effect of FLT3 and Nox activity on the morphology and migration of 
MOLM-13 cells. Similar effects observed in another FLT3-ITD expressing cell line 
MV4-11, suggests that this scenario may operate broadly in FLT3-ITD driven AML.  
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Chapter 5 
 
Regulation of phosphatase expression and activity by 
FLT3-ITD in the MOLM-13 cell line 
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Abstract 
Growth factor-driven tyrosine phosphorylation signalling cascades operate through 
the co-ordination of the activities of protein tyrosine kinases and protein tyrosine 
phosphatases. The negative regulation of potentially oncogenic tyrosine 
phosphorylation signalling by phosphatases has prompted the classification of 
several protein tyrosine phosphatases as tumour suppressors. Such phosphatases are 
frequently downregulated in tumours, at the level of transcription or through post-
translational modifications leading to suppression in phosphatase activity. FLT3-ITD 
has been shown to promote tyrosine phosphorylation through the redox-activation of 
Src kinase but, as demonstrated in this section, also regulates a range of 
phosphatases to facilitate increased duration and intensity of the phosphorylation 
signal. Inhibition of FLT3-ITD using PKC412 resulted in changes at the level of 
phosphatase protein expression which reflected changes to the transcription of 
selected phosphatase genes. In addition to this, FLT3-ITD was shown to negatively 
regulate the tumour suppressor phosphatase SHP-1 at a post-translational level 
through increased ubiquitination and proteasomal degradation of SHP-1 protein.  
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Introduction  
 Efficient functioning of tyrosine phosphorylation as a signal transduction 
device requires co-operation and communication between the PTKs and the PTPs. 
The nature of the cellular functions dictated by tyrosine phosphorylation signalling, 
i.e. proliferation, cell cycle and survival, renders this signalling mechanism 
potentially oncogenic, should it become de-regulated. Indeed, it is estimated that up 
to 80% of all proto-oncogenes code for PTKs (Laczmanska and Sasiadek, 2011), 
making  tight negative regulation of the phosphorylation cascade by PTPs especially 
crucial. It is understandable therefore, that many PTPs, such as Phosphatase and 
tensin homolog (PTEN), have been designated as tumour suppressors  (Laczmanska 
and Sasiadek, 2011; Song et al., 2012), and that the amount of genes which code for 
PTPs approximates the number which code for PTKs (Tonks, 2006) such is their 
responsibility to curb aberrant kinase activity.  
 The PTP superfamily, coded for by107 genes (Alonso et al., 2004), includes 
the classical PTPs that are specific for tyrosine and also the dual specificity 
phosphatases (DSPs) which, due to a different active site structure, can de-
phosphorylate serine and threonine as well as tyrosine residues and inositol 
phospholipids (Andersen et al., 2004).  A third subgroup within this superfamily is 
the pseudophosphatase PTPs which appear to be catalytically inactive although 
structurally resembling classical PTPs (Wishart and Dixon, 1998).   
 Although many PTPs play a role in negative regulation of potentially 
oncogenic signalling, it is worth noting that some can have a pro-oncogenic role by 
facilitating activation of pro-survival kinases through removal of an inhibitory 
phosphate or the inactivation of an inhibitory binding partner. An example of such a 
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PTP is SHP-2, which is known to become activated by EGFR and in turn activates 
the Ras -MAPK signalling pathway as well as SFKs (Matozaki et al., 2009). There is 
some ambiguity surrounding the exact mechanism whereby SHP-2 activates these 
kinases, one model proposes that SHP-2 directly de-phosphorylates the p120 
RasGAP binding site on Ras, thereby preventing the binding of the inhibitory 
molecule (Montagner et al., 2005). Another possibility is that SHP-2 indirectly 
activates Ras-MAPK via the activation of SFK intermediates, in multi-step process 
which is thought to involve the dephosphorylation of a Csk-binding protein, 
preventing recruitment of Csk to the SFKs (Ren et al., 2004; Zhang et al., 2004).  A 
further option proposed by Hanafusa et al. (2004), illustrates how SHP-2 may 
promote Ras-MAPK signalling through the inhibition, via dephosphorylation, of 
Sprouty, a negative regulator of Ras-MAPK.  
 In addition to its role in EGFR signal transduction, SHP-2 has also been 
implicated in the signalling pathways of Bcr-Abl, fibroblast-growth-factor receptor 3 
(FGFR3), Ret and ERBB2, a member of the EGFR (Ostman et al., 2006).  SHP-2 is 
something of a node for the convergence of signals from a number of growth factor 
receptors and the relaying of those signals to a variety of substrates.  So potent is its 
position as a signalling hub within the cell that autosomal dominant mutations in the 
SHP-2 gene PTPN11are thought to lead to 50% of cases of the complex Noonan 
syndrome which is associated with juvenile myelomonocytic leukaemia (JMML) 
(Tartaglia et al., 2001).  Incidence of PTPN11activating mutations are also found in 
ALL (Tartaglia et al., 2004) and sporadic JMML patients (Tartaglia et al., 2003), as 
well as AML, particularly of the M5 subgroup (Tartaglia et al., 2005).  
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 In addition to the activating mutations of SHP-2, the non-mutated form of the 
PTP is frequently found to be overexpressed and over-activated in FLT3-ITD 
containing leukaemic cells (Gu et al., 2011; Xu et al., 2005). SHP-2 appears to play 
an important role in normal haematopoiesis (Qu et al., 2001; Nabinger and Chan, 
2012) as well as leukemogenesis (Loh et al., 2004) and is a crucial component of the 
wild type FLT3 signalling pathway. SHP-2  is known to interact with the wild type 
FLT3 receptor after FL stimulation and promote the downstream activation of 
MAPK (Zhang et al., 1999; Muller et al., 2008b).  
 The example of SHP-2 demonstrates how PTPs can both directly and 
indirectly facilitate pro-survival signalling downstream of growth factor stimulation. 
Specifically with regard to the AML situation, SHP-2 represents an important 
mechanism of FLT3-ITD-driven signal propagation via upregulation of a PTP which 
contributes positively to the signalling pathway.  
 PTPs, whether they function as positive or negative regulators of a growth 
factor signalling, are themselves subject to stringent regulation. The modes of 
regulation of PTP activity range from control of PTP gene transcription, to protein 
turnover via ubiquitination and degradation, and via post-translation modifications 
such as phosphorylation and oxidation, which render the enzyme temporarily, or 
sometimes permanently, inactive.  
 The mechanism of PTP oxidative regulation has been discussed in Chapter 4 
as it provides a model for the oxidative regulation of other enzymes such as kinases, 
and appears to be co-ordinated with PTP phosphorylation (Chiarugi and Buricchi, 
2007) to provide an efficient means of inactivating PTPs to facilitate oxidant-
associated growth factor signalling.  The functional relevance of PTP oxidation is 
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constantly expanding, as is the range of PTPs affected, hinting at a prevalence of   
growth factor-driven redox regulation of PTPs.  
 Indeed, oxidation of PTPs appears to be indispensible for the functioning of 
certain intracellular signalling pathways. Recent work by Choi et al., (2011) shows 
how redox-mediated inactivation of SHP-1 participates in the M-CSF-induced 
proliferation of  haematopoietic progenitors. They observed that the transient 
oxidation of SHP-1 affects the PI3K/Akt but not the MAPK survival pathway to 
stimulate BMM proliferation. This demonstrates how the specificity and integrity of 
the signal initiated by M-CSF binding its receptor c-Fms, and subsequently 
transmitted via ROS, can be maintained. Interestingly, Choi et al., also report that 
SHP-2 was not oxidised in their system, even upon exogenous addition of H2O2, 
despite its accepted status as redox-sensitive phosphatase in other systems (Meng et 
al., 2002; Weibrecht et al., 2007). Oxidation of PTPs in a signalling context requires 
the specificity of an enzyme-substrate reaction in order to maintain the integrity of 
the propagated signal. The sensitivity of individual PTPs to different oxidant species 
is one mechanism whereby this differential regulation is ensured. 
 Similarly, Juarez et al., (2008) recently demonstrated that PTP1B is inhibited 
by H2O2 in vivo, but not by , the main type of ROS produced upon stimulation of the 
EGFR, which is itself negatively regulated by PTP1B. Although the role of 
endogenous antioxidants such as SODs are generally understood to be as safeguards 
against harmful increases in oxidants, the scenario described by Juarez et al., depicts 
SOD as a positive regulator of EGFR signalling, facilitating increases in H2O2 levels, 
inactivation of PTP1B and propagation of the proliferative signal through the 
MAPK/Erk pathway downstream of EGFR.  
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 The role of GF-mediated PTP oxidation in the physiology of normal cells has 
provided insights into how aberrant ROS production can compound stimulation of 
survival pathways by oncogenic RTK. The significance and complexity of PTP 
redox regulation in the context of oncogenic signalling was recently highlighted by 
Karisch et al. (2011). Here the authors used a global proteomic approach to assess 
the „PTPome‟ or global cellular profile of PTPs,  and then further modified this 
approach to quantify the „PTP redoxome‟ or proportion of PTPs which are oxidised 
in normal and neoplastic cells. They observed an increase in PTP oxidation in 
tumour cells, with each tumour type having its own unique profile of oxidised PTPs.  
 The list of PTPs which are redox regulated in response to GF signalling 
continues to grow and amongst the most recent additions to this list, and of particular 
relevance to this study  is the tumour suppressor DEP-1, which was shown by 
Godfrey et al. (2012) to be redox-inactivated in response to aberrant redox signalling 
driven by FLT3-ITD.  The authors previously used shRNA-based screens to identify 
PTPs which negatively regulate FLT3-ITD signalling (Arora et al., 2011)  with the 
premise that constitutive oncogenic signalling from FLT3-ITD was likely to involve 
the negative regulation of inhibitory PTPs. The significance of this finding lies with 
the authors‟ observation that transformation of mouse haematopoietic progenitor 
cells by FLT3-ITD is so dependent on the redox regulation of DEP1, that blocking 
the ROS burst induced by FLT3-ITD was sufficient to halt transformation in vivo 
and in vitro. This effect was reversed upon knockdown of DEP1, both establishing 
the powerful tumour suppressive role of this phosphatase in leukaemia, as well as 
uncovering further details of the relatively obscure FLT3-ITD signalling pathway.  
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 Much of the focus on the source of GF-stimulated ROS production centres on 
the Nox family of enzymes, however, the Lox were the subject of a recent study by 
Conrad et al. (2010). The authors reported on the oxidising mediators produced by 
12/15-Lox which can act as second messengers by inactivating PTPs to amplify and 
prolonging PDGF-β receptor signalling. The signalling molecules in question were 
shown to be peroxidised arachadonic acid-derived lipids which induced oxidation of 
SHP-1, PTP-H1 and TC-PTP in vitro. This previously unrecognised class of 
oxidising mediators introduces another dimension to the already complex situation 
of PTP redox regulation, and they may also help to account for features of redox 
signalling which cannot be attributed to diffusible ROS.  
 While oxidation and phosphorylation allow the regulation of PTPs by 
effectively switching the enzyme on or off, modulation of PTP protein turnover rate 
is also an important aspect of PTP regulation. Ubiquitination is a post-translational 
modification which, through covalent labelling of proteins with ubiquitin moieties, 
directs their sub-cellular localisation and intracellular trafficking (Haglund and 
Dikic, 2005). The degree of ubiquitination determines the consequences of this 
labelling for the protein. Mono-ubiquitination, the reversible addition of single 
moiety to a single lysine residue, can signal that the protein is due to be endocytosed, 
targeted for endosomal sorting or nuclear export (Di Fiore et al., 2003). The addition 
of chains of ubiquitin moieties either to a single lysine on the target protein, termed 
multiple monoubiquitination (Haglund et al., 2003a), or to the lysine residues of 
target-bound ubiquitin itself, polyubiquitination (Pickart and Fushman, 2004), 
introduces further levels of complexity and tends to have more terminal 
consequences. Multiple monoubiquitination of activated RTKs leads to their 
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trafficking to the lysosome and degradation (Haglund et al., 2003b), while the 
polyubiquitination, via ubiquitination of Ub
Lys48  
can label a range of targets for  
proteasomal degradation as established by Ciechanover,  Hershko, and Rose (1998), 
and  recognised by the 2004  Nobel Prize in Chemistry. Once degraded in the 
proteasome, the protein may be replaced by a newly synthesised version and the 
ubiquitin is recycled (Mani and Gelmann, 2005).  
 Physiologically, this process is crucial to eliminate damaged or misfolded 
proteins as well being necessary for the termination of endocytosed RTK signalling. 
Disruptions to the ubiquitination-proteasomal pathway resulting in increased 
degradation of proteins with a tumour-suppressive function, or retention and 
sustained activity of proto-oncogenic RTKs can contribute to oncogenesis 
(Ciechanover et al., 1991; Rogers et al., 1986) and is a feature in a range of tumour 
types including renal cell carcinoma (Clifford et al., 2001),  colorectal cancer 
(Sparks et al., 1998), human papilloma virus(HPV)-driven cervical cancer (Scheffner 
et al., 1993), BRCA1-dependent breast cancer (Starita and Parvin, 2003), 
glioblastoma (Schmidt et al., 2003) and  FLT3-ITD positive AML (Caligiuri et al., 
2007; Sargin et al., 2007).  Upregulation of PTP ubiquitination and degradation in 
particular, presents a possible mechanism whereby oncogenic RTKs can manipulate 
phosphorylation signalling cascades.  
 As well as post-translational modifications of the PTP proteins, PTPs, like 
many other proteins are regulated at the level of gene expression, through the 
requirements for binding of specific transcription factors, transcriptional activators, 
repressors and enhancers. Downregulation of the transcription of tumour suppressor 
PTPs, and PTPs which are presumed tumour suppressive due to their negative effect 
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on pro-oncogenic kinase signalling,  is common in oncogenesis (Julien et al., 2011; 
Song et al., 2012).  However, there is a scarcity of data regarding the specific 
expression profiles of PTPs in AML.  A recent study from Arora et al. (2012) sought 
to address this by using RT-qPCR to analyse the mRNA levels of 92 PTPs in both 
patient samples and AML cell lines, including the MV4-11 cell line but not the 
MOLM-13 cell line. The authors‟ objective was to identify PTPs which were 
differentially expressed in FLT3-ITD AML compared to wild type AML and 
reported an up-regulation of several DSPs correlating with FLT3-ITD expression 
suggesting that oncogenic FLT3 signalling incorporates the functions of some PTPs.  
However this study did not identify any PTPs which showed decreased expression in 
FLT3-ITD samples compared to wild type FLT3 samples and concluded that in 
general very few differences in PTP mRNA expression could be observed between 
samples.  
 Although informative, the scope of the study was somewhat limited and it 
can be argued that comparison of a single FLT3-ITD cell line MV4-11 with three 
FLT3 wild type cell lines THP1, EOL1, RS4-11, may not be the most ideal model 
for establishing the relevance of FLT3-ITD signalling, as additional genetic lesions 
present in the individual cell lines are likely to be contributing to the PTP expression 
profiles. For the same reason any differences in PTP expression which might have 
been observed between the cell lines could not have been singularly attributed to 
FLT3-ITD. The use of 32D cells transfected with FLT3-ITD and wild type FLT3 
provided the possibility of comparison to parental cells with the same genetic 
background. However, the changes in 32D PTP expression upon introduction of 
FLT3, disagreed with some of the data obtained from comparison of MV4-11 with 
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the wild type cell lines, and appeared to show that the wild type receptor was 
dictating the upregulation of the DSPs. In addition to this, the AML patient samples 
displayed discrepancies between the PTP expression levels as determined by RT-
qPCR and those detected by Affymetrix.  
 In contrast, a study by Chen et al. (2005) showed that FLT3-ITD activity 
correlated to an increase in tyrosine phosphorylation which could not be explained 
by simply an increase in kinase activity but required a concomitant suppression of 
PTP activity, which the authors traced to a decrease SHP-1 mRNA expression, but it 
is possible that many other contributing PTPs are likely to be similarly affected.  
 These ambiguities in relation to FLT3 regulation of PTPs prompted the 
initiative of the next chapter, with the objective of identifying PTPs which are 
regulated by FLT3-ITD signalling in the MOLM-13 cell line, in order to further 
contribute to our model of the tyrosine signalling network which operates 
downstream of this receptor.  
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Results 
Kinexus
TM 
Phosphatase Expression Profile of MOLM-13 and MV-411 cells 
 To date, 107 genes coding for PTPs have been identified in the human 
genome (Alonso et al., 2004) highlighting the importance of these molecules and the 
pathways that they regulate. Due to the role of phosphatases in negatively regulating 
proliferation and  survival, cancer cells which successfully circumnavigate this 
innate regulation often display inactivating mutations, or methylation and silencing 
of regulatory phosphatase genes (Ostman et al., 2006). The result of this is that 
cancer cell lines may only express functional proteins from a fraction of the total 
number of phosphatase genes which they contain. In examining the p-Tyr signalling 
mechanisms of FLT3 in the AML cell lines MOLM-13 and MV-411, the role of 
tyrosine phosphatases is important to consider and to do this it is necessary to first 
establish which phosphatases are expressed in these cell lines. 
 The Kinexus™ Phosphatase Screen 1.2 is a commercially available service 
which uses multi-immunoblotting to generate a phosphatase expression profile for a 
submitted lysate. The screen examined the expression of 30 tyrosine, 
serine/threonine and dual specificity phosphatases, in both cell lines and the results 
are represented as K_001 in Figures 43, 44, 45 and Table 2, 3 and 4.  
 As expected, almost half of the phosphatases were not expressed at the 
protein level, including Cdc25B, Cdc25C and cyclin-dependent kinase associated 
phosphatase (KAP/CDK inhibitor 3), all of which regulate the cell cycle, the dual-
specificity MAP-kinase protein phosphatase PAC1 and CD45. Both cell lines also 
had very low levels of PTEN. Down-regulation of PTEN is frequently observed in 
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cancer, both at the level of transcription, where the PTEN gene can become 
methylated or heavily regulated by transcription factors, competitive endogenous 
PTEN pseudogene RNA, and microRNAs, as well at the level of aberrant post-
translational modifications to the PTEN protein such as phosphorylation, oxidation, 
ubiquitination and acetylation (Carracedo et al., 2011).  
 In general, MV4-11 had higher levels of phosphatase expression than 
MOLM-13 but because of the possibility of regulation by post-translational 
modifications this may not reflect the differences of phosphatase activity within the 
cells.  
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Figure 43. Kinexus
TM
 phosphatase expression screen K_001. 
Histogram represents the results of the multi-immunoblotting carried out by 
Kinexus
TM
 Phosphatase Expression Screen KPPS 1.2, to generate the phosphatase 
expression profiles of MV4-11 (blue), designated as control sample, and MOLM-13 
(purple), designated as test sample. The identification and detection of each of 30 
phosphatases (vertical axis) was based on immunoreactivity and apparent molecular 
mass. The corrected trace quantity of each band is expressed as counts per minute 
(CPM) (horizontal axis).  
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Table 2: Kinexus
TM
 phosphatase expression screen K_001, Comparison Report 
Comparison of the corrected trace quantity of each protein expressed as counts per 
minute (CPM) in the two samples MV4-11 and MOLM-13. The normalised trace 
quantity of each band is given. This adjustment is based on the difference in the total 
signal from the sum of all of the bands on individual immunoblots.  
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Figure 44. Kinexus
TM
 phosphatase expression screen K_001, multi-immunoblot 
for MV4-11. Multi-immunoblot of MV4-11 sample with the detected bands A) 
unmarked and  B)  numbered according to lane and number of bands appearing per 
lane.  Lanes 1 and 21 denote molecular weight markers used by Kinexus
TM
. Band 
1=201 kDa, Band 2= 156 kDa, Band 3= 106 kDa, Band 4=79 kDa, Band 5=48 kDa, 
Band 6= 37kDa. 
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Table 3. Kinexus
TM
 phosphatase expression screen K_001, sample report  for 
MV4-11. Quantitative information regarding band intensities with reference to the 
immunoblot in Figure 44B, including the identities of all the target proteins 
identified as numbered bands, the estimated molecular mass for each numbered 
band, the relative quantity of the band expressed as a percentage of the total intensity 
of data in the lane in which the band appears, the trace quantity of each band taken to 
be the area under the band's intensity profile curve, the corrected trace quantity of 
each band expressed as counts per minute (cpm).  
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Figure 45. Kinexus
TM
 phosphatase expression screen K_001, multi-immunoblot 
for MOLM-13. Multi-immunoblot of MOLM-13 sample with the detected bands A) 
unmarked and B)  numbered according to lane and number of bands appearing per 
lane.  Lanes 1 and 21 denote molecular weight markers used by Kinexus
TM
. Band 
1=201 kDa, Band 2= 156 kDa, Band 3= 106 kDa, Band 4=79 kDa, Band 5=48 kDa, 
Band 6= 37kDa. 
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Table 4. Kinexus
TM
 phosphatase expression screen K_001, sample report  for 
MOLM-13. Quantitative information regarding band intensities with reference to the 
immunoblot in Figure 45B, including the identities of all the target proteins 
identified as numbered bands, the estimated molecular mass for each numbered 
band, the relative quantity of the band expressed as a percentage of the total intensity 
of data in the lane in which the band appears, the trace quantity of each band taken to 
be the area under the band's intensity profile curve, the corrected trace quantity of 
each band expressed as counts per minute (cpm).  
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Effects of FLT3-ITD inhibition on phosphatase expression in MOLM-13 cells 
 To determine whether the expression of any of the phosphatases detected in 
MOLM-13 cells are subject to regulation by FLT3-ITD, a second phosphatase 
expression screen was carried out to compare the phosphatase profiles of untreated 
MOLM-13 cells compared to those treated with 250 nM PKC412 for 24 hours 
(K_002, Figure 46, 47, 48 and Table 5, 6 and 7). Inhibition of FLT3-ITD signalling 
resulted in alterations to most of the phosphatases detected and both increases and 
decreases in expression could be observed, suggesting that FLT3-ITD may 
negatively regulate the expression of some phosphatases and have a positive 
influence on others. Kinexus
TM
 note that a change of >25% may be considered a real 
change. 
 Interestingly, many of the differences observed in phosphatase expression 
between MV4-11 cells and MOLM-13 cells, were reflected in the changes which 
occurred in MOLM-13 cells when treated with PKC412. As MV4-11 cells are 
homozygous for the FLT3-ITD mutation and MOLM-13 cells are heterozygous, 
there is likely to be decreased FLT3-ITD signalling in MOLM-13 cells, a situation 
analogous to the comparison of untreated MOLM-13 cells and those treated with 
PKC412.  Many of the phosphatases displayed decreased expression upon FLT3-
ITD inhibition, suggesting that there may be a common transcription factor under the 
control of FLT3-ITD. A decrease in phosphatase expression upon FLT3-ITD 
inhibition was not interpreted as being definitive evidence of a positive regulation, as 
it is possible that subsequent FLT3-driven post-translational modifications actually 
determine the activity of the enzyme. Upregulation of a range of proteins is likely to 
occur downstream of oncogenic FLT3 signalling, as FLT3-ITD is known to  
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influence several myeloid transcription factors such as PU.1 (Rosenbauer et al., 
2004)and C/EBPα (Radomska et al., 2006) as well as STAT5 (Choudhary et al., 
2007) and FOXO (Takahashi, 2011).  Not all of the upregulated proteins would 
necessarily contribute to the FLT3-ITD signalling pathway, it could be argued that 
thriving FLT3-ITD tumour cells are the ones in which upregulation of inhibitory 
phosphatases, occurring as a consequence of aberrant transcription factor activity, 
has been ameliorated to some extent by extensive negative regulation of the 
phosphatase proteins at the level of post-translational modifications. It is also 
possible that the expressed proteins are the non-functional products of mutated genes 
and neither represent an aid nor a threat to the FLT3-ITD signalling pathway, but 
again are simply by-products of increased transcription factor activity.  
 This profiling screened for only 30 phosphatases, of which 14 were not 
expressed in MOLM-13 cells. Of the 16 which were expressed, 9 were classified as 
serine/threonine phosphatases (PSTP), so the scope for examination of expression of 
classical tyrosine phosphatases (PYP) or dual specificity phosphatases (PSTYP or 
PTYP) became quite limited.  
 When deciding which phosphatases to progress with PTEN, SHP-2, PTP1B, 
VHR, MKP2, PP2B/Aa and SHP-1 were considered. The levels of PTEN appeared 
to be quite low in MOLM-13 cells as detected by the Kinexus
TM
 expression screen 
(Figure 47, Table 6) prompting concerns for the detection of this protein using 
conventional western blotting. It was recently reported by Godfrey et al. (2012) that 
PTEN is not oxidised downstream of FLT3-ITD in AML cells, reinforcing our 
evidence that in MOLM-13 cells PTEN appears to be regulated by FLT3 at the level 
of protein expression, though as this gene is frequently mutated in tumours it is 
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possible that the expression detected here may be of a dysfunctional mutant PTEN.  
As the mechanisms of regulation of PTEN expression are quite well elucidated, as is 
its role in leukemogenesis prevention (Zhang et al., 2006; Yilmaz et al., 2006), and it 
was decided that focusing on this phosphatase would not contribute the required 
element of novelty.   
 SHP-2 was also discounted from further study as its involvement in 
leukaemia and the FLT3-ITD signalling pathway in particular have been well 
documented recently (Nabinger and Chan, 2012; Muller et al., 2008b).  Of the 
remaining PTPs the two with the highest expression in untreated MOLM-13 cells as 
determined by the Kinexus
TM
 screen, were chosen to ensure detection  using 
conventional western blotting, PTP1B and SHP-1. These phosphatases were also 
selected because they represented opposing consequences of regulation downstream 
of FLT3-ITD.  PTP1B expression decreased upon FLT3-ITD inhibition whereas the 
expression of SHP-1 increased.  
 It was also decided at this point to include two serine/threonine phosphatases 
for comparison. PP6C was selected due its high levels of expression in MOLM-13 
cells, which decreased dramatically by 71% upon PKC412 treatment. PP2Cα was 
also an intriguing target as it appeared to be unexpressed in the untreated MOLM-13 
cells yet its expression was induced upon FLT3-ITD inhibition.  
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Figure 46. Kinexus
TM
 phosphatase expression screen K_002. 
Histogram represents the results of the multi-immunoblotting carried out by 
Kinexus
TM
 Phosphatase Expression Screen KPPS 1.2, to compare the phosphatase 
expression profiles of MOLM-13 cells which were untreated (blue), designated as 
control sample, and treated with 250 nM PKC412 for 24 hours (purple), designated 
as test sample. The identification and detection of each of 30 phosphatases (vertical 
axis) was based on immunoreactivity and apparent molecular mass. The corrected 
trace quantity of each band is expressed as counts per minute (CPM) (horizontal 
axis).  
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Table 5: Kinexus
TM
 phosphatase expression screen K_002, Comparison Report 
Comparison of the corrected trace quantity of each protein expressed as counts per 
minute (CPM) in the two samples of MOLM-13 cells untreated and treated with 250 
nM PKC412 for 24 hours. The normalised trace quantity of each band is given. This 
adjustment is based on the difference in the total signal from the sum of all of the 
bands on individual immunoblots.  
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Figure 47. Kinexus phosphatase expression screen K_002, Multi-Immunoblot 
for untreated MOLM-13 sample.  Multi-immunoblot of untreated MOLM-13 
sample with the detected bands A) unmarked and B)  numbered according to lane 
and number of bands appearing per lane.  Lanes 1 and 21 denote molecular weight 
markers used by Kinexus
TM
. Band 1=201 kDa, Band 2= 156 kDa, Band 3= 106 kDa, 
Band 4=79 kDa, Band 5=48 kDa, Band 6= 37kDa. 
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Table 6. Kinexus
TM
 phosphatase expression screen K_002, Sample report for 
untreated MOLM-13. Quantitative information regarding band intensities with 
reference to the immunoblot in Figure 47B, including the identities of all the target 
proteins identified as numbered bands, the estimated molecular mass for each 
numbered band, the relative quantity of the band expressed as a percentage of the 
total intensity of data in the lane in which the band appears, the trace quantity of 
each band taken to be the area under the band's intensity profile curve, the corrected 
trace quantity of each band expressed as counts per minute (cpm).  
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Figure 48. Kinexus
TM
 phosphatase expression screen K_002, Multi-Immunoblot 
for PKC412-treated MOLM-13 sample.  Multi-immunoblot of PKC412-treated  
MOLM-13 sample with the detected bands A) unmarked and B)  numbered 
according to lane and number of bands appearing per lane.  Lanes 1 and 21 denote 
molecular weight markers used by Kinexus
TM
. Band 1=201 kDa, Band 2= 156 kDa, 
Band 3= 106 kDa, Band 4=79 kDa, Band 5=48 kDa, Band 6= 37kDa. 
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Table 7. Kinexus
TM 
phosphatase expression screen K_002, Sample report for 
PKC412-treated MOLM-13. Quantitative information regarding  band intensities 
with reference to the immunoblot in Figure 48B, including the identities of all the 
target proteins identified as numbered bands, the estimated molecular mass for each 
numbered band, the relative quantity of the band expressed as a percentage of the 
total intensity of data in the lane in which the band appears, the trace quantity of 
each band taken to be the area under the band's intensity profile curve, the corrected 
trace quantity of each band expressed as counts per minute (cpm).  
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Effect of FL stimulation on phosphatase expression in HL60 and MOLM-13 
cells 
 While the use of PKC412 demonstrates a role for FLT3-ITD in regulating the 
expression of the selected phosphatases, it possible that this avenue of the FLT3-ITD 
signalling pathway overlaps with that of the wild type FLT3 receptor, as has been 
shown to be the case with regard to Ezrin and Src in previous chapters. To 
investigate this further, HL60 cells were treated with 50 ng/ml of the FL over a time 
period of 15 minutes to 24 hours and the expression of PP2Cα, PTP1B, PP6C and 
SHP-1 were examined by western blotting (Figure 49).  Expression of PP2Cα was 
shown to increase upon PKC412 treatment but did not decrease upon FL stimulation 
of HL60 cells. PTP1B expression decreased in PKC412 treated cells and increased 
slightly after 30 minutes of FL stimulation of HL60 cells. PP6C levels decreased 
dramatically in PKC412 treated MOLM-13 cells but failed to increase in HL60 cells 
treated with the FL. Expression of SHP-1 increased in MOLM-13 cells upon FLT3-
ITD inhibition but did not change in HL60 cells after stimulation with the FL.  
Therefore, with the exception of PTP1B, the expression of the phosphatases in HL60 
cells treated with the FL did not reflect the opposite effects of PKC412 treatment in 
MOLM-13 cells.  
 Just as the levels of phosphatase expression in the MOLM-13 and MV4-11 
cell lines differed, it is likely that the basal levels of phosphatase expression in HL60 
cells are also different to those of MOLM-13 cells and may be a reason why 
stimulation of HL60 cells with the FL did not result in the changes in phosphatase 
expression which would be expected if the FLT3 wild type receptor was involved.   
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Figure 49. Effect of FLT3 ligand on the expression of phosphatases in HL60 
cells. Western blot analyses of PP2Cα, PP6C, PTP1B and SHP-1 in  HL60 cells 
stimulated with 50 ng/ml FL for 15 or 30 minutes or 1, 2, 8 or 24 hours. β-Actin is 
shown as a loading control. 
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 Therefore, the effects of the FL stimulation on the expression of the selected 
phosphatases was investigated using the MOLM-13 cells, which are heterozygous 
for the FLT3 wild type receptor and have been demonstrated in Chapter 4 to respond 
to ligand stimulation, though understandably not to the same extent as the HL60 
cells. However, the FL did not elicit a change in phosphatase expression in MOLM-
13 cells (Figure 50), with the exception of PTP1B which, similarly to the result in 
HL60 cells, did undergo an increase in expression upon 30 minutes of FL 
stimulation. At this point it was concluded that the expression of PP2Cα, PP6C and 
SHP-1 are regulated by the FLT3-ITD signalling pathway in MOLM-13 cells, but 
not as a result of signalling from the wild type receptor. In contrast, expression of 
PTP1B appears to involve a pathway that is common to both.  
Discrepancy in Kinexus
 TM 
_002 data 
 Upon investigating the effect of the FL stimulation on phosphatase 
expression in MOLM-13 cells, a discrepancy was observed between the levels of 
PP2Cα observed using conventional western blotting methods and those recorded by 
Kinexus
TM
 phosphatase expression profiling in screen K_002. As mentioned 
previously PP2Cα was determined by K_002 to be expressed upon inhibition of 
FLT3-ITD but was not detected in the untreated MOLM-13 cells. However in Figure 
50, expression of PP2Cα protein can clearly be observed in the untreated MOLM-13 
cells. This prompted a re-assessment of the levels of PP2Cα expressed in untreated 
and PKC412-treated MOLM-13 cells. Western blotting revealed that in contrast to 
the data reported in K_002, PP2Cα expression decreased upon MOLM-13 cell 
treatment with PKC412 (Figure 51). 
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Figure 50. Effect of FLT3 ligand on the expression of phosphatases in MOLM-
13 cells. Western blot analyses of PP2Cα, PP6C, PTP1B and SHP-1 in  MOLM-13 
cells stimulated with 50 ng/ml FL for 15 or 30 minutes or 1, 2, 8 or 24 hours. β-Actin 
is shown as a loading control. 
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 Densitometric analyses confirmed that this decrease amounted to 
approximately 30% (Figure 51B). The reason for this anomaly cannot be fully 
determined; it is possible that the antibody used by Kinexus
 TM
 to detect PP2Cα 
differed from our own, although this is unlikely to be the root of the problem as 
expression of PP2Cα can also be observed in both MOLM-13 and MV4-11 cells in 
K_001. Therefore it appears that there was a problem with this particular screen, 
perhaps some amount of PP2Cα degradation within the untreated sample.  
Confirmation of Kinexus
 TM
 data concerning PP6C, PTP1B and SHP-1 
 Whatever the reason for this inconsistency was, it caused some concern that 
the changes in expression reported in K_002 for other phosphatases may not reflect 
the actual effects of FLT3-ITD inhibition in MOLM-13 cells. Therefore western 
blotting was carried out to confirm the K_002 data for the selected phosphatases 
PP6C, PTP1B and SHP-1 (Figure 52). The trends observed in K_002 matched those 
observed in MOLM-13 cells using conventional western blotting, with both PP6C 
and PTP1B expression decreasing in PKC412 treated samples, and SHP-1 levels 
increasing.  
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Figure 51: Confirmation of effect of PKC412 on PP2Cα expression in MOLM-
13 cells. A) Western blot analysis of PP2Cα in untreated MOLM-13 cells and cells 
treated with 250 nM PKC412 for 24 hours. β-Actin is shown as a loading control. B) 
Histogram represents the densitometric analysis carried out on three individual 
biological replicates of MOLM-13 cells treated with 250 nM PKC412 for 24 hours.  
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Figure 52. Validation of K_002 data.  
Western blot analysis of PP6C, PTP1B and SHP-1 in untreated MOLM-13 cells and 
cells treated with 250 nM PKC412 for 24 hours. β-Actin is shown as a loading 
control. 
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FLT3-ITD regulates phosphatase expression at the level of transcription  
 Having determined that inhibition of FLT3-ITD signalling using PKC412 
affects the protein levels of selected phosphatases, it was necessary to clarify 
whether this regulation was occurring at the level of gene expression, or was directly 
as a consequence of protein turnover.  Quantitative reverse transcriptase polymerase 
chain reaction (RT-qPCR) was used to determine the whether the amount of mRNA 
being transcribed from each of the selected phosphatase genes was subject to change 
depending on FLT3-ITD activity.  GAPDH was used as a housekeeping gene, 
despite being redox-sensitive (Butterfield et al., 2010), as no changes to its 
expression could be observed under the range of redox conditions used in previous 
western blotting experiments. Therefore it was concluded that GAPDH was stably 
expressed in our system, and was not sensitive to FLT3-ITD induced redox 
alterations. 
 The integrity of the isolated RNA was examined by separation of 500 ng of 
isolated RNA on a 0.8% Cyber Safe agarose gel. RNA was determined to be of good 
integrity if distinct, sharp bands for 28s and 18s rRNA were distinguishable, with no 
additional bands or smearing of the sample (Figure 53A). Amplification of the 
intended target transcripts, without amplification of secondary non-specific 
transcripts was confirmed by the appearance of single bands of the appropriate size 
after the amplification step (Figure 53B).  
 Quantification of the amplified transcripts revealed that transcription of 
PP2Cα was significantly decreased in MOLM-13 cells which had been treated with 
the FLT3-ITD inhibitor PKC412 for 24 hours (Figure 54), corresponding to the 
decrease in PP2Cα protein expression established in Figure 51. Similarly, 
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transcription of PP6C was also determined to be significantly decreased in PKC412- 
treated cells, which again correlated to the decrease in PP6C protein levels as 
detected by K_002 and confirmed in Figure 52. PTP1B mRNA was reduced in the 
PKC412-treated sample and although not a significant decrease, did correlate with 
the decrease in PTP1B protein observed in K_002 and confirmed in Figure 52.  
 The levels of SHP-1 mRNA also decreased upon PKC412 treatment. 
However, while the decrease in mRNA observed for the other phosphatases agreed 
with a decrease in protein in each case, SHP-1 had been shown to increase at the 
level of protein expression upon FLT3-ITD inhibition (K_002 and Figure 52), 
suggesting that additional regulation at a post-translational level was being applied 
which was affecting the rate of  SHP-1 protein turnover.  
SHP-1 is ubiquitinated downstream of FLT3-ITD  
 SHP-1 protein levels increased upon inhibition of FLT3-ITD yet its mRNA 
levels were observed to decrease, implying that although the amount of transcript 
being produced was positively regulated by FLT3-ITD, the resulting protein was 
being degraded at a fast rate. The net effect of this multi-layered regulation was 
lower levels of SHP-1 protein being present in untreated MOLM-13 cells than those 
in which FLT3-ITD is inhibited.  
As SHP-1 is known to function in a tumour suppressive capacity (Wu et al., 2003b), 
it is possible that upregulation of its transcription as a result of aberrant transcription 
factor activity, poses a threat to the FLT3-ITD signalling agenda. An increase in 
SHP-1 protein as a result of increased transcription could be effectively cancelled out 
by a high rate of SHP-1 degradation, so that the protein produced does not have the 
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chance to disrupt the oncogenic signals. As discussed in the introduction to this 
section, covalent addition of ubiquitin moieties is a mechanism of labelling proteins 
destined for degradation, and examination of the extent of ubiquitination of a 
particular protein can determine whether it is likely to be subject to proteasomal 
degradation. 
Therefore, SHP-1 was immunoprecipitated from untreated and PKC412-treated 
MOLM-13 cells and the extent of its ubiquitination was determined using an anti-
ubiquitin antibody. Cells were treated with lactacystin, an inhibitor of the 
proteasome, for duration of the PKC412 treatment, to prevent the degradation of the 
ubiquitinated SHP-1 and ensure its visualisation. Increased ubiquitination of SHP-1 
was observed in the untreated MOLM-13 cells compared to those treated with 
PKC412 (Figure 55), confirming that although mRNA levels of SHP-1 decrease 
upon FLT3-ITD inhibition, the rate of SHP-1 turnover is higher when FLT3-ITD is 
active.  
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Figure 53: Integrity of RNA and RT-PCR amplification products 
A) 500 ng of isolated RNA separated on 0.8% Cyber Safe agarose gel with 28s and 
18s rRNA bands indicated. B) Amplification of the intended target transcripts, with 
product sizes indicated. 
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Figure 54. Effect of PKC412 on transcription of phosphatase mRNA in MOLM-
13 cells. Histograms represent the mRNA fold change of A) PTP1B, B) PP2Cα, C) 
PP6C and D) SHP-1 as determined by qRT-PCR analysis. Results are expressed as 
fold change of each transcript relative to GAPDH. Statistical analysis was performed 
using Student‟s t-test to evaluate the difference between untreated and PKC412-
treated samples. Significance was defined at the level of P<0.05. 
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Figure 55. Effect of PKC412 on the ubiquitination of SHP-1 in MOLM-13 cells. 
Western blot analysis of SHP-1 immunoprecipitated from untreated MOLM-13 cells 
and cells treated with 250 nM PKC412 for 24 hours and immunoblotted using an 
anti-ubiquitin antibody. Both samples were treated with 5 µM Lactacystin for 24 
hours to inhibit proteasomal degradation of ubiquitinated proteins. Total SHP-1 is 
shown as a loading control.  
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Oxidation state of phosphatases downstream of FLT3-ITD 
 The effect of FLT3-ITD on the transcription and ubiquitination of selected 
phosphatases shows that the oncogenic receptor dictates the regulation of 
phosphatases through several mechanisms. A recent study from Godfrey et al. 
(2012) highlighted the selective regulation of PTPs downstream of FLT3-ITD 
through oxidation and described how PTPs such as DEP-1 appear to be highly 
expressed in AML cells but are rendered enzymatically inactive through oxidation. 
With a view to further contributing to the data regarding PTP oxidation downstream 
of FLT3-ITD, it was decided to utilise a combination of BIAM-labelling of reduced 
proteins and the Kinexus
TM
 phosphatase expression screen to identify phosphatases 
which are oxidised in response to FLT3-ITD signalling. The experimental procedure 
involved the labelling of MOLM-13 cell lysates, untreated and PKC412-treated, with 
BIAM. The reduced phosphatases became labelled with biotin and were then 
depleted from the total lysate by incubation in spin columns containing streptavidin 
conjugated to sepharose beads. In theory, the biotin-depleted flow-through contains 
phosphatases which are not reduced, i.e. oxidised and by comparing the phosphatase 
profiles of the depleted untreated and depleted PKC412-treated samples it should be 
possible to identify phosphatases which are redox regulated as a result of FLT3-ITD 
activity.  
 The method required some optimisation, as initial results showed that 
although there was higher BIAM-labelling in the PKC412 treated samples (Figure 
56A, bottom panel) corresponding to a decrease in ROS, the flow-through which 
should be biotin-negative actually still contained a lot of biotin-labelled protein 
(Figure 56C, bottom panel). Compared to the flow-through, the fraction of protein 
200 
 
eluted from the streptavidin beads did show increased biotin labelling  (Figure 56B, 
bottom panel), but the fact that so much biotin-labelled protein was escaping capture 
by the beads meant that there was little discernible difference in protein quantity 
between the untreated and PKC412-treated samples  after depletion (Figure 56C, top 
panel), despite the increased biotin-labelling of the PKC412-treated sample 
suggesting that there should be quite an observable contrast.  
 An increase in the quantity of streptavidin-sepharose beads was shown to 
affect the amount of biotin-labelled protein which was being retained (Figure 57A), 
with three times the initial volume of beads finally depleting the flow-through 
substantially enough to result in a difference in protein yield between the depleted 
untreated and PKC412-treated samples (Figure 57B).  The resulting depleted flow-
through samples were used for Kinexus
TM
 phosphatase expression screening K_003.  
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Figure 56. Preparatory analysis for K_003  
Coomassie and Ponceau staining of total protein content and HRP-SA detection of 
BIAM-labelled (reduced) fraction of A) total lysates from untreated MOLM-13 cells 
and cells treated with 250 nM PKC412 for 24 hours, B) lysate eluted from 
streptavidin-sepharose beads, C) lysate flow-through after streptavidin-sepharose 
bead incubation.  
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Figure 57. Optimisation of sample preparation for K_003. 
A) HRP-SA detection of BIAM-labelled (reduced) fraction of lysate flow-through 
after incubation with increasing volumes of streptavidin-sepharose beads. B) 
Coomassie staining showing difference in protein content of untreated and PKC412-
treated samples after depletion of BIAM-fraction using increased volume of 
streptavidin-sepharose beads. 
 
 
 
 
204 
 
 The results of the Kinexus
TM
 phosphatase profiling of the biotin-depleted 
untreated and PKC412-treated MOLM-13 samples (Figures 58, 59, 60 and Tables 8, 
9 and 10) proved quite challenging to decipher. It was expected that some 
phosphatases would appear at decreased levels in the PKC412-treated sample 
compared to the untreated, representing phosphatases which are reduced in absence 
of FLT3-ITD signalling and oxidised in its presence. However, the differential 
expression of phosphatases in untreated and PKC412-treated samples made 
differences based on redox states hard to detect. Ideally, phosphatases would be 
observed to have similar expression levels in untreated and PKC412-treated samples, 
as determined by K_002, and then appear at a decreased level in the PKC412 sample 
after depletion of the reduced fraction. This would represent phosphatases which are 
oxidised downstream of FLT3-ITD, however this category failed to emerge in 
K_002, with no phosphatase showing equal levels in the untreated and PKC412-
treated samples.  
 Another possibility which was anticipated was that phosphatases with 
increased levels of expression in PKC412-treated samples compared to untreated 
(determined by K_002), and decreased in PKC412-treated after biotin depletion (as 
determined by K_003), would represent a category of phosphatases which are 
negatively regulated by FLT3 at level of expression (i.e. PKC412  triggers an 
increase in expression) and at level of activity (PKC412 triggers an increase in the 
reduced, active fraction), however, this category was also not identified, probably 
due to the differences in expression masking any changes attributable to oxidation. 
The phosphatases were grouped and categorised according to their profiles in screens 
K_002 and K_003 and the results can be best summarised as follows; 
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Category 1)  
Represents: Phosphatases which are regulated by FLT3-ITD at level of expression 
(transcription or translational) but not at level of oxidation.  
 Identified by: Differences in expression between untreated and PKC412-treated 
samples remain approximately the same despite depletion of Biotin-labelled/reduced 
fraction. These phosphatases do not undergo redox regulation but do incur changes 
at the level of protein expression.  
Significance: FLT3-ITD regulates the activity of these phosphatases through their 
expression but not via redox modulation of their oxidation states.  
Accounts for: SHP-1, PP1/Cα, PTEN  
 
Category 2)  
Represents: Phosphatases which appear to be positively regulated by FLT3-ITD at 
both the levels of expression and activity. 
Identified by: Phosphatases are increased in untreated sample, as determined by 
K_002 and decreased in untreated samples after biotin-depletion, as determined by 
K_003.  
Significance:  FLT3-ITD positively regulates the protein expression of these 
phosphatases and also reduces their oxidation.   
Accounts for: VHR, PP2A/Cα, PP5C, PP2Cα  
 
Category 3) 
Represents:  Phosphatases which appear to be negatively regulated by FLT3-ITD at 
level of expression but positively regulated at level of activity. 
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Identified by: Phosphatases are increased in PKC412-treated samples compared to 
untreated samples at level of expression, as determined by K_002, and this increase 
is even more noticeable after biotin-depletion, suggesting that the untreated sample 
has been subject to greater depletion.  
Significance: FLT3-ITD negatively regulates the expression of these phosphatases 
but does not affect their oxidation and may actually prevent it.  
Accounts for: MKP2, PP2A/Aa/b 
 
Category 4)  
Represents: Phosphatases which appear positively regulated by FLT3 at level of 
expression and activity 
Identified by: Similarly to Category 2, phosphatases in this category show increased 
expression in untreated samples and are also increasingly present in untreated 
samples post biotin-depletion, but the difference between untreated and PKC412-
treated is less noticeable after depletion, i.e. more protein has been removed from 
untreated sample during biotin-depletion than from the PKC412 treated sample. 
Signifies: FLT3-ITD may positively regulate these phosphatases expression and also 
decrease their oxidation, though the latter effect may simply be due to induced 
changes in their sub-cellular localisation and removal from the vicinity of oxidant 
sources. 
Accounts for: PP1/Cb, PP1/Cg , PP4C, PP6C, and PTP1B.  
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Figure 58: Kinexus
TM
 phosphatase expression screen K_003. 
Histogram represents the results of the multi-immunoblotting carried out by 
Kinexus
TM
 Phosphatase Expression Screen KPPS 1.2, to compare the phosphatase 
expression profiles of BIAM-labelled and depleted MOLM-13 cells which were 
untreated (blue), designated as control sample, and treated with 250 nM PKC412 for 
24 hours (purple), designated as test sample. The identification and detection of each 
of 30 phosphatases (vertical axis) was based on immunoreactivity and apparent 
molecular mass. The corrected trace quantity of each band is expressed as counts per 
minute (CPM) (horizontal axis).  
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Table 8: Kinexus
TM
 phosphatase expression screen K_003, Comparison Report 
Comparison of the corrected trace quantity of each protein expressed as counts per 
minute (CPM) in the two samples of BIAM-labelled and depleted MOLM-13 cells 
untreated and treated with 250 nM PKC412 for 24 hours. The normalised trace 
quantity of each band is given. This adjustment is based on the difference in the total 
signal from the sum of all of the bands on individual immunoblots.  
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Figure 59. Kinexus
TM
 phosphatase expression screen K_003, Multi-Immunoblot 
for BIAM-labelled and depleted untreated MOLM-13 sample.  Multi-
immunoblot of BIAM-labelled and depleted untreated  MOLM-13 sample with the 
detected bands A) unmarked and B)  numbered according to lane and number of 
bands appearing per lane.  Lanes 1 and 21 denote molecular weight markers used by 
Kinexus
TM
. Band 1=201 kDa, Band 2= 156 kDa, Band 3= 106 kDa, Band 4=79 kDa, 
Band 5=48 kDa, Band 6= 37kDa. 
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Table 9. Kinexus
TM
 phosphatase expression screen K_003, Sample report for 
BIAM-labelled and depleted untreated MOLM-13. Quantitative information 
regarding band intensities with reference to the immunoblot in Figure 59B, including 
the identities of all the target proteins identified as numbered bands, the estimated 
molecular mass for each numbered band, the relative quantity of the band expressed 
as a percentage of the total intensity of data in the lane in which the band appears, 
the trace quantity of each band taken to be the area under the band's intensity profile 
curve, the corrected trace quantity of each band expressed as counts per minute 
(cpm).  
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Figure 60. Kinexus
TM
 phosphatase expression screen K_003, Multi-Immunoblot 
for BIAM-labelled and depletedPKC412-treated MOLM-13 sample.  Multi-
immunoblot of BIAM-labelled and depleted PKC412-treated MOLM-13 sample 
with the detected bands A) unmarked and B)  numbered according to lane and 
number of bands appearing per lane.  Lanes 1 and 21 denote molecular weight 
markers used by Kinexus
TM
. Band 1=201 kDa, Band 2= 156 kDa, Band 3= 106 kDa, 
Band 4=79 kDa, Band 5=48 kDa, Band 6= 37kDa. 
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Table 10. Kinexus
TM
 phosphatase expression screen K_003, Sample report for 
BIAM-labelled and depleted PKC412-treated MOLM-13. Quantitative 
information regarding band intensities with reference to the immunoblot in Figure 
60B, including the identities of all the target proteins identified as numbered bands, 
the estimated molecular mass for each numbered band, the relative quantity of the 
band expressed as a percentage of the total intensity of data in the lane in which the 
band appears, the trace quantity of each band taken to be the area under the band's 
intensity profile curve, the corrected trace quantity of each band expressed as counts 
per minute (cpm).  
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Discussion 
 The Kinexus
TM
 phosphatase expression profiling allowed comparison of the 
expression of 30 PTPs, serine/threonine phosphatases and dual specificity 
phosphatases, under different experimental conditions. It was used by this study 
firstly to gain an insight into the range of phosphatases expressed by MOLM-13 
cells. This provided the opportunity to identify phosphatases which are not being 
expressed by these cells, possibly due to mutation, deletion, gene silencing or 
downregulation at the level of translation. Phosphatases which negatively regulate 
pro-survival signalling are frequently found to be deleted, silenced or otherwise 
transcriptionally suppressed and downregulated in a range of tumours.  
 Perhaps the best example of this is the prototypical tumour suppressor PTEN. 
The PTEN gene is estimated to be the second most frequently mutated and deleted  
in human tumours after TP53 (Yin and Shen, 2008) and, when it does remain un-
affected through mutation, efficient transcription of PTEN  is often prevented 
through microRNAs, competitive endogenous RNAs (the PTEN pseudogene), 
methylation and downregulation of it transcription factors (Carracedo et al., 2011).  
Kinexus
TM
 screen K_001 showed that PTEN is expressed at very low levels in both 
the MOLM-13 and MV4-11 AML cell lines compared to the other phosphatases. In 
contrast, Arora et al. (2012) reported that PTEN was amongst the most abundantly 
expressed phosphatases in both the AML cell lines, including MV4-11, and the 
AML patient samples which they examined , and Gauffin et al. (2009) noted that 
PTEN was overexpressed in the tissue microarrays that they conducted using 
samples taken from patients of paediatric ALL. However, the fact that PTEN was 
expressed to a greater extent in those studies is not a guarantee that the PTEN protein 
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is functional, nor does it preclude the likelihood of extensive post-translational 
modifications rendering the phosphatase inactive. 
 The second Kinexus
TM
 screen, K_002, which compared the expression of 
phosphatases in the presence and absence of FLT3-ITD signalling, showed that 
PTEN levels decreased even further in PKC412-treated cells, suggesting that its 
protein expression is somehow linked to FLT3-ITD signalling. A role for PTEN in 
normal haematopoietic development and prevention of leukemogenesis has been 
repeatedly demonstrated (Peng et al., 2010; Yilmaz et al., 2006; Zhang et al., 2006), 
and is known to negatively regulate a key component of the FLT3-ITD signal 
transduction necessary for myeloid cell transformation, the PI3K/Akt pathway 
(Brandts et al., 2005).  Peng et al. (2010) showed that PTEN expression is 
downregulated at the mRNA level by oncogenic Bcr-Abl in CML, and that 
restoration of the PTEN expression delays CML development, reduces the number of 
CML stem cells, and also slows progression of Bcr-Abl-driven B-ALL. Therefore, it 
is likely that in thriving leukaemic cell lines this phosphatase has been functionally 
suppressed to a large extent, either at a genetic level or through inhibitory post-
translational modifications. Godfrey et al. (2012) concluded that PTEN is not 
oxidised downstream of FLT3-ITD in their AML model, but the phosphatase has 
been shown to undergo oxidative inactivation in association with growth factor 
signalling in other systems (Kwon et al., 2004; Lee et al., 2002) including T-ALL  
(Muller et al., 2008a).   
 Similarly, in the third Kinexus
TM
 phosphatase screen which used BIAM-
labelling and depletion to examine the redox status of phosphatases in the context of 
FLT3-ITD signalling, the difference in the levels of PTEN between untreated and 
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PKC412-treated samples were almost identical to the differences observed in K_002, 
suggesting that the proportions of oxidised and reduced PTEN were the same 
regardless of FLT3-ITD signalling. It can be concluded that the apparent 
upregulation of PTEN observed upon FLT3-ITD activity, must be countered by 
alternative, non-redox, negative modulations of the proteins activity in order to 
remove any impedance to FLT3-ITD signalling. Of course the possibility that the 
PTEN being expressed and detected represents a non-functional gene product of 
mutated PTEN must also be taken into account.  
 The K_001 screen revealed that 14 of the phosphatases screened for were not 
detected in MOLM-13 cells. Of these, several are of interest from an oncogenic 
perspective.  Cell division cycle 25B phosphatase (Cdc25B), cell division cycle 25C 
phosphatase (Cdc25C) and CDK inhibitor 3 (KAP/CIP2) are involved in the 
regulation of the cell cycle (Malumbres and Barbacid, 2009; Srivastava et al., 2007; 
Xiao et al., 2004).  Dual specificity MAPK protein phosphatase (PAC-1) and MAPK 
phosphatase 1(VH1), are both inducible nuclear phosphatases (Owens and Keyse, 
2007) and  negative regulators of the MAPK pathway (Camps et al., 2000). 
Interestingly, the PAC-1 gene is a transcriptional target of p53, induced upon 
oxidative stress (Yin et al., 2003) and leading to apoptosis through the negative 
regulation of its substrates Erk and p38 (Chu et al., 1996).  Although the MOLM-13 
cells are reported to express wild type p53 (Kojima et al., 2005) a downregulation of 
its activity could account for the lack of PAC-1 expression.  
 The leukocyte common antigen-related (LAR) receptor tyrosine phosphatase 
is a member of a subgroup of PTPs which contain an extracellular adhesion-
molecule-like domain in addition to the classical PTP domain (Eswaran et al., 2006). 
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Alternatively spliced isoforms of this phosphatase have been associated with breast 
carcinoma (Yang et al., 1999) and it is possible that the antibodies used in the 
Kinexus
TM
 screen do not detect these variants, accounting for the lack of detection of 
LAR.  
 Leukocyte common antigen CD45 receptor  tyrosine phosphatase (CD45) is 
an antigen  specific to haematopoietic cells and frequently used in cell sorting to 
identify leukocytes including AML cells of the myelomonocytic lineage (Saunders 
and Johnson, 2010).  Godfrey et al. (2012) report that CD45 activity is slightly 
reduced in FLT3-ITD 32D cells.  The absence of CD45 in our screen could again 
be due to the fact that two alternatively spliced variants of the protein are generated  
(Oberdoerffer et al., 2008) and both may not be detectable using the Kinexus
TM
 
antibodies.  
 The relevance of several of the phosphatases identified is difficult to interpret 
as the data refers to specific isoforms of subunits which contribute to a phosphatase 
holoenzyme, for example protein serine phosphatase 2A catalytic subunit β isoform 
(PP2A/Cb), which does not appear to be expressed by either MOLM-13 or MV4-11. 
There is a scarcity of published data regarding such isoforms and so the significance 
of their lack of expression is not easily determined. Should the isoform represent a 
crucial component of the holoenzyme complex, for example a catalytic subunit, then 
it could be predicted that the enzyme may not function in its absence. Specifically 
with regard to PP2A/C, the β isoform is known to be the less abundant of two 
isoforms of the catalytic subunit (Sablina et al., 2010) and the α isoform appears to 
be very highly expressed according to K_001 and K_002 . As both of the regulatory 
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subunits of PP2A, PP2A/Aa/b are present it may be that overall the PP2A 
holoenzyme is functional.  
 As the phosphatases which were not expressed in untreated MOLM-13 cells, 
remained un-expressed even after inhibition of FLT3-ITD signalling (K_002), it is 
likely that their suppression may not be linked to FLT3-ITD, and may be due to 
additional lesions. They may also represent gene deletion events which were 
originally connected to FLT3-ITD-driven transformation but are obviously 
irreversible, even upon relief of FLT3-ITD signalling.   
 The phosphatases which were selected for further study, PP2Cα, PTP1B, 
PP6C and SHP-1 showed changes in expression upon FLT3-ITD inhibition 
according to K_002. With the exception of PTP1B, the changes in expression were 
not reflected in counter-changes upon FL stimulation. This suggests that PP2Cα, 
PP6C and SHP-1 are subject to regulation by an aspect of FLT3-ITD pathway which 
deviates from that shared with the wild type receptor, while PTP1B, similarly to 
Ezrin and Src, is downstream of an effector or sequence of effectors common to 
both.  
 It was originally intended choose two phosphatases which increased in 
expression upon FLT3-ITD inhibition, PP2Cα and SHP-1, and two which underwent 
a reduction in expression when FLT3-ITD was inhibited, PP6C and PTP1B. 
However, PP2Cα was subsequently shown to be incorrectly recorded by the 
Kinexus
TM
 K_002 screen, and was re-categorised as undergoing a decrease in 
expression in PKC412-treated samples. RT-PCR was used to establish whether the 
changes in phosphatase expression could be attributed to changes at the level of 
transcription, and this was concluded to be the case for the three phosphatases with 
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decreased expression in PKC412-treated samples, PP6C, PP2C α and PTP1B. As 
SHP-1 protein had been shown to increase in PKC412 samples, the decrease 
observed in its mRNA levels was seemingly contradictory until ubiquitination assays 
revealed that the upregulation of the transcription of SHP-1 in untreated MOLM-13 
cells precedes extensive ubiquitination of the protein product, resulting in an 
increased rate of SHP-1 degradation downstream of FLT3-ITD.  
 To induce increased ubiquitination of SHP-1, FLT3-ITD is either regulating 
SHP-1 directly to render it more susceptible to ubiquitination, or is manipulating the 
ubiquitin ligase enzymes responsible for SHP-1 labelling and degradation. Simoneau 
et al. (2008) describe how phosphorylation of Ser 591on SHP-1 by cyclin dependent 
kinase 2 (CDK2) results in the proteasomal degradation of the phosphatase, 
removing its inhibitory effect on cell cycle progression. FLT3-ITD has been shown 
to downregulate a transcriptional repressor of CDK2, C/EBPα (Mizuki et al., 2003) 
and in doing so may promote CDK2-mediated  ubiquitination of SHP-1. 
 Alternatively, FLT3-ITD may regulate aspects of the ubiquitination 
machinery within the cell. Recent evidence from Habif et al. (2013) has shown that 
Ubiquilin 4, a ubiquitin-like protein which has been shown to both prevent and 
inhibit the degradation of targets proteins (Riley et al., 2004), is subject to alterations 
in tyrosine phosphorylation downstream of FLT3-ITD, though it is unclear as to the 
consequences of this modification on the functioning of Ubiquilin 4. In the situation 
described by Woolley et al. (2012) FLT3-ITD controls the ubiquitination and 
degradation of p22phox via the inhibition of GSK3β, the kinase responsible for the 
phosphorylation of p22phox, which targets p22phox and many other proteins for 
degradation (Lee et al., 2007; Leng et al., 2010).  If FLT3-ITD can indeed influence 
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the activity of enzymes involved in the ubiquitination pathway then it is likely that 
many more targets of FLT3-ITD-driven ubiquitination and proteasomal degradation 
will emerge.  
 SHP-1 has been designated as a putative tumour suppressor because of the 
negative impact it has on pro-survival, anti-apoptotic signalling pathways (Wu et al., 
2003a) and has been shown to de-phosphorylate FLT3 (Godfrey et al., 2012).  SHP-
1 expression has been shown to be downregulated or completely abrogated in most 
leukaemia and lymphoma cell lines and tissues, as well as in oestrogen receptor (ER) 
negative breast cancer cell lines and some colorectal cancer cell lines (Wu et al., 
2003a). FLT3-ITD signalling has been reported to cause downregulation of SHP-1 
activity through suppression of SHP-1 expression at both the mRNA and protein 
level  (Chen et al., 2005), though Arora et al.  (2012) did not detect a difference in 
SHP-1 mRNA when comparing FLT3-ITD and wild type FLT3 cell lines. Our own 
data seem to point to an upregulation of SHP-1 at the level of transcription upon 
FLT3-ITD activity.  
 By utilising the combined resources of the SABiosciences Text Mining 
Application, a text-mining utility, an automated data extraction system and the 
UCSC Genome Browser, which contains reference sequence and working draft 
assemblies for a large collection of genomes, it was possible to determine the 
predicted transcription factor binding sites in the promoter of the gene which codes 
for SHP-1, PTPN6. Amongst the most relevant transcription factors predicted in this 
way were CREB, c-Myc, AP-1 and STAT5, all known to be stimulated by FLT3-
ITD (Choudhary et al., 2007; Gwin et al., 2010; Rosen et al., 2010) .  
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 This study also proposes a downregulation of the activity of the protein itself 
through proteasomal degradation. Although SHP-1 is known to become oxidised 
downstream of growth factor signalling in other systems (Weibrecht et al., 2007), by 
comparing its differential expression in K_002 and K_003 its redox state was 
determined to be independent of FLT3-ITD activity in this study.  
  PTP1B was shown to be downregulated at the level of protein expression in 
cells treated with PKC412. This decrease was further determined to be due to a 
decrease in PTP1B transcription upon PKC412 treatment. The SABiosciences Text 
Mining Application and the UCSC Genome Browser predicted binding sites in the 
promoter of the PTP1B gene, PTPN1, for CREB, the proto-oncogene which is 
activated downstream of FLT3-ITD and is also predicted to bind the FLT3 gene 
promoter (Fukuda et al., 2009; Shankar et al., 2005); STAT5 and c-Myb, both of 
which are known effectors of FLT3-ITD (Gwin et al., 2010; Obermann et al., 2010). 
 Although this suggests that PTP1B expression is positively regulated by 
FLT3-ITD signalling, the reality may be that PTP1B activity is highly suppressed 
because of the threat it poses to the FLT3-ITD pathway. Evidence favours a role for 
PTP1B as a negative regulator of FLT3 through its de-phosphorylation (Godfrey et 
al., 2012) and by preventing mis-localised FLT3-ITD signalling from the ER where 
PTP1B is resident (Bo et al., 2005; Schmidt-Arras et al., 2009).  PTP1B is oxidised 
to varying degrees in tumour cell lines (Lou et al., 2008) and is highly sensitive to 
H2O2 in particular (Groen et al., 2005), yet despite this has been reported to be not 
oxidised downstream of FLT3-ITD (Godfrey et al., 2012) which correlates with the 
data from K_003. Another option for negative regulation of PTP1B in this scenario 
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is through its serine phosphorylation by Akt (Ravichandran et al., 2001), a 
constitutively active downstream effector of FLT3-ITD (Brandts et al., 2005).  
 PP2Cα, also known as protein phosphatase 1A, is a serine threonine 
phosphatase which negatively regulates Smad1 and MAPK , and is also thought to 
be involved in TGF-β, CDK and pro-apoptotic p53 signalling, which has prompted  
the classification of PP2Cα as a tumour suppressor (Lammers et al., 2007; Takekawa 
et al., 1998). Re-evaluation of the expression of this phosphatase in MOLM-13 cells, 
after discrepancies were noted with regard to its detection in the Kinexus
TM
 screens, 
confirmed that it is downregulated at the level of mRNA and protein upon FLT3-
ITD inhibition. Similarly to the previously discussed phosphatases, the tumour 
suppressive nature of PP2Cα predicts that it would disrupt the FLT3-ITD oncogenic 
signalling, so it is likely to be inhibited at a post-translational level in order to 
contend with its upregulation at the mRNA level, which is probably due to the 
extensive induction of transcription factors downstream of FLT3-ITD.  
 The SABiosciences Text Mining Application and the UCSC Genome 
Browser predicted binding sites in the PP2Cα promoter for transcription factors such 
as CREB, c-Myc, an oncogene implicated in the FLT3-ITD pathway and 
downregulated upon FLT3-ITD inhibition (Radomska et al., 2006) and STAT5 
which is downstream of FLT3-ITD but not the wild type FLT3 receptor (Choudhary 
et al., 2007). 
 K_003 suggests that PP2Cα is not oxidised downstream of FLT3-ITD and 
indeed there is no literature evidence to imply that it is redox regulated at all. It is 
more likely in this case that PP2Cα is subject to inhibitory phosphorylation, as has 
been demonstrated to occur  (Kobayashi et al., 1998). 
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 PP6C is also a serine/threonine phosphatase which was shown in K_002 to 
be very highly expressed in untreated MOLM-13 cells, with this expression 
decreasing by 71% upon FLT3-ITD inhibition.  Previously published data shows that 
PP6C is involved in synchronising the cell cycle with DNA repair and has been 
hypothesised to play a preventative role in the development of breast cancer 
(Douglas et al., 2010; Zhong et al., 2011).  Data concerning the regulatory 
transcription factor binding sites in the PP6C gene was retrieved using 
SABiosciences Text Mining Application and the UCSC Genome Browser. The 
results predicted binding sites for a range of transcription enhancers and repressors 
including C/EBPα, a myeloid transcriptional regulator and FLT3-ITD-target (Mizuki 
et al., 2003); CREB, and c-Myb, another proto-oncogenic transcription factor which 
contributes to the differentiation block driven by FLT3-ITD signalling (Zheng et al., 
2002). 
 The K_003 data appeared to show that PP6C was less oxidised in untreated 
cells, which could be explained by a shift in sub-cellular localisation from the 
cytoplasm, where there are abundant oxidant sources, to the nucleus, where there is 
less. If FLT3-ITD activity stimulated such a translocation, it could reflect the 
irradiation-induced shift in PP6C sub-cellular localisation observed by Douglas et 
al.(2010) and could represent an attempt to pre-empt any DNA damage which may 
occur due to the FLT3-ITD-induced ROS increase.   
 The procedure of BIAM-labelling and depletion of lysates combined with 
Kinexus
TM
 phosphatase expression profiling was an ambitious enterprise, the results 
of which proved somewhat difficult to interpret. Inherent differences in the 
expression levels of phosphatases between untreated and treated samples appeared to 
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mask differences in redox status and perhaps this procedure would be better suited to 
the examination of redox regulation of proteins which are also not subject to changes 
at the level of protein expression.  It did provide some information regarding 
phosphatases which appeared to be indifferent to the changes in ROS levels 
downstream of FLT3-ITD signalling.  
 In conclusion, FLT3-ITD regulation of phosphatase activity, both PTPs and 
DSPs, is complex and multi-layered. Interpretation of correlations between FLT3-
ITD signalling and increases in phosphatase expression as being a novel indication 
of their contribution to the FLT3-ITD pathway is tempting but shallow. The 
upregulation of transcription factor activity downstream of FLT3-ITD inevitably 
results in the increase and decrease of a wide variety of proteins, and as the SHP-1 
data demonstrates, FLT3-ITD may promote the expression of a phosphatase 
apparently at odds with its oncogenic agenda, but this does not guarantee that this 
phosphatase will be allowed to fulfil its function. Successful FLT3-ITD signalling 
incorporates the capacity to override such obstacles.  
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 At the time of writing, clinical trials are ongoing to determine the safety, 
tolerability, pharmacokinetics and pharmacodynamic activity of  the TK inhibitor 
Midostaurin/PKC412 for use in patients suffering from both MDS and AML 
(Fischer et al., 2010; Stone et al., 2005). Midostaurin is one of the more recent 
incarnations of FLT3-ITD inhibitors which have undergone clinical examination. It 
follows on from Sorafenib (Nexavar®; Bayer Pharmaceuticals) and Sunitinib 
(Sutent®; Pfizer Inc.), two multi-targeting kinase inhibitors which were 
demonstrated to have especially potent activity against FLT3 (Al-Kali et al., 2011; 
O'Farrell et al., 2003) and have also been approved for use in solid tumours due to 
their concomitant anti-angiogenic properties (Kim et al., 2009). Other targeted 
FLT3-ITD inhibitors currently in clinical trials for myeloproliferative disorders are 
Lestaurtinib/CEP-701 (Knapper et al., 2006), which also targets the oncogenic 
JAK2/STAT5 signalling axis (Hexner et al., 2008); Tandutinib/MLN518 which has 
been shown to be highly effective in inhibiting FLT3, PDGFRb, and Kit and is 
progressing to Phase II clinical trials (DeAngelo et al., 2006; Shepard et al., 2012); 
AC220, one of the first to completely inhibit FLT3 activity ex vivo at clinically 
relevant doses (Chao et al., 2009; Zarrinkar et al., 2009) and also currently in Phase 
II trials, and KW-2449, a multi-kinase inhibitor of FLT3, Abl, Abl-T315I, and 
Aurora kinase (Shiotsu et al., 2009) also awaiting progression to Phase II (Pratz et 
al., 2009). 
 The success of the Bcr-Abl inhibitor, Imatinib, in provoking a clinical 
response in patients with CML (Douglas Smith, 2011), and more recently in 
Philadelphia chromosome positive (Ph+) ALL  (Maziarz, 2005),  heightened 
expectations of targeted FLT3-ITD inhibitors which were anticipated to offer similar 
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success in the realm of AML.  However, to date, FLT3-ITD inhibitors have proven 
somewhat less effective in a clinical setting than in pre-clinical studies (Pratz et al., 
2009), and have  resulted in the rapid development of drug-resistant clonal cells 
associated with relapse (Wiernik, 2010).   
 The failure in translating the efficiency of FLT3-ITD inhibitors from pre-
clinical cell culture studies to clinical responses in patients has been attributed, 
amongst other reasons, to the use of cell lines which are homozygous for the FLT3-
ITD mutation, while most patients who are initially diagnosed with AML are 
heterozygous for the mutant allele and the wild type allele (Wiernik, 2010).  Mori et 
al. (2009) showed that the presence of the FL-responsive wild type FLT3 receptor 
can interfere with the effectiveness of inhibitors in cells which express both the wild 
type and mutant forms of FLT3. Initially it was assumed that the reduced potency of 
targeted FLT3-ITD inhibitors against the wild type receptor would prevent 
suppression of normal haematopoietic progenitors in the bone marrow (Mori et al., 
2009), however it is now accepted that, to generate a clinically relevant response, the 
inhibitor must be demonstrated to be effective against the heterozygous leukaemic 
blasts. Another hypothesised reason for the lack of sustained FLT3-ITD inhibition in 
patients is pharmacokinetic failure. Target inhibition and cytotoxicity are confirmed 
in pre-clinical studies but, in patient trials, consideration of safety and tolerability 
becomes paramount and inhibition of FLT3-ITD signalling in vivo is not evaluated 
(Pratz et al., 2009).  
 This highlights the importance of studies such as this one, which use 
clinically relevant AML models such as the MOLM-13 cell line which is 
heterozygous for the FLT3-ITD and wild type mutations. The effectiveness of the 
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FLT3-ITD inhibitor PKC412 was demonstrated across a range of signalling 
parameters and at the level of cell motility, yet this dose was shown to not 
significantly impact the viability of MOLM-13 cells. This allowed the signalling 
data to be attributed to the inhibition of FLT3-ITD only, without activation of 
apoptotic-related signalling pathways complicating the issue. To induce cytotoxicity 
in MOLM-13 cells, the duration of incubation must be increased beyond the point 
where FL-stimulation can compensate for the sustained inhibition of FLT3-ITD, but 
determining this point was beyond the scope of this study. By focusing on sub-lethal 
FLT3-ITD inhibition, it was possible to observe the effects on novel downstream 
targets of FLT3 signalling before apoptosis occurs. Identification of such novel 
FLT3-signalling effectors is vital in illuminating the relatively obscure FLT3 signal 
transduction pathway.  
 In his discussion of FLT3-ITD inhibitors, Wiernik (2010) predicts that in 
order to combat drug resistance and promote optimal application of these inhibitors, 
combinations of inhibitors as well as combinations of inhibitors and conventional 
chemotherapy will have to be considered.  In fact many of the current clinical trials 
are demonstrating synergy between FLT3-ITD inhibitors and chemotherapeutic 
agents such as daunorubicin and cytarabine in the case of PKC412 (Stone et al., 
2012). However, Wiernik points to the exploitation of the cross-talk between FLT3-
ITD and downstream pathways such as Ras/Raf/MEK/Erk, JAK/STAT and 
PI3K/Akt as promising equally effective synergistic effects and possibilities of 
overcoming the rapid resistance observed with FLT3-ITD inhibitors alone (Weisberg 
et al., 2009; Wiernik, 2010).  
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 To facilitate such multi-targeted therapeutic approaches, this study has 
provided evidence to support a role for Nox, Src kinase and Ezrin in the downstream 
signalling pathway of FLT3.  The position of p22phox-dependent Nox in translating 
the growth factor signals originating at FLT3 into proteomic changes renders these 
enzymes potential targets in the treatment of FLT3-ITD-driven AML. Recently, Nox 
have become recognised as therapeutic targets in cardiovascular disease (Cave, 
2009) and in neurodegenerative disorders (Gao et al., 2012), two pathologies 
characterised by increased oxidative stress but seemingly untreatable using anti-
oxidant-based approaches. Targeted suppression of Nox activity provides an 
alternate means of combating the redox-basis for these conditions, as it does for 
tumours in which Nox-derived ROS operate as oncogenic signalling mediators.  
 Several excellent reviews have recently discussed the potential for Nox-based 
therapeutics and highlighted the range of diseases which could benefit from such 
developments, but all have emphasised the lack of specificity of existing inhibitors 
which is hampering progression to clinically-relevant studies  (Jaquet et al., 2009; 
Krause et al., 2012; Lambeth et al., 2008). To date, there are no licensed Nox-based 
therapeutics but this is set to change. Currently a dual Nox 1 and 4 inhibitor 
GKT137831 (GenKyoTex) is completing Phase I clinical trials for the treatment of 
diabetic nephropathy, a complication of diabetes associated with increased Nox 4-
mediated oxidative stress in the kidney (Sedeek et al., 2010). Further progress in the 
development of similar isoform-specific small molecule inhibitors (Cifuentes-
Pagano et al., 2012; Jaquet et al., 2009) may be able to provide the option, in the 
near future, of combining FLT3-ITD and Nox inhibition for effective intervention of 
the redox signalling pathway downstream of FLT3. In the meantime it is vital to use 
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studies such as this one to draw attention to the role of Nox enzymes in the 
pathology of AML. 
 The revelation of the redox-regulation of Src downstream of FLT3-ITD is 
another interesting outcome of this study, and introduces another possible avenue for 
therapeutic intervention. There are a multitude of Src kinase inhibitors in 
development to address the causative role of Src in solid tumours (Puls et al., 2011) 
but its involvement in AML deserves further investigation. The role for Src in 
promoting the proliferation of AML blasts has already been established (Ozawa et 
al., 2008), as has its position as a mediator of FLT3-ITD signalling (Leischner et al., 
2012; Robinson et al., 2005) and TK inhibitors which target Src have already 
progressed through clinical trials for the treatment of CML (Schenone et al., 2010).  
Insights into the oxidative activation of Src and the circumstances under which it 
occurs, such as those illustrated in this study, will allow the targeting of this aspect 
of oncogenic Src activation.  
 Furthermore, the indications are that Src is simply one of many redox-
activated kinases, which function in physiological signal transduction but may also 
become deregulated under conditions of oxidative stress. The possibility of direct 
kinase activation through oxidation is a reality for a wide range of redox-mediated 
pathologies but requires much more examination if it is to become a therapeutically 
valuable target.  
 The identification of Ezrin as a downstream target of both Nox-derived ROS 
and FLT3, directed the focus of the study towards a much-neglected aspect of the 
pathology of leukaemia- the metastasis of leukaemic blasts. Metastasis is a 
phenomenon most often associated with solid tumours, despite the obvious ease at 
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which leukaemic cells may migrate throughout the body. Clinically, it is the 
overgrowth of bone marrow-resident leukaemic blasts which receive most attention, 
yet the aberrant migration and extramedullary infiltration of secondary sites such as 
distal marrow, gums, meninges, skin and lungs by circulating blasts remains a major 
complicating factor (Stefanidakis et al., 2009; Voermans et al., 2002). Such 
migration can manifest as myeloid sarcoma in up to 10% of AML cases (Krause, 
1979; Wiernik and Serpick, 1970), and leukaemic cutis in 3% of cases (Agis et al., 
2002). When occurring as complications of AML, both conditions tend to present at 
the same time as the progression to systemic bone marrow leukaemia, and often at 
relapse stage suggesting that the opportunity to address this complication is in the 
early phases of the disease (Bakst et al., 2011).  
 The ability of the leukaemic blasts to home to secondary sites appears 
provide a point of intervention, by disrupting the cellular adhesion molecules and 
chemokine signalling axes involved (Chen and Massagué, 2012; Voermans et al., 
2002) but interference with the cytoskeletal mechanics of the cancer cell motility is 
also worth considering. Ezrin has been touted as a potentially therapeutic target in 
the metastasis of solid tumours (Li et al., 2008; Wu et al., 2011), and small molecule 
inhibitors of Ezrin have already been  screened and shown to be effective in 
combating invasive osteosarcoma by impairing Ezrin phosphorylation and actin-
interactions (Bulut et al., 2012). Studies such as ours and that of Zhou et al. (2010) 
show that the therapeutic applications of such inhibitors need not be limited to the 
metastases of solid tumours.  
 Finally, elucidation of the FLT3-ITD phosphorylation signal transduction 
pathway would not have been complete without consideration of the phosphatases 
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which are regulated by FLT3 signalling. This area was discovered to be complex and 
multi-faceted, and rich in potential for further study. It appears that FLT3-ITD is 
responsible for the increased transcription of a range of phosphatases whose anti-
tumourigenic functions appear to be at odds with the FLT3-ITD signalling agenda. 
The identification of binding sites for FLT3-ITD-responsive oncogenic transcription 
factors in the promoter regions of these phosphatases provided an explanation for 
this upregulation, and prompts the question of how FLT3-ITD cells suppress the 
activity of these phosphatases once they have been produced. The situation of SHP-1 
provides an example of how the upregulation of a tumour suppressive phosphatase at 
the level of transcription is ameliorated by subsequent post-translational 
modifications, such as ubiquitination and proteasomal degradation.  
 Again this area is potentially useful from a therapeutic point of view, if 
putative tumour suppressor proteins are upregulated as a consequence of FLT3-ITD 
signalling, then perhaps it would be possible to prevent the subsequent suppression 
of their activity and exploit their presence as anti-oncogenic agents.  
 In conclusion, the FLT3-ITD signal transduction pathway has been shown to 
invoke the production of ROS through the Nox family of enzymes, resulting in the 
redox-regulation of Src kinase and its downstream effector Ezrin. These findings 
demonstrate a molecular basis for leukaemic cell migration, offering opportunities 
for therapeutic intervention. In addition, FLT3-ITD has been shown to regulate the 
expression and post-translational modification of a number of anti-tumourigenic 
phosphatases, which also provides the opportunity of exploitation for therapeutic 
purposes. 
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Figure 61. The downstream targets of FLT3 redox signalling in AML 
Schematic illustrating the molecular basis of FLT3 signal transduction pathways 
operating in the AML cell, as elucidated by this study.  
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